Prostate specific antigen negative prostate cancer. by Birtle, A.J.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree H O  Y e a rX o o ^  Name of Author A O
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
c o pVright  d ecla ra tio n
I recognise trait the copyright of tie  above-described thesis rests with the author and 
^thatrib quotation from it or information derived from it may be published without the 
written consent of the author.. iorfer
. WflWPW may not be lent to individuals^ but the Senate House Library may tend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
jMatitises of those libraries. Application should be made to: Inter-Library Loans, 
|  Senate House Library, Senate House, Maiet Street, London WC1E 7HU.
1 -  1 
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the Senate House Library. Enquiries should be addressed to the 
Theses Section of the Library. Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the
author. (The Senate House Library will provide addresses where possible).
B* 1962-1974. In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C. 1975 -1988. Most theses may be copied upon completion of a Copyright
Declaration.
D. 1989 onwards. Most theses may be cx>pied.
LThis thesis comes within category D.
- f ' -  ■
This copy has been deposited in the Library of Uci
This copy has been deposited in the Senate House Library, Senate House, 
Maiet Street, London WC1E 7HU.

Prostate Specific Antigen Negative Prostate Cancer 
A submission for the award of MD thesis by 
Dr Alison Jane Birtle
UMI Number: U59194B
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591943
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Abstract
Prostate specific antigen (PSA) has been used in the diagnosis and monitoring of 
prostate cancer for almost 20 years. Most men who present with metastatic prostate 
cancer have markedly elevated serum levels of PSA. However, approximately 1% of 
cases have serum PSA levels that are much lower than the tumour burden would 
suggest - so-called “PSA-Negative” tumours. Their diagnosis may be delayed, and 
management compromised. Little is known about this patient group. The aim of this 
study was to improve the understanding and management of "PSA-negative" prostate 
cancer.
The clinical history and tissue from 33 patients who presented with treatment-naive 
metastatic prostate cancer and a serum PSA < 10 ng/ml were included in this study, 
the largest series so far reported. Clinical and immunohistochemical features were 
defined and alternative biomarkers investigated. Potential mechanisms underlying 
PSA-negativity were explored using prostate cancer cell lines and archival tissue.
From the clinical case notes review, patients presenting with low serum PSA and 
metastatic prostate cancer have a similar pattern of disease to men with high PSA 
prostate cancer. However, response duration to first line hormonal treatment and 
overall survival were shorter.
Immunohistochemistry performed on archival prostatic tissue has shown that the 
majority of the cancers are positive for PSA, despite low serum levels. The extent of 
PSA immunostaining is patchy and could be missed on biopsy. PSMA and AR are 
expressed, however, and represent alternative diagnostic aids. The study indicates that 
PSMA and PAP should be explored as potential serum biomarkers in this patient
2
group.
The androgen receptor (AR) remains expressed in over 90 % 
therefore defects in this pathway are unlikely to explain the low 
Neither loss of heterozygosity nor gene methylation of AR or 
mechanisms underlying low serum PSA levels.
of these cases and 
serum PSA levels. 
PSA appear to be
3
Table of Contents
Abstract.......................................................................................................................................2
Table of Contents......................................................................................................................4
Index of Tables...........................................................................................................................8
Index of Figures........................................................................................................................ 9
Publications.............................................................................................................................. 10
Papers....................................................................................................................................10
Presentations........................................................................................................................11
Declaration............................................................................................................................... 12
Acknowledgements................................................................................................................. 13
Chapter 1 General Introduction..............................................................................................15
1.1 Prostate Cancer Overview........................................................................................... 15
1.1.1 Prostate Cancer Incidence....................................................................................15
1.1.2 Epidemiology of Prostate Cancer....................................................................... 15
1.1.3 Diagnosis of Prostate C ancer..............................................................................19
1.1.4 Histopathology of Prostate Cancer.................................................................... 20
1.1.5 Presentation of Prostate C ancer.........................................................................22
1.1.6 Staging of Prostate Cancer..................................................................................22
1.1.7 Treatment of Prostate Cancer............................................................................. 24
1.2 PSA-Negative Prostate C ancer..................................................................................25
1.2.1 Definition...............................................................................................................25
1.2.2 Clinical and Pathological Aspects of PSA-Negative Prostate Cancer 25
1.3 PSA as a Tumour Marker............................................................................................28
1.3.1 Definition of Tumour M arker............................................................................ 28
1.3.2 Sensitivity and Specificity of PSA .................................................................... 29
1.3.3 Improving PSA specificity..................................................................................32
1.4 The Biochemistry of P S A ...........................................................................................34
1.4.1 General O verview ................................................................................................ 34
1.4.2 PSA as a Tissue Kallikrein..................................................................................34
1.4.3 Role of Kallikreins............................................................................................... 35
1.4.4 Specific Function of PSA....................................................................................36
1.4.5 PSA in Monitoring Treatment Response.........................................................38
1.5 Hypotheses for PSA Negativity................................................................................ 39
1.5.1 Gene Transcription...............................................................................................40
1.5.2 Gene Translation.................................................................................................. 43
1.5.3 Control of PSA Transcription............................................................................44
1.5.4 Methylation and Deacetylation..........................................................................51
1.5.5 L O H ........................................................................................................................52
1.5.6 PSA Protein Degradation Pathways..................................................................52
1.5.7 PSA Protein Processing and Secretion............................................................. 53
1.6 Alternative Markers for PSA-Negative Prostate C ancer...................................... 60
1.6.1 P A P ........................................................................................................................ 60
1.6.2 A R ...........................................................................................................................61
1.6.3 Kallikreins............................................................................................................. 61
1.6.4 PSM A..................................................................................................................... 61
1.6.5 AM ACR.................................................................................................................62
1.7 Rationale for Thesis.................................................................................................... 64
Chapter 2 Materials and M ethods........................................................................................76
4
2 .1 Principal Techniques................................................................................................... 76
2.1.1 Immunohistochemistry on Cells Grown on Coverslips.................................. 76
2.1.2 Immunohistochemistry on Formalin Fixed Paraffin Embedded Sections . 77
2.1.3 Protocols for Cell Line Experiments................................................................. 80
2.1.4 LOH Protocols......................................................................................................86
2.2 Reagents & Buffers......................................................................................................90
2.2.1 Reagents for Immunohistochemistry................................................................ 90
2.2.2 Buffers for Immunohistochemistry................................................................... 91
2.2.3 Reagents for Tissue Culture and Molecular Biology..................................... 91
2.2.4 Buffers for Tissue Culture and Molecular Biology (Electrophoresis) 92
2.2.5 Reagents for Western blotting............................................................................ 92
2.3 Chemicals & Reagents Suppliers...............................................................................94
Chapter 3 The Clinical Features of Patients Presenting with Treatment-Naive 
Metastatic Prostate Cancer and Serum Prostate Specific Antigen (PSA) < 10 ng /
ml - the “PSA-Negative” Patients.........................................................................................96
3.1 Introduction................................................................................................................... 96
3.2 Aims............................................................................................................................... 96
3.3 Materials and Methods.................................................................................................97
3.4 Results............................................................................................................................ 98
3.4.1 Cases Collected.....................................................................................................98
3.4.2 Patient Demographics..........................................................................................99
3.4.3 Histopathology......................................................................................................99
3.4.4 Treatm ent............................................................................................................. 100
3.4.5 Responses to Treatm ent.....................................................................................100
3.4.6 Survival................................................................................................................ 101
3.5 Discussion....................................................................................................................101
Chapter 4 The Immunohistochemical Features of Treatment-Naive Metastatic 
Prostate Cancer Presenting with a Serum PSA < 10 ng/m l........................................... 112
4.1 Introduction................................................................................................................. 112
4.2 A im s............................................................................................................................113
4.3 Materials and M ethods............................................................................................ 113
4.3.1 Cases Studied.................................................................................................... 113
4.3.2 Specific Immunohistochemical Staining (see Section 2.1.2 for 
Immunohistochemistry General Technique)..........................................................113
4.3.3 PSMA Immunostaining....................................................................................114
4.3.4 Potential Diagnostic Markers as Therapeutic Targets................................. 115
4.4 Results.......................................................................................................................... 115
4.4.1 Clinical and Histopathological Features........................................................ 115
4.4.2 PSA Immunostaining.........................................................................................116
4.4.3 AR Immunostaining......................................................................................... 116
4.4.4 PAP Immunostaining.........................................................................................116
4.4.5 PSMA Immunostaining....................................................................................116
4.4.6 Chromogranin A Immunostaining...................................................................117
4.4.7 Urothelial M arkers........................................................................................... 117
4.5 Discussion....................................................................................................................117
Chapter 5 Loss of Heterozygosity as a Mechanism for PSA-Negativity..................... 128
5.1 Introduction................................................................................................................128
5.1.1 Definition.............................................................................................................128
5.1.2 Background to LOH Detection........................................................................ 128
5.1.3 Clinical Relevance of LOH...............................................................................128
5
5.1.4 Microsatellite Instability (M SI)....................................................................... 129
5.1.5 Assessment of LO H .........................................................................................129
5.2 Aim s.............................................................................................................................130
5.3 Materials and Methods.............................................................................................. 130
5.3.1 Clinical Specimens............................................................................................. 130
5.3.2 LCM ..................................................................................................................... 130
5.3.3 DNA Extraction................................................................................................. 131
5.3.4 PCR Optimisation.............................................................................................. 132
5.3.5 Annealing Temperature......................................................................................132
5.3.6 Construction of Plate for Genotyping............................................................. 133
5.3.7 Data Analysis......................................................................................................134
5.4 Results......................................................................................................................... 136
5.5 Discussion...................................................................................................................136
Chapter 6 Methylation as a Mechanism for PSA-Negativity........................................147
6.1 Introduction.................................................................................................................147
6.2 Aims.............................................................................................................................148
6.3 Materials and Methods.............................................................................................. 148
6.3.1 Cell Lines.............................................................................................................148
6.3.2 Demethylation Optimisation............................................................................. 149
6.3.3 Demethylation of Prostate Cancer Cell Lines by Treatment with 5-Aza. 149
6.3.4 RT-PCR using Primers for AR and P S A ........................................................150
6.3.5 Demethylation of Prostate Cancer Cell Lines and Assessment of PSA
and AR Status by Immunohistochemistry............................................................... 151
6.3.6 Demethylation of Prostate Cancer Cell Lines and Assessment of PSA
and AR Protein Expression by Western Blotting.................................................... 152
6.4 Results.......................................................................................................................... 153
6.4.1 RT-PCR using AR and PSA Primers.............................................................. 153
6.4.2 Immunohistochemical Staining for PSA and AR after Demethylation of 
Prostate Cancer Cell Lines..........................................................................................154
6.4.3 PSA and AR Expression after Demethylation using Western Blotting... 154
6.5 Discussion................................................................................................................... 155
Chapter 7 General Discussion............................................................................................. 163
7.1 Definition of the Clinical Features of PSA-Negative Untreated Metastatic 
Prostate Cancer................................................................................................................ 163
7.2 The Immunohistochemical Characteristics of Serum PSA-Negative
Prostate Cancer................................................................................................................ 163
7.3 Alternative Diagnostic Tissue Markers.................................................................. 164
7.4 Potential Serum Markers...........................................................................................165
7.5 Alternative Therapeutic Targets (Appendix 2 ) ..................................................... 165
7.6 The Mechanism of Low Serum PSA Levels - “PSA-Negativity” ...................... 166
7.6.1 Protein Synthesis................................................................................................ 166
7.6.2 PSA Degradation................................................................................................ 167
7.6.3 PSA Secretion.....................................................................................................167
7.7 Further Work............................................................................................................... 168
Appendix 1 Documentation For Clinical Features S tudy............................................ 169
Appendix 2 Potential Diagnostic Markers As Therapeutic Targets For Serum 
PSA-Negative Prostate C ancer...........................................................................................175
A2.1 Introduction..............................................................................................................175
A2.1.1 Her-2/neu (C-erb-B2)..................................................................................... 175
A2.1.2 Matrix Metalloproteinase 2 (MMP2) and its tissue inhibitor (TIMP2) 176
6
A2.1.3 Fibroblast Growth Factors (FGF)..................................................................176
A2.1.4 Bcl-2.................................................................................................................. 177
A2.2 Materials and M ethods...........................................................................................177
A2.2.1 General immunostaining................................................................................177
A2.2.2 HER-2/neu immunostaining.......................................................................... 178
A2.3 Results...................................................................................................................... 178
A2.4 Discussion................................................................................................................179
References..............................................................................................................................186
7
Index of Tables
Table 1.1 Previous Studies of PSA-Negative Prostate Cancer (Serum PSA < lOng/ml)
 66
Table 1.2 Molecular Forms of PSA (from Lilja et al 1991)............................................. 67
Table 3.1 Patient Demographics......................................................................................... 106
Table 3.2 Histopathology..................................................................................................... 107
Table 3.3 Treatment and Response.....................................................................................108
Table 4.1 Summary of Primary Antibody and Conditions.............................................122
Table 4.2 Summary of Immunohistochemistry Results in 33 C ases............................123
Table 6.1 Cell Line Numbers with/without Demethylation............................................158
Table A 2.1 Summary of Primary Antibody and Conditions...........................................184
Table A2.2 Immunohistochemistry Results of Additional Markers Panel in 10
Selected Cases..............................................................................................................185
8
Index of Figures
Figure 1.1 Gene Locus of the New Kallikrein Family Around Chromosome 19q 13.4
at a 300kb Region...........................................................................................................68
Figure 1.2 Gene Regulatory Elements in Transcription.................................................... 69
Figure 1.3 Mechanism of Androgen A ction.......................................................................70
Figure 1.4 The Major Transcriptional Regions Regulating PSA Gene Expression.....71
Figure 1.5 Proteins Interacting with the AR (from Androgen Receptor Database
www.mcgill.ca/androgendb)........................................................................................ 72
Figure 1.6 Schematic Illustration of LOH and Microsatellite Instability......................73
Figure 1.7 Structure of PSA Isoforms..................................................................................74
Figure 1.8 Model of the Metabolism of PSA in Extracellular Fluid and Circulation..75 
Figure 3.1 Histopathological Grading of PSA-Negative Metastatic Prostate Cancer
and Metastatic Prostate Cancer Overall (data from local centres)....................... 109
Figure 3.2 Progression Free Survival in Patients with PSA-Negative Metastatic
Prostate Cancer.............................................................................................................. 110
Figure 3.3 Overall Survival of Patients with PSA-Negative Metastatic Prostate Cancer
......................................................................................................................................... I l l
Figure 4.1 Immunohistochemical Features Illustrated by 2 C ases ............................... 125
Figure 4.2 Positive Controls.................................................................................................126
Figure 4.3 Negative Controls...............................................................................................127
Figure 5.1 Showing Tissue Acquisition (top) and Tissue Transfer (bottom) During
LCM ................................................................................................................................140
Figure 5.2 Examples of Microdissected Prostate T issue................................................141
Figure 5.3 Electrophoresis C ircuit......................................................................................142
Figure 5.4 PCR Products for PSA Primer using Microdissected D N A ....................... 143
Figure 5.5 Example of Non-Informative Homozygous Sam ple....................................144
Figure 5.6 Heterozygous Informative Result....................................................................145
Figure 5.7 Microsatellite Instability................................................................................... 146
Figure 6.1 RT-PCR Results using PSA, AR and GAPDH Primers after
Demethylation Treatment of Prostate Cancer Cell Lines with 5-Aza..................159
Figure 6.2 PCR Results using PSMA and PAP Primers after Demethylation of
Prostate Cancer Cell Lines with 5-A za.....................................................................160
Figure 6.3 Immunohistochemical Staining of Prostate Cancer Cell Lines Grown on
Coverslips.......................................................................................................................161
Figure 6.4 Western Blotting of Prostate Cancer Cell Lines Treated with 5-Aza to
Investigate Re-Expression of PSA and AR after Demethylation..........................162
Figure A2.1 Her-2/Neu Immunostaining.......................................................................... 182
Figure A2.2 Bcl-2 Immunostaining................................................................................... 183
9
Publications
Publications arising during the course of the work presented in this dissertation:
Papers
A.J.Birtle, A.Freeman, H.A.Payne, J.R.W Masters, S.J.Harland, & Contributors to the 
BAUS Section of Oncology Cancer Registry. “The clinical features of patients who 
present with metastatic prostate cancer and serum PSA < 10 ng/ml- the “PSA- 
negative” patients.” Cancer, 2003;98(11):2362-2367
A.J.Birtle,A.Freeman, H.A.Payne, J.R.W.Masters & S.J.Harland. “Neuroendocrine 
differentiation in human prostate tissue: is it detectable and treatable ?” British 
Journal o f Urology International.September 2003(92):490-492
A.J.Birtle, A.Freeman, H.A.Payne, J.R.W.Masters, S.J.Harland & Contributors to the 
BAUS Section of Oncology Cancer Registry. “The immunohistochemical 
characteristics of patients presenting with metastatic prostate cancer and a serum PSA 
of less than 10 ng/ml” In submission to the American Journal of Surgical Pathology.
A.J.Birtle, A.Freeman, H.A.Payne, J.R.W.Masters, S.J.Harland & Contributors to the 
BAUS Section of Oncology Cancer Registry. “Serum prostate specific antigen (PSA)- 
negative metastatic prostate cancer: histopathology and an alternative diagnostic 
marker.” BCRM 2003 abstracts
10
Presentations
United States & Canada Academy of Pathology Meeting, Vancouver, March 2004. 
“Prostate specific membrane antigen (PSMA) may assist in the diagnosis of prostate 
cancer in patients presenting with low serum prostate specific antigen (PSA) relative 
to clinical stage.”
British Association of Urological Surgeons Annual Meeting, Manchester, June 2003 
“The clinical features of untreated metastatic PSA-negative prostate cancer”
British Cancer Research Meeting, Bournemouth, July, 2003. 
“Serum prostate specific antigen (PSA)-negative metastatic prostate cancer: 
histopathology and an alternative diagnostic marker”
11
Declaration
I hereby declare that this thesis is the result of my own work, and includes nothing 
which is the outcome of work done in collaboration, unless otherwise stated.
I further state that my thesis is not substantially the same as any I have submitted for a 
degree or diploma or any other qualification at any other University, and that no part 
has already been or is concurrently submitted for any such degree, diploma or other 
qualification.
Alison Birtle 
August 2004.
Acknowledgements
This thesis represents much more than two years laboratory-based research and would 
have proved impossible without the efforts of particular individuals.
For the initial concept for the project and continued support, both intellectual, 
practical, psychological and financial, I must credit the unfailing backing of three 
people without whom this work would not have begun, Dr Steve Harland, Dr Heather 
Payne and Professor John Masters. Dr Alex Freeman and Dr Connie Parkinson from 
the UCLH Histopathology Dept not only formed a vital part of the 
immunohistochemistry and pathology research, but gave me much better 
understanding of Urological pathology to utilise in my continuing clinical life. 
Philippa Munson was responsible for the technical assistance for the 
immunohistochemistry and Miss Charlotte Foley was invaluable in guiding me 
through the LOH work.
The laser capture microdissection, whilst causing great problems, was finally 
completed after support from Chris Jones and Pete Simpson in the Breakthrough 
Breast Cancer Laboratories of the Institute of Cancer Research. Magali Williamson 
will have my never-ending gratitude for continual encouragement, support and 
suggestions, when molecular biology results were non-forthcoming. Magali, together 
with Michele Cummings, Clair McGurk & David Hudson made an almost competent 
scientist out of an oncologist!
I would have been unable to carry out the work without the help of the British 
Association of Urological Surgeons Cancer Registry’s in identifying suitable patients, 
and Sarah Fowler, the BAUS data manager proved invaluable. The financial support
13
provided by the Co vent Garden Cancer Research Trust, the Barbour Trust and 
Prostate Cancer UK, allowed this work to progress.
Finally to my parents, friends, and especially my ever-patient computer help-desk 
husband Steve, you kept me on the side of sanity, gave up weekends, and were always 
there- this work is for you.
14
Chapter 1 General Introduction
1.1 Prostate Cancer Overview
1.1.1 Prostate Cancer Incidence
Prostate cancer is the second most frequent cause of male cancer deaths in the western 
world, accounting for 15.3 % of male cancers with 534,000 new cases worldwide 
(Greenlee 2001). In the UK, there are around 20,000 new cases and almost 10,000 
deaths per annum (Parkin, et al. 2001). With an increasingly ageing population, the 
number of clinically significant cases will grow and it is likely that the incidence of 
prostate cancer will overtake that of lung cancer within the next 5 years (Office for 
National Statistics 1999).
1.1.2 Epidemiology of Prostate Cancer
1.1.2.1 Age
The mean age of men presenting with prostate cancer in the UK is 72.3 years with
80.5 % diagnosed over the age of 65 years (British Association of Urological Surgeons 
Section of Oncology 2002). From autopsy studies, it has been suggested that the 
majority of men aged 85 and above have histological evidence of prostate cancer 
(Breslow et al. 1977; Sakr et al. 1993), albeit small foci in many cases. For the majority 
of these men, prostate cancer was neither symptomatic nor a contributory factor in their 
deaths. It is important therefore, to identify those tumours that are more likely to cause a 
clinical problem by virtue of such prognostic factors as tumour size, histopathological 
grade and PSA.
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1.1.2.2 Geography
There is a significant geographical and racial variation in prostate cancer incidence, 
with the highest incidence in Caribbean men, African-Americans in the USA (137 per 
100,000 per year) and in Scandinavia, with the lowest incidence in Asia, particularly 
China (1.9 per 100,000 per annum). Whilst screening plays a part in the number of 
cases detected in the USA, it is clear that in the three main ethnic groups in the USA, 
there is a continuing disparity between incidence rates, with blacks having a 60% 
greater rate than Caucasians and 200 % higher than Orientals (JCNI Editor 1997). It is 
likely that multifactorial environmental and genetic factors are involved.
1.1.2.3 Genetic Predisposition to Prostate Cancer
A full description of this topic is beyond the scope of this thesis. It is, however, 
important to set the subject in context. 10-15 % of patients with prostate cancer have at 
least one relative who is also affected (Whittemore et al. 1995) and first-degree relatives 
of men with prostate cancer have a 2-3 times increased risk of developing prostatic 
malignancy. The risk is increased with the number of relatives affected and a younger 
age at diagnosis of the index case. Monroe (Monroe et al. 1995) suggested a recessive 
or X-linked pattern of inheritance, although an autosomal dominant inheritance of a 
high-risk gene has also been proposed (Carter et al. 1992a). Linkage analysis studies 
have mapped high risk loci to chromosomes 1, X, 20, 17 and 8 (Berry et al. 2000;Smith 
et al. 1996;Xu et al. 2001). Smith also showed evidence of a linkage to chromosome 
region lq24-25 in North American and Swedish families, particularly in those with 
early onset disease and this locus was named H PC1. Polymorphisms of genes regulating 
androgen metabolism and apoptosis may also be involved in prostate cancer risk (Lange 
et al. 2000). The androgen receptor gene contains three polymorphic repeats. In
16
particular, the CAG repeat in exon 1, which codes for a polyglutamine track, has been 
studied. In vitro analysis has shown that the length of the repeat is inversely related to 
the transcriptional activity of the AR (Chamberlain, et al. 1994; Kazemi-Esfarjani et al. 
1995). It has been suggested that there is heightened sensitivity to androgenic 
stimulation in prostatic epithelial cells with short CAG repeats (Elo & Visakorpi 2001) 
and thus increased oncogenic potential. The prevalence of short CAG repeats (< 22) is 
higher among African Americans than Caucasians (Irvine et al. 1995), with the longest 
repeats found among Chinese men (Hsing et al. 2000). This may partly explain the 
much higher risk of prostate cancer among African Americans, particularly when 
compared to Chinese men. Other polymorphisms that have been suggested to be 
associated with the risk of prostate cancer affect genes such as those for 5a-reductase 
type 2 (SRD5A2), cytochrome P450 family members (CYP3A4 and CYP17), and 
HPC2/ELAC2 (Elo & Visakorpi 2001). Mutations in BRCA1 and BRCA2, genes most 
usually associated with high-risk breast and/or ovarian malignancy, have been 
associated with a genetic predisposition for prostate cancer. Germline mutations in 
BRCA2 account for up to 5 % of cases of prostate cancer in familial cancer clusters. 
Edwards et al (2003) calculated an overall relative risk of 4.6 (3.5-6.2) for prostate 
cancer in 173 families identified as having BRCA2 gene mutations. In these families, 
germline mutations were present in 2% of men with prostate cancer who were aged 55 
or younger (Edwards et al. 2003). The ongoing European IMPACT study 
(identification of men with a genetic predisposition to prostate cancer and their clinical 
treatment) should provide information on the role of both BRCA1 and BRCA2 in 
familial cases of prostate malignancy.
Chromosomal loss, in particular of 8p and 13q, is implicated in prostate cancer. It is
17
likely that inactivation of tumour suppressor genes at these loci is an early event in the 
development of prostate cancer (DeMarzo et al. 2003). In addition to mutation, an 
alternative mechanism to inactivate the remaining allele of a tumour suppressor gene is 
hypermethylation of the CpG islands of the promoter of the gene (see section 1.5.4). 
The most common genetic event in prostate cancer is probably hypermethylation of the 
Tt-class glutathione S -transferase (GSTP1) gene promoter (Lee et al. 1994). GSTP1 can 
detoxify environmental electrophilic carcinogens and oxidants, and may prevent 
oxidative DNA damage and hence mutational susceptibility (Nelson et al. 2001). Other 
genes known to be involved in the pathogenesis of the disease include metastasis 
suppressor genes such as CDH1 (E-cadherin) (Umbas et al. 1994), KA11 (Dong et al. 
1995), CD44 (Gao et al. 1997) and PTEN (Liaw et al. 1997). Loss of tumour suppressor 
genes such as Rb (Bookstein et al. 1990) and p53 (Konishi et al. 1995) have also been 
implicated. Oncogenes identified as having a potential role in prostate carcinogenesis 
include ras, which is more common in Japanese rather than in western study populations 
of prostate cancer (Carter et al. 1990), c-myc (Buttyan et al. 1987) and c-erbB2 (Her- 
2/neu) (Zhau et al. 1996).
1.1.2.4 Environmental and Lifestyle Factors
The western diet, in particular high consumption of red meat, fat and dairy products 
(Chan et al. 2001;Hayes et al. 1999) has been linked to prostate cancer whilst diets high 
in phyto-oestrogens such as soya appear to have a protective effect (Strom et al. 1999). 
It may be the cooking process, in particular frying or charcoal grilling, which leads to 
the formation of potentially carcinogenic heterocyclic amines, rather than the meat 
intake itself, that is the contributory factor (Augustsson et al. 1999). Lycopene (an 
antioxidant found in tomato sauce), selenium and vitamin E have also been found to
18
have a preventative role (Giovannucci et al. 2002; Heinonen et al. 1998; Redman et al.
1998). Finally, insulin-like growth factor 1 (IGF-1), a growth factor involved in cancer 
cell metabolism, appears to confer a 1.7-4.3-fold increased risk of prostate cancer when 
present in high concentrations (Stattin et al. 2000).
1.1.2.5 Hormones
As prostate cancer does not occur in eunuchs, it is clear that there must be androgenic 
involvement in the development of the disease. Prostate cancer is known to be an 
androgen-responsive tumour and androgens are vital for the development of the normal 
prostate. Prostate cancer may be treated with medical or chemical castration, with 
response rates of around 80 % in the context of metastatic disease. In animal studies, 
both testosterone and its derivative dihydrotestosterone (DHT), which is produced 
within the prostate, have shown oncogenic ability (Gronberg 2003). It is attractive 
therefore, to link androgen concentrations to the pathogenesis of prostate cancer. Some 
authors have noted increased DHT levels in black men, lowest in Asian men, consistent 
with prostate cancer incidence in these racial groups (Parnes et al. 2005).
1.1.3 Diagnosis of Prostate Cancer
The majority of prostatic neoplasms produce a serum glycoprotein, prostate specific 
antigen (PSA) that may be used in both the diagnosis and monitoring of treatment of 
prostate cancer. Debate exists with regard to the usefulness of PSA-screening but it is at 
present the only serum marker validated for detection of prostate cancer in the 
asymptomatic patient. The combination of digital rectal examination (DRE), serum PSA 
level and transrectal ultrasonography (TRUS) form the basis of establishing a diagnosis 
of prostatic malignancy (Gerber & Chodak 1991). Histopathological diagnosis is
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required to confirm the presence of carcinoma, and tissue is usually obtained by 
multiple core biopsies of the prostate performed under TRUS guidance. If a result using 
either DRE, TRUS or PSA is abnormal, the positive biopsy rate is 6-25 %; with two 
abnormalities this rises to 18-60 %, and if all three modalities are positive, the positive 
biopsy rate is 56-72 % (Gustafsson et al. 1992).
1.1.4 Histopathology of Prostate Cancer
The majority of prostate cancers (> 70 %) arise in the peripheral prostate zone with 5- 
15 % in the central region and the rest arising from the transition zone. Microscopic foci 
of latent prostate cancer are a common autopsy finding and approximately 30 % of men 
over the age of 40 have evidence of latent disease. Many of these microscopic tumours 
never become clinically evident due to the slow growth rate, but any tumour with a 
volume of greater than 0.5cm3 or one which is moderately or poorly differentiated is 
thought to be clinically significant (Partin et al. 1990). The histopathological pattern of 
prostate cancer correlates significantly with the biological behaviour. The Gleason 
grading system, which is based on the Veterans Administration Co-operative Urological 
Research Group (VACURG) study of more than 4000 patients between 1960 and 1975, 
is the most widely accepted method of histopathological grading. Although both intra­
observer and inter-observer variability have been reported with the Gleason system 
(Cintra & Billis 1991 ;di Loreto et al. 1991), grade remains one of the strongest 
predictors of biological behaviour in prostate cancer, being strongly correlated with 
overall survival, disease free survival, and time to progression. The grade is used in 
nomograms to predict the likelihood of disease extension outside the prostate (Partin et 
al. 2001) and hence to determine treatment options. For example, a man with organ
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confined disease but Gleason 8-10 will be offered different management strategies than 
if he had a well differentiated tumour. Poorly differentiated tumours have an 
improvement in survival and local control by the addition of long term hormonal 
therapy with an LHRH agonist to radical radiotherapy, (Bolla et al. 1997;Bolla et al. 
2002).
Absence of the basal cell layer is critical in the diagnosis of adenocarcinoma of the 
prostate. Basal cells may be mimicked by compressed stromal fibroblasts but are 
usually only seen focally at the periphery of the glands. An intact basal cell layer is 
present at the periphery of benign glands, whereas in carcinoma, the basal cell layer is 
absent. Occasionally, diagnosis is hampered by observing small adenocarcinoma foci 
clustering around larger benign glands which have an intact basal cell layer, and 
confirmatory monoclonal antibody immunohistochemistry with such antibodies as 
cytokeratin 7 and 20, 5 and 14 (Bassily et al. 2000) or 34pE12 (Varma et al. 2003) is 
required to evaluate the basal cell layer. Perineural invasion and microvascular invasion, 
although not significantly associated with tumour grade, tend to be associated with more 
aggressive biological behaviour of the tumour (Epstein et al. 2000).
The percentage of biopsy cores involved with tumour has also been found to be 
predictive of the likelihood of recurrent or aggressive tumour, particularly in screen- 
detected T ic  tumours where the probability of recurrence of disease strongly dictates 
management options (Gretzer et al. 2002). The percentage of cores positive for cancer 
has also been found to be a significant predictor of pathological stage after radical 
prostatectomy (Epstein et al. 2000;Gancarczyk et al. 2003).
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1.1.5 Presentation of Prostate Cancer
Patients may present with asymptomatic prostate cancer detected at routine PSA 
evaluation, as an incidental finding in approximately 10% of men undergoing 
transurethral resection of the prostate or with symptoms attributable to the underlying 
neoplasm. The presenting symptoms of prostate cancer fall into two main groups: 
symptoms of urinary outflow obstruction (60-70%) and symptoms of advanced disease 
(30-40%), including haematuria, dysuria, incontinence, perineal pain, loin pain, rectal 
bleeding or obstruction, impotence and haematospermia. The classical pattern of 
metastatic disease is of lymph node metastases, bone metastases, and less commonly 
lung or liver (Small 1998). Bone metastases occur predominantly within the axial 
skeleton (85%) (Whitmore, Jr. 1984) pelvis and long bones, and may present with bone 
pain, spinal cord compression or be asymptomatic.
1.1.6 Staging of Prostate Cancer
The most frequently used staging system is the 2002 TNM (Tumour Node Metastasis) 
(Sobin & Wittekind 2002). The assessment of local tumour stage, in particular the 
distinction between intracapsular (T1 -T2) and locally advanced (T3-T4) disease has 
the greatest impact on treatment decisions. Clinical examination using DRE may 
underestimate the tumour extension and some authors have documented a positive 
correlation between DRE and pathological tumour stage in less than 50 % of cases 
(Spigelman et al. 1986). Both computed tomography (CT) and magnetic resonance 
imaging (MRI) may be utilised for the staging of local disease and pelvic lymph nodes 
with a reported accuracy of 66-83 % in distinguishing between organ-confined and 
extracapsular disease (Schiebler et al. 1993).
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Elevated serum alkaline phosphatase levels may indicate the presence of bone 
metastases in 70 % of affected patients (Wolff et al. 1996). Bone scintigraphy using 
technetium diphosphonate is the most sensitive method of assessing bone metastases, 
being superior to clinical evaluation, bone radiographs, or serum levels of alkaline 
phosphatase or prostate specific acid phosphatase (McGregor et al. 1978).
Serum PSA levels increase with increasing age and age-related thresholds above which 
the likelihood of malignancy is greater have been established (Oesterling et al.1995). 
However, if PSA level alone is used in an individual patient, it seems to have a limited 
ability to predict the final pathological stage accurately. As PSA is produced by both 
benign and malignant prostatic tissue, there is a complex relationship between serum 
PSA concentration and clinical and pathological tumour stage. In the great majority of 
patients with metastatic disease, serum PSA is markedly elevated (Daver et al. 1988; 
Pantelides et al. 1992). However, when considering patients with apparently localised 
disease for potentially curative treatment options such as radical prostatectomy, radical 
external beam radiotherapy or Iodine125 brachytherapy, a combination of serum PSA 
level, Gleason score on prostate biopsy and clinical T stage have been used to construct 
nomograms to predict the likelihood of organ confined disease, seminal vesicle 
involvement and lymph node spread for particular PSA levels (Partin et al. 1997;Partin 
et al. 2001).
In the staging of newly diagnosed cases, various studies have recommended a threshold 
below which imaging investigations are unlikely to reveal metastases and hence argued 
against the need for imaging in certain circumstances because of the low cost:benefit 
ratio. In a study by Levran of 861 men with a PSA below 20 ng / ml, eight (0.9%) had
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positive bone scans and 13 (1.5%) had CT- defined nodal disease (Levran et al. 1995). 
In reviewing 167 cases of M l prostate cancer presenting over a 11 year period, eight 
cases with a serum PSA of less than 10 ng / ml were identified (Yamamoto et al. 
2001a). Although the risk of having a positive bone scan increases with advancing 
tumour stage and grade, the positive predictive value remains low even in higher risk 
poorly differentiated tumours. Up to 5% of T ib  or T ic  have a positive bone scan 
(Gleave et al. 1996) and it can be argued that only in well differentiated, low stage with 
PSA <10 ng/ml tumours could a staging bone scan be potentially omitted.
1.1.7 Treatment of Prostate Cancer
The treatment of early prostate cancer can be divided into four therapies: radical 
prostatectomy, radical radiotherapy using external beam or brachytherapy implant, 
hormonal therapy alone or active surveillance. Decision-making is based upon the 
prognostic factors as described above and the patient’s preferences. The current UK 
ProTecT (Prostate testing for cancer and treatment) study aims to randomise 100,000 
men, counselled before PSA testing with regards to the implications of a raised PSA, 
and to randomise patients with a histologically proven tumour, to either active 
monitoring, radical prostatectomy or radical radiotherapy, with primary endpoints of 10 
and 15 year survival. In addition, disease progression, complications, health economics 
and quality of life assessments will form the secondary endpoints (Donovan et al. 2003).
For locally advanced disease, combined modality treatment with external beam 
radiotherapy and hormonal therapy is usually pursued. In the context of metastatic 
disease, hormonal treatment remains the mainstay, with palliative radiotherapy reserved 
for areas of symptomatic discomfort. The median response duration to first line
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hormonal therapy in metastatic disease, usually with an LHRH analogue, is around 18 
months (Eisenberger et al. 1998). On initiation of second-line hormonal therapy, usually 
with the addition of an anti-androgen or oestrogen such as diethylstilboestrol, responses 
are seen in 35-45 % of patients, (Small & Vogelzang 1997) with a median survival time 
of 9-12 months after commencing second -line treatment (Hussain et al. 1994). Median 
overall survival in treated metastatic prostate cancer is around 27 months from the time 
of diagnosis. (Eisenberger et al. 1998).
1.2 PSA-Negative Prostate Cancer
1.2.1 Definition
In general terms, a “PSA-negative” prostate cancer produces much lower serum levels 
of PSA than the tumour burden would suggest. A PSA value of less than 10 ng/ml is 
often used as the value for determining suitability for radical prostatectomy. For the 
purposes of this thesis, therefore, I have defined PSA-negative disease as patients with 
serum PSA levels of less than 10 ng/ml despite the presence of widespread progressive 
metastatic disease.
1.2.2 Clinical and Pathological Aspects of PSA-Negative Prostate 
Cancer
PSA-negative prostate cancer may be divided into two groups:
□ Treatment-naive patients in whom the serum PSA is never raised : Primary 
PSA-negative
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□ Patients relapsing after previous treatment, usually for clinically localised 
prostate cancer, whose initial tumour was PSA-positive but now fails to 
produce raised levels of serum PSA: PSA-negative at recurrence
1.2.2.1 Primary PSA-Negative
At initial presentation serum PSA levels are much lower than expected given the 
volume of disease present. These may be locally advanced or metastatic tumours. The 
level of serum PSA in the great majority of patients presenting with metastatic disease 
is markedly increased (Daver et al. 1988). Given that 10 ng/ml is the usual cut-off for 
consideration of radical surgery (Peschel & Colberg 2003), a serum level below this 
value in a patient with clinically apparent metastatic disease is remarkable (Oommen et 
al. 1994;Wolff et al. 1998;Yamamoto et al. 2001a). PSA-negative disease has been 
estimated at occurring in 0.5-1% of prostate cancer patients with PSA levels below 10 
ng/ml. (Oesterling et al. 1993b). There is a paucity of information on these tumours and 
the majority of the literature is based on small series and case reports. The literature is 
summarised in Table 1.1. Advanced prostate cancer associated with low PSA has 
generally been linked to highly undifferentiated tumours (Gleason 8-10) (Partin et al. 
1990). This is in contrast to the majority of poorly differentiated prostate cancers which 
tend to be associated with higher levels of serum PSA because they are more advanced 
(Partin et al. 1990). In 7/8 cases presenting with serum PSA< 10 ng/ml and widespread 
metastatic disease over an 11 year period, 3 year survival was less than 33 % 
(Yamamoto et al 2001). The median survival for M l prostate cancer overall has been 
reported as 24-27 months (Hussain et al 1994). The small series of PSA-negative 
prostate cancer reported in the literature have suggested a sub-optimal response to 
primary hormonal manipulation, and this has been postulated by Gaffney (Gaffney et
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al. 1992) as being associated with a so-called “functional dedifferentiation” and more 
aggressive biological behaviour. An alternative model is that the tumours more closely 
resemble prostate stem cells and thus lack the cytological markers of terminal 
differentiation. A high rate of visceral metastases (up to 55 %) has also been suggested 
(Sella et al. 2000) and a non-typical pattern of bone metastases observed, with lytic 
rather than the characteristic osteloblastic and sclerotic bone lesions usually seen in 
prostate cancer. A significant link (p<0.0001) between low PSA (< 20 ng/ml) metastatic 
prostate cancer and osteolytic bone metastases has also been noted (Doherty et al.
1999).
Some histological subtypes of prostate cancer, including ductal adenocarcinoma, small 
cell carcinoma or those with neuroendocrine differentiation are associated with lower 
levels of PSA. These subtypes may occur in the treatment naive patient or in the setting 
of disease recurrence after primary therapy.
1.2.2.2 PSA-Negative at Recurrence
This group of patients initially present with raised levels of PSA appropriate to their 
stage of disease as previously outlined. Following initial treatment with either radical 
prostatectomy, radical radiotherapy or androgen deprivation, they are deemed to have 
responded to treatment and continue on follow-up. They subsequently develop a local 
recurrence or distant metastases, but now fail to produce appropriate levels of PSA. It is 
possible that prostate tumours may dedifferentiate on recurrence and this can be 
associated with a secondary failure to produce PSA. A repeat biopsy in this setting often 
shows a large percentage of cells with neuroendocrine features, particularly in the 
context of previous hormonal treatment. Mai and colleagues (Mai et al., 1996) reported
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two cases of hormone treated organ confined prostate cancer, which at subsequent 
metastatic relapse, had normal levels of serum PSA and complete absence of 
immunostaining at tissue level for PSA or PAP. Sciarra recently suggested that 
neuroendocrine markers such as Chromogranin A and neuron specific enolase (NSE), 
might complement the PSA assay in selected cases of poorly differentiated tumours 
(Sciarra et al. 2003). Further, that an increase in Chromogranin A expression, despite 
low PSA levels, may indicate progression and a poor prognosis. Tissue neuroendocrine 
markers including Chromogranin A and NSE were identified in a series of 18 patients 
with clinically progressive androgen-independent prostate cancer and low serum PSA, 
(Sella 2000) leading to the belief that the majority of low serum PSA metastatic 
prostate cancers were neuroendocrine in origin. It has been suggested that hormonal 
therapy enhances neuroendocrine differentiation, although this remains controversial 
(Van de Voorde et al. 1994). It is postulated that the hormonal treatment suppresses the 
non-neuroendocrine cells while having minimal effect on the neuroendocrine 
population, which themselves lack androgen receptors (Bonkhoff, Stein et al. 1993). 
Thus several authors have argued that both treatment naive metastatic prostate cancer 
and those cases of clinically progressive hormone refractory prostate cancer which have 
extensive and multifocal neuroendocrine features are similar and that this is the 
mechanism for the low serum levels of PSA (Abrahamsson 1996;Bonkhoff 1998).
1.3 PSA as a Tumour Marker
1.3.1 Definition of Tumour Marker
A substance detectable in body fluids that is produced by, or in association with, 
tumours (Malkin 1992). Tumour associated antigens are those associated with tumours
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arising from specific organs, but antigens with absolute specificity have not been 
isolated for any type of cancer.
Some uncertainty exists as to the first identification of PSA, thought to be by Ablin 
(1970), although the protein purification is generally attributed to Wang in 1979 (Wang 
et al. 2002) and PSA was first isolated from the serum of patients with prostate cancer 
in 1980 (Papsidero et al. 1980). The landmark description of PSA as a tumour marker 
was some years later (Stamey et al. 1987) and PSA was pioneered as a screening test for 
prostate cancer by Cooner (1988) and Catalona (1991) in the 1980’s. Early biopsy 
studies by Cooner (1988) in patients with abnormalities detected on ultrasound, showed 
a strong correlation between biopsy results and sensitivity, specificity, and both positive 
and negative predictive values for PSA above a threshold of 4.0 ng/ml for ultrasound 
detected abnormality. Together with other studies, this led to the threshold of 4 ng/ml 
being used by many clinicians as an indication for biopsy. Between one third and one 
half of men with a PSA level above 4.0 ng/ml will have cancer on sextant biopsy of the 
prostate (Partin et al. 1990). The difficulty lies in determining which of these tumours 
would have become clinically significant.
1.3.2 Sensitivity and Specificity of PSA
1.3.2.1 Definition
Sensitivity describes the accuracy in detecting individuals who have malignancy 
whereas specificity is the ability to exclude non-malignancy.
1.3.2.2 PSA Screening
Although PSA has shown 58-90% sensitivity for the detection of prostate cancer, when 
examining large series of men with a PSA of > 4.0 ng/ml, particularly when compared
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to its predecessor prostatic acid phosphatase (PAP) (Myrtle et al 1986), its specificity of 
around 60 % is not sufficient to allow its use as a sole agent in mass screening. Using a 
single value for men of all ages leads to the exclusion of a large number of patients with 
clinically significant early-stage disease. This is because 20-50% of such tumours occur 
in men with serum total PSA (tPSA) levels of <4 ng/ml (Schroder et al. 2000;Stenman 
et al. 1994). As serum PSA usually increases with age, partly due to BPH, age-related 
cut-off values have been suggested to increase the sensitivity in young patients and the 
specificity in older populations (Oesterling et al. 1993a). However, there remains debate 
about the use of these age-specific ranges as some authors argue that they result in 
missing an unacceptable number of clinically significant tumours in older men 
(Catalona et al. 2000).
With the advent of PSA screening in the USA in the 1990’s, there has been a stage 
migration in prostate cancer at presentation, with a substantial increase in the numbers 
of early prostate cancers detected (Han et al. 2001). In the USA, T ic  tumours are 
currently the most commonly diagnosed prostate tumour (> 60%) (Partin et al. 1990). In 
the U.K. this trend has also been noted to a lesser extent, with T ic  cases representing
17.4 % of new prostate cancer diagnoses on the BAUS Cancer Registry 2001 database 
(British Association of Urological Surgeons Section of Oncology 2002). In total, 57.9 % 
of patients presented with organ confined disease (compared with 51.8 % in 1999),
30.2 % with locally advanced and 11.9 % with metastatic tumours. In addition, more 
men are presenting with well to moderately differentiated tumours (Gleason 4-6) and 
PSA levels of less than 10 ng/ml, often used as a cut-off for considering radical 
prostatectomy (Peschel & Colberg 2003). Although the incidence of prostate cancer in 
the USA has begun to fall (Hankey et al. 1999), it would appear that the cases had
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begun to plateau before the advent of PSA screening, and that screening alone has not 
been responsible for the decline (Paquette et al. 2002). In other countries declines in 
prostate cancer mortality were observed within a few years of the introduction of wide- 
scale screening (Bartsch et al. 2001; Chirpaz et al. 2002),and so any screening effect 
must be due to early deaths avoided. This is perplexing, as the average mean lead time 
for PSA screening (the time screening brings forward the diagnosis in time) is at least 5 
years, (Etzioni et al. 1998) while median survival of localised prostate cancer is > 10 
years compared to around 30 months for advanced disease (Beemsterboer et al. 1999). 
Hence no effect would be expected for at least 5 years from starting a screening 
programme, other than that due to the earlier detection and management of advanced 
disease. Improved survival among cases diagnosed before screening commenced, due to 
more aggressive treatment options could well have contributed to the fall in deaths, 
especially since a similar decrease in prostate cancer mortality has been observed in the 
UK, despite the relative lack of PSA screening in the UK (Oliver et al. 2000). 
Conflicting advice exists in the USA with regard to prostate screening however. Current 
guidelines from the American Cancer Society and the American Urological Association 
are for annual PSA and DRE in men who are over the age of 50 and have a life 
expectancy of 10 years (Cookson 2001). In contrast, the Guide to Clinical Preventive 
Services from the US Preventive Services Task Force is not in favour of screening 
(diGuiseppi 1996). Crawford and colleagues recommended stratifying patients with 
PSA of less than 4 ng/ml, and that 5 yearly PSA testing was adequate for men with 
initial readings of <1, and 2 yearly for those with a PSA of 1-1.9. This lead to an earlier 
potentially positive test being missed in only 2.6 % of men (Crawford et al. 1999). In 
the UK, no formal guidelines currently exist for PSA testing, other than in men with
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symptoms of bladder outflow obstruction, although the introduction of information 
packs outlining the pros and cons of PSA testing for men enquiring about PSA checks 
has begun.
At present two large-scale multi-centre randomised controlled trials are in progress: the 
European Randomised Study of Screening in Prostate Cancer (ERSPC) and the 
Prostate, Lung, Colon and Ovary Trial (PLCO) in the US, with more than 200,000 men 
randomised since the trials began in 1994 and 1995 respectively (de Koning et al. 
2002). Together they have sufficient statistical power to detect a mortality reduction of 
20 % or more after about 10 years of follow-up. At present in the ERSPC trial, over a 
third of prostate cancers identified were in the group of men with PSA concentrations 
lower than 4 ng/ml. (Schroder et al. 2000). Because of this, a protocol amendment has 
meant that prostatic biopsies are now performed on all men with PSA of 3 ng/ml and 
greater in the ERSPC study (Schroder & Wildhagen 2001). The first trial analyses, 
expected around 2008, should provide valuable evidence with regard to the benefit or 
not of population-based PSA screening for prostate cancer.
1.3.3 Improving PSA specificity
1.3.3.1 Use of Free PSA / Total PSA Ratio
In normal prostate, most free PSA (fPSA) consists of the mature protein that has been 
inactivated by internal proteolytic cleavage. In prostate cancer, the cleaved fraction is 
relatively decreased, resulting in lower fPSA to tPSA ratios (PSA index). In studies of 
men with tPSA between 4 and 10 ng/ml, a PSA index greater than 25 % indicates a risk 
of prostate cancer of less than 8 %, whilst the corresponding risk with a PSA index of 
less than 10% is much greater, more than 56 % (Catalona et al. 1997;Van Cangh et al.
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1996). There appears to be an inverse relationship between fPSA percentage and 
increased histopathological grade and hence more aggressive tumours (Li et al. 1999). It 
may be of use in detecting unfavourable pathological findings in the presence of 
inconspicuous values of tPSA. The PSA index may also increase the sensitivity and 
specificity of PSA testing in men with < 4ng/ml tPSA, potentially reducing unnecessary 
biopsies (Djavan et al. 1999;Vashi et al. 1997).
1.3.3.2 PSA Density
To compensate for larger prostates which contain more PSA-producing epithelium, and 
the contribution of BPH to serum PSA levels, serum PSA is normalised to the prostate 
volume by dividing the PSA value by a TRUS derived volume, giving the PSA density. 
Densities greater than 0.15 have been thought more suggestive of prostate cancer 
(Benson et al. 1992). This method is limited, however, by variations in prostate shape, 
and also the ratio of epithelium to stroma. Catalona (1994) in a study comparing PSA 
and PSA density in detecting early prostate cancers, found that nearly half the cancers 
would be missed if the 0.15 density level was used as the determinant for a biopsy. It is 
likely that using free PSA and PSA density together may improve diagnostic accuracy.
1.3.3.3 PSA Velocity
PSA velocity is the slope of increase in PSA levels over time (Carter et al. 1992b) with 
values greater than 0.75ng/ml/year being thought predictive of clinical prostate cancer. 
However, this test is limited by the need for previous values being recorded, the 
uncertainty about the optimum time between PSA measurements and biological 
variations in PSA levels from non-malignant causes. The latter is particularly relevant 
as biological variability may account for a 25-30% difference between two PSA
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measurements (Nixon et al. 1997).
1.4 The Biochemistry of PSA
1.4.1 General Overview
PSA is a serine protease, with a molecular weight of 28,430 daltons, and is a member of 
the tissue kallikrein family of proteases (Yousef & Diamandis 2001). It is produced 
principally by prostatic ductal and acinar epithelium. Small amounts are also found in 
paraurethral and perianal glands, apocrine sweat glands, breast tissue and thyroid, 
although these make no appreciable contribution to measurable serum levels. It has also 
been recorded at low levels in breast cancer (Partin et al. 1990) but the expression as 
determined immunohistochemically tends to decrease with increasing grade 
(Abrahamsson et al. 1988). Normal prostatic tissue contributes on average 0.2 ng/ml per 
gram of tissue to the serum concentration of PSA. The corresponding value for BPH 
tissue is 0.6 ng/ml and for cancerous tissue it is 2.0 ng/ml (Stamey et al. 1987). The 
normal prostate contains PSA levels about one million-fold higher than in serum with 
seminal fluid levels in the order of 0.2-5 mg/ml (Rittenhouse et al. 1998).
1.4.2 PSA as a Tissue Kallikrein
Kallikreins were initially described as serine proteases which digest particular high 
molecular weight proteins to reduced kinins or bioactive peptides. Two subdivisions 
exist: tissue and plasma kallikreins. 15 tissue kallikrein genes have been identified, 
(KLK 1 to 15), located on chromosome 19Q13.3-ql3.4 (Yousef & Diamandis 2001). 
The genes cluster in a 60kb region and KLK1 is closest to the centromere (Figure 1.1). 
There is 40-80% sequence homology between kallikreins at both the DNA and protein 
level (Yousef et al. 1999), particularly between KLK1, 2 and 3 which are known as the
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classical kallikreins, 4-15 being termed “new” kallikreins. KLK3 encodes for hK3 
(human kallikrein 3) better known as PSA. The major difference between classical and 
new kallikreins is that the new ones contain extra exons (either 5’ or 3’) (Yousef & 
Diamandis 2001). The “kallikrein loop” is a 9-11 amino acid peptide sequence found 
only in classical kallikreins and precedes the aspartic acid in the active site (Yousef & 
Diamandis 2001). KLK3 (PSA) has been found to have splice variants in addition to the 
main 1.6kb transcript and the gene contains 4 introns and 5 exons, in common with the 
other classical kallikreins (Riegman et al. 1989). At least 12 of the kallikrein genes are 
steroid hormone regulated (Yousef & Diamandis 2001) and are expressed in multiple 
tissues. In the prostate, KLK 2, 4, 10, 11, 13 and 15 are all expressed and may share 
regulatory factors that are organ specific. KLK2 and its product hK2 (prostate specific 
glandular kallikrein) in particular shares 80 % sequence homology with PSA and is thus 
the subject of interest as a tumour marker (Stephan et al. 2000). Co-ordinated levels of 
expression of hK2 and PSA (Herrala et al. 2001) in both abnormal and normal prostatic 
tissue have been demonstrated and hK2 can activate the conversion of inactive 
(proPSA) to active PSA (see section 1.5.7) (Kumar et al. 1997). Herrala et al (2001) 
also demonstrated almost double the expression of mRNA for hK2 in prostate 
carcinoma tissues compared with PSA and the use of hK2 may enhance prostate cancer 
detection. The KLK 15 gene is also up regulated at the mRNA level in prostate cancer 
in comparison to normal prostatic tissue and has been associated with more aggressive 
tumours (Yousef et al. 2001).
1.4.3 Role of Kallikreins
The exact role of the tissue kallikreins in malignancy is not clear. Serine proteases are
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involved in tumour progression, such as invasion, proliferation and tumour metastasis 
(Carroll & Binder 1999; DeClerck et al. 1997; Tryggvason et al. 1987). However, 
conflicting data suggests that they also act as tumour suppressors (Goyal et al. 1998), as 
anti-angiogenic factors (Fortier et al. 1999b), as apoptotic molecules (Balbay et al.
1999) or negatively regulate cell growth (Lai et al. 1996). KLK 10 expression is down- 
regulated in aggressive forms of prostate cancer (Luo & Diamandis 2000) and has been 
shown in animal models to act as a tumour suppressor gene in breast cancer (Liu et al.
1996).
1.4.4 Specific Function of PSA
Villoutreix and colleagues (Villoutreix et al. 1994) have shown that in comparison with 
other serine proteases, aspartate 189 is replaced with serine in the substrate binding 
pocket of PSA giving it a chymotrypsin-like activity and is hence responsible for the 
liquefaction of semen by the cleavage of semenogelin I and II in the seminal fluid (Lilja 
et al. 1987). The proteolytic action of PSA may cleave key signalling molecules such as 
insulin, interleukin-2, fibrinogen, PTHrP (Cramer et al. 1996) and TGFp (Killian et 
al.1993). For example, insulin-like growth factor binding protein-3 (IGFBP-3), which is 
the major serum binding protein for insulin-like growth factor-1 (IGF-1) can be cleaved 
by PSA (Cohen et al. 1992). IGF-1 appears to have a mitogenic effect on prostate 
cancer and increased serum levels of this factor have been identified as a risk factor for 
prostate cancer (Chan et al. 1998). Cohen et al (1994) have demonstrated that cleavage 
of IGFBP-3 by PSA in vitro reduces binding of IGF-1 and can increase proliferation in 
response to added IGF-1. However, the significance of this PSA-induced cleavage in 
vivo is uncertain, although after definitive local treatment of prostate cancer by
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prostatectomy, serum levels of IGFBP-3 have been found to be raised, suggesting an 
anti-tumour effect of intact IGFBP-3 (Bubley et al. 2002). PSA may play a role in bone 
metastases and osteoblastic responses. Potent mitogenic effects on osteoblasts in vitro 
by PSA have been shown, mediated either through TGFp, or by alterations in cell 
surface receptors of the osteoblasts (Killian et al. 1993). In contrast, PSA’s action of 
cleavage on PTHrP reduces the mitogenic action. Given that osteoblastic bone 
metastases are characteristic of prostate cancer, it is likely that PSA plays a key but as 
yet ill-understood role in the development of bone metastases.
It has been suggested that PSA may affect proteins involved in cell migration and 
invasion, facilitating tumour progression. It is involved in the cleavage of components 
of the extracellular matrix, and neutralising antibodies to PSA have been shown to 
prevent micro invasion of LNCaP cells, a prostate cancer cell line derived from a lymph 
node metastasis, in vitro (Webber et al. 1995). PSA, like hK2, can activate urokinase- 
type plasminogen activator by cleavage, which may promote invasion (Yoshida et al.
1995). However, PSA may have a tumour inhibiting rather than a tumour promoting 
capacity. It has been shown to inactivate fibroblast growth factor 2 (FGFR-2) 
(Heidtmann et al. 1999) and vascular endothelial growth factor (VEGF) (Fortier et al. 
1999a), both factors being angiogenic in their normal state. This has been supported by 
in-vivo work examining paraffin-embedded prostate cancer sections, in which an 
inverse relationship was seen between PSA expression and microvessel density, this 
microvessel densitiy being used as an index of tumour angiogenesis (Papadopoulos et 
al. 2001). It is clear that the role of PSA as a tumour promoter or tumour suppressor is 
complex and has yet to be established. It can be argued that if PSA contributed 
significantly to the invasive potential of prostate cancer, one would expect the disease to
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behave in a much more aggressive fashion than it actually appears to do.
1.4.5 PSA in Monitoring Treatment Response
After definitive primary treatment, PSA levels can be used to monitor the patient. Any 
detectable PSA subsequent to radical prostatectomy is interpreted as a sign of disease 
recurrence. PSA levels after radical radiotherapy are more complex to interpret: PSA 
levels usually remain low but still detectable after treatment, particularly after seed 
brachytherapy where a PSA “bounce” of between 0.2-0.3 ng/ml, is seen during the first 
3 years after the implant (Cavanagh et al. 2000). The ASTRO definition of 3 successive 
rises after radiation therapy is in common use, although nadir PSA levels are also 
helpful in predicting relapse (Critz et al. 1996).
1.4.5.1 PSA in Recurrent Prostate Cancer
Killian et al. (1985) described how PSA elevation was seen prior to clinical relapse in 
92 % of patients after primary local therapy. However, there is wide variation in the 
time from PSA relapse to clinical relapse, one study showing an 8-year interval in 
patients after radical prostatectomy (Pound et al. 1999). PSA doubling time was found 
to be of help, particularly when doubling occurred in less than 10 months (Partin et al. 
1994).
1.4.5.2 PSA in Metastatic Prostate Cancer
In patients with metastatic prostate cancer serum PSA falls significantly after medical 
castration with LHRH analogues, and is accompanied by improvements in clinical 
symptoms. A PSA nadir of < 4 ng/ml has been identified as an indicator of the likely 
duration of remission (Miller et al. 1992). Debate exists as to whether PSA is an 
acceptable surrogate marker of response in metastatic disease. Its use in this setting is
38
attractive, given that it is often difficult to measure improvement of index lesions on
bone scans accurately, due to the comparatively slow improvement in scan appearances.
However, PSA responses may not reflect tumour responses, particularly in androgen- 
independent disease. In one study of orchidectomy and flutamide versus orchidectomy 
alone (Eisenberger et al. 1998), a PSA nadir of < 4 ng/ml was achieved by significantly 
more patients in the combination arm, but there was no association with increased 
overall survival. In contrast, retrospective series, (Kelly et al. 1993; Scher et al. 1999) 
suggest that a greater than 50 % fall in PSA after treatment is predictive of improved 
survival and thus PSA remains an important, albeit flawed, marker of response in the 
metastatic setting.
1.5 Hypotheses for PSA Negativity
Three main hypotheses may be considered, each of which will be discussed in greater 
detail:
a) Changes at the gene regulatory level
b) Alterations in the protein degradation pathways within prostatic tissue.
c) An alteration in protein processing and secretion
Before looking at the potential factors involved in the regulation o f the PSA gene, an 
overview o f the key processes is required.
The expression of a protein-encoding gene involves several steps: transcription of the 
gene; extensive processing of the initial product, the “precursor” messenger RNA; and 
export of the correctly processed “mature” mRNA from the nucleus to the body of the 
cell.
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1.5.1 Gene Transcription
1.5.1.1 Definition
The process whereby one DNA strand is used as a template to synthesise a
complementary RNA sequence.
1.5.1.2 General Control of Transcription
DNA is transcribed into RNA by DNA-dependent RNA polymerases (RNA pol). The 
polymerases are part of the transcription complex, a larger aggregate of proteins that 
moves in a 5’ to 3’ direction along the DNA from a point of initiation to a point of 
termination (Lewin B 1994b). There are three RNA polymerases, RNA pol I, II and III, 
transcribing ribosomal RNA, messenger RNA and transfer RNA respectively. The 
activity of RNA polymerase II, and hence the rate of transcription and expression, is 
tightly controlled. The control involves two particular components - promoter or 
enhancer sequences upstream or downstream of the gene and transcription factors.
1.5.1.3 Promoters
Each promoter contains specific sets of short conserved sequences, recognised by the 
transcription factors and / or RNA pol. A promoter consists of a number of short 
conserved motifs or nucleotide sequences, the vast majority of which lie upstream of the 
start point. Although RNA pol I and III recognise a comparatively restricted group of 
promoters, those used by RNA pol II exhibit a greater sequence variation. The same 
DNA motif may be shared by multiple promoter sequences. One such is the consensus 
sequence TATA, the “TATA box”. This sequence is usually located 25 base pairs 
upstream of the transcription start site. The factors that can act together with RNA pol II 
include basal factors, upstream factors and inducible factors. Basal factors interact with
40
RNA pol to form a complex around the start point and hence are involved in initiating 
RNA synthesis at all promoters. Upstream factors are DNA-binding proteins, which 
recognise specific short consensus elements upstream of the start point. These factors 
are themselves ubiquitous, and may act upon any promoter with the correct DNA 
binding site. These upstream factors improve initiation efficiency. Inducible factors act 
in a regulatory capacity and have a similar mode of action to the upstream factors. They 
are, however, activated at particular times, or are tissue specific. They bind key areas in 
genes known as response elements.
1.5.1.4 Enhancers
The activity of a promoter may be increased by an enhancer, a conserved sequence that 
may be positioned at a point varying from a few hundred to many thousand kilo bases 
from the transcriptional start site (Muller et al. 1988). The position of the enhancer 
relative to the promoter is not fixed and may be either upstream or downstream of a 
gene. Indeed, it can also function with the nucleotide sequence in either orientation. The 
essential role of an enhancer may be to increase the transcription factor concentration in 
the local environment of the promoter. Figure 1.2 illustrates some of the gene regulatory 
elements of transcription.
Initiation by RNA pol II may occur in a variety of ways; however the key factor is the 
binding of upstream or inducible factors to the specific sequence elements upstream of 
the start point. This binding leads to the formation of the transcription complex.
1.5.1.5 Transcription Factors.
These are proteins that bind to specific DNA sequences within promoters and 
enhancers, but are not themselves part of RNA polymerase. Some transcription factors
41
bind to multiple promoter regions and are essential in the transcription process. In 
contrast, some ensure tissue-specific expression of a gene, by binding only to promoters 
and enhancers associated with particular genes. The transcription factors often share 
short conserved amino acid sequences specific for DNA binding. These include the 
leucine zipper, which contains a leucine amino acid every seven residues along the 
polypeptide chain of the transcription factor. It is likely that these residues allow 
dimerisation of the transcription factors such as API prior to DNA binding. In API, the 
oncogenic proteins Jun and Fos form heterodimers necessary for API activation.
1.5.1.6 Basal Transcription Apparatus
RNA pol II, together with transcription factors, forms the basal transcription apparatus, 
required for gene transcription (Nikolov & Burley 1997). Initiation requires the 
transcription factors to act in a specific order to assemble the complex and as each 
factor is added, an increasing length of DNA is covered. Most promoters contain a 
sequence located 25 basepairs upstream of the start point found in all eukaryotes, the 
TATA box. The initial step in transcription complex formation is binding of a particular 
factor to a region upstream of the TATA box. This factor contains TBP (TATA-binding 
protein) and smaller subunits known as TBP- associated factors or TAF’s. TBP is a 
small protein of approximately 30 kD, which binds in the DNA minor groove, allowing 
other DNA -binding proteins to act in the major groove. Subsequently, other basal 
transcription factors add to the complex, the binding of transcription factor IIF bringing 
RNA polymerase II to the complex. Once the RNA polymerase has initiated 
transcription, it moves along the template until it reaches a terminator sequence, at 
which point the completed RNA product is released and RNA pol dissociates from the 
DNA template (Hirose & Manley 2000).
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The initial gene transcript pre-mRNA is subsequently spliced to remove introns and to 
form messenger RNA (Sharp et al. 1987). The junctions between the introns and exons 
contain short consensus signal sequences, which act as recognition signals for proteins 
that bind to these sites and allow mRNA cutting and splicing. The reactions are carried 
out by spliceosomes, which are built from five RNA molecules (known as small nuclear 
RNA’s, snRNA’s) and more than 50 proteins. Alternative splicing leads to the 
formation of multiple mRNA’s and hence potential splice variants of the protein 
product. Splicing enhances the export of mRNA and certain proteins, including Aly, are 
required not only for mRNA export but are also involved in transcription and are thus 
multifunctional (Keys & Green 2001).
1.5.2 Gene Translation
1.5.2.1 Definition
In translation, transfer RNA (tRNA) molecules enable each codon, a particular triplet of 
nucleotides in mRNA, to be translated into the sequence of amino acids in the protein. 
Each tRNA is specific for a particular amino acid and a specific codon.
The growing mRNA is translated by ribosomes moving in a proximal to distal direction. 
A protein chain is released from the ribosome when any one of three stop codons is 
reached.
1.5.2.2 Control of Translation
The expression of most genes is controlled at the transcription level as detailed above. 
The control of transcription and translation is tightly linked. Some genes, however, are 
transcribed at a constant level and switched on and off by post-transcriptional regulatory 
processes. These processes include:
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□ Premature termination of the RNA transcript.
□ RNA interference- small RNA molecules bind to the complementary 
portion of an mRNA (Lewin B 1994a). This may either prevent it from 
being translated by ribosomes or trigger its destruction.
□ Alternative RNA-splice site selection
□ Failure of a poly-A tail being added to 3’ end which is necessary for RNA
export.
□ Control of transport from the nucleus to the cytosol
□ RNA editing of RNA transcript sequences changing the meaning of the
message.
□ Control of the initiation of translation by specific factors such as elF-2, 
which is phosphorylated by specific protein kinases to decrease the overall 
rate of protein synthesis.
□ Regulation of RNA degradation.
The majority of these control processes require specific sequences in the RNA 
molecules being regulated, to be recognised by either a regulatory protein or a 
regulatory RNA molecule.
1.5.3 Control of PSA Transcription
Before considering PSA specifically, it is necessary to briefly outline normal prostatic 
androgen action (Figure 1.3). Testosterone, which is the main circulating androgen, 
circulates in the blood primarily bound to sex hormone binding globulin (SHBG) and 
albumin. On entering prostate cancer cells, free testosterone is converted by the 
enzymes 5 a  reductase, into dihydrotestosterone (DHT). These factors have a five-fold
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greater affinity for the androgen receptor (AR) than testosterone.
1.5.3.1 The role of the AR
The AR is a member of the steroid-thyroid-retinoid nuclear receptor super family 
(Quigley et al. 1995) that act by binding DNA and inducing transcription. It is a 110- 
kDa protein composed of an N-terminus ligand-independent transcriptional activation 
domain, (AF1) spanning amino acids 141-338, a central domain containing 2 zinc 
fingers which are involved in DNA binding and a C terminal ligand binding domain 
(LBD) (Chang et al. 1995). The LBD contains a ligand dependent transactivation 
domain AF2. In the basal state, the AR is bound to heat shock proteins (HSP), as a 
heteromeric complex which prevents DNA binding (Smith & Toft 1993). Binding of 
androgens induces a conformational change in the AR such that HSP’s are released and 
the receptor is phosphorylated, partly mediated by protein kinase A (Nazareth & Weigel
1996). Within the nucleus AR homodimer complexes are formed, which can bind 
androgen response elements (ARE) in the promoter region of PSA and other target 
genes. The steroid receptor-DNA complex then recruits co-regulatory proteins, co­
activators or co-repressors to the AR complex. The binding of the ligand causes a 
change in the position of helix 12 of the receptor, forming a surface to which the co­
activators can bind. The co-activators allow the AR complex to interact with the general 
transcription apparatus (GTA) causing stimulation or inhibition of transcription of PSA 
(McKenna et al. 1999). Many co-activators contain one or multiple copies of an a  
helical LXXLL motif (where L =leucine and X = any amino acid residue); this signature 
motif mediates ligand-dependent co-activator-nuclear receptor interactions (Heery et al.
1997).
45
1.5.3.2 Androgen Response Elements (ARE)
ARE's are found in the promoters of genes expressed in different tissues, including 
prostate, brain, kidney, liver and testis. The androgen regulation of PSA expression is 
mediated by three ARE within the 5.8 kb pair PSA promoter (Cleutjens et al. 1997) (see 
figure 1.4). Two of the ARE’s are located within the proximal region of the promoter, 
together with the TATA box, at -170  (ARE I) and -395 (ARE II) (Cleutjens et al.
1996). ARE II functions as an ARE only in the presence of ARE I, and is termed an 
androgen responsive region (Cleutjens et al. 1996). The third (ARE III) is much more 
distal, located 4.2 kb upstream of the PSA promoter (Cleutjens et al. 1997) within a 440 
bp PSA distal enhancer. Five additional low affinity ARE’s, close to ARE III have also 
been located within the enhancer. They appear to participate in co-operative binding of 
multiple AR molecules to the PSA enhancer (Reid et al. 2001).
Multiple co-regulators and suppressors of the AR have been identified (Figure 1.5) Co­
regulator complexes modulate AR-mediated PSA activation by interaction with general 
transcription factors or by remodelling chromatin. Most co-regulators appear to function 
as co-activators of the AR. Amplified levels of co-activators could lead to activation of 
the AR by less potent or by lower levels of androgens (Gregory et al. 2001). Certainly 
over expression of two co-activators, TIF2 and SRC1 are associated with increased AR 
activation, even at physiological levels of androgen (Gregory et al. 2001).
It is known that mutations of the AR are often present in androgen independent prostate 
cancer (AIPC) (Taplin et al. 1995). These may alter the ligand specificity of the AR, 
leading to its activation by non-androgens. In addition, amplification of the AR has 
been found in the context of advanced or metastatic disease, and put forward as a
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potential mechanism underlying androgen independence (Visakorpi et al. 1995).
1.5.3.3 Growth Factors
Alternative pathways have been described whereby the AR may be activated or 
bypassed, allowing PSA transcription to occur (Feldman & Feldman 2001). A ligand 
independent activation of the AR: an “outlaw receptor pathway’’ (Culig et al. 1994) 
allows induction of PSA in the absence of androgen. Both growth factor-activated and 
receptor tyrosine kinase-activated pathways have been implicated. Insulin-like growth 
factor-1 (IGF-1) causes a five-fold rise in PSA secretion in LNCaP cells (Culig, 
Hobisch et al. 1994). Keratinocyte growth factor (KGF) and epidermal growth factor 
(EGF) are both ligands for receptor tyrosine kinases and initiate complex signalling 
cascades. Her-2/neu (c-erb-b2) is a member of the EGF-receptor family of receptor 
tyrosine kinases and has been shown to activate oestrogen receptor in the absence of the 
oestrogen ligand (Pietras et al. 1995). Over-expression of Her-2/neu can activate AR 
dependent genes, including PSA, in the absence of androgen, but not in the absence of 
the AR (Craft et al. 1999). This “outlaw” AR created by Her-2/neu over expression 
cannot be blocked by bicalutamide, an anti-androgen, showing that the pathway is 
separate to the AR ligand binding domain (Craft et al. 1999). Her-2/neu may also 
activate the AR through a mitogen-activated protein kinase (MAPK) pathway (Yeh et 
al. 1999). Another alternative pathway for Her-2/neu is by activation of the 
phosphatidylinositol/protein kinase B pathway (Zhou et al. 2000). The 3-phosphorylated 
inositols are second messengers that activate protein kinase B, which can phosphorylate 
the AR at two separate serine residues (Wen et al. 2000), turning it into an androgen- 
independent outlaw receptor.
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Transforming growth factor p (TGFp) has been found to be significantly elevated in 
patients with clinically evident metastases and correlated with increasing serum PSA 
levels (Ivanovic et al. 1995). It can enhance interaction between the AR and Smad3, a 
downstream mediator of TGFp in the prostate cancer cell lines LNCaP and DU 145 
(Kang et al. 2001). The addition of Smad3 also increased PSA expression.
Interleukin 6 (IL-6) can activate the androgen-responsive promoters in LNCaP cells in 
the absence of androgen and increase PSA mRNA levels. Bicalutamide, an anti­
androgen, abolished the IL-6 effect. In addition, pre-treatment with a MAPK inhibitor 
blocked the PSA rise secondary to IL-6, showing there is cytokine-mediated induction 
of the AR promoter (Lin et al. 2001).
The AR may be bypassed completely, facilitating PSA production and proliferation 
even in the absence of androgens and the AR. The anti-apoptotic gene Bcl-2 has been 
suggested as working this way in prostate cancer and has been found to be up-regulated 
in AIPC in both human and murine models (Colombel et al. 1993).
In summary, it is clear that the AR plays a vital role in PSA transcription and it may 
represent the key factor in the failure of PSA production in PSA-negative tumours.
1.5.3.4 Transcription Factors
It is likely that multiple transcription factors, some prostate specific, are involved in the 
regulation of the PSA gene.
A novel family of Protein Inhibitor of Activated ST AT proteins (where ST AT is a 
signal transducer and activator of transcription) have been found to both positively and 
negatively affect AR-mediated transcriptional activity of PSA. Whilst the members
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PIAS 1 and 3 enhance this transcription, PIASy is a potent inhibitor in prostate cancer 
cells (Gross et al. 2001).
GAT A transcription factors, which are known to have a role in general mammalian 
development (Simon 1995) have been implicated in the development of metastatic 
AIPC in a transgenic mouse model (Perez-Stable et al. 1997). Six GATA transcription 
sites which flank an ARE in the far upstream PSA enhancer (Schuur et al. 1996) are 
required for optimum PSA expression and stimulation by androgen. In particular, the 
GATA-binding proteins 2 and 3 appear to modulate androgen induction of the PSA 
promoter (Perez-Stable et al. 2000).
Other putative consensus sites for transcription factors have been identified on the PSA 
promoter that could potentially activate PSA expression by other signal transduction 
pathways. These include an API site, which partially overlaps with the ARE II. If the 
AP-1 family proteins (which include the jun and fos oncogenes) are elevated, AP-1 
may bind to its DNA-binding site and block the binding of the androgen receptor (Sadar 
et al. 1999). Another potential site of PSA regulation is the cAMP response element 
(CRE), located at -3196 of the PSA enhancer, because transcriptional factors responsive 
to cAMP, including activating transcription factor (ATF) and CREB can bind at this site 
(Sadar et al. 1999).
1.5.3.5 Non-Androgen Dependent Transcription Factors
A novel prostate derived Ets transcription factor (PDEF) has been shown to interact 
with the AR and play a role in PSA gene regulation. Ets factors play a crucial role in 
haematopoiesis, angiogenesis and organogenesis, and several distinct chromosomal 
translocations involving Ets factors have been discovered in human cancers (Graves &
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Petersen 1998). There are high affinity sites in the PSA promoter for PDEF and PDEF 
causes an 11-fold enhancement of PSA promoter activity in LNCaP cells, (a PSA and 
AR expressing prostate cancer cell line) in the absence of androgen. A 57- fold 
activation of the promoter activity was seen in the presence of both androgen and 
PDEF, showing that PDEF mediated PSA promoter transcription has both an androgen 
dependent and independent component (Oettgen et al. 2000).
P53, a known tumour suppressor gene, has been found to negatively regulate PSA 
expression, by blocking N-C interaction of the AR, thought to be responsible for 
homodimerisation of the receptor (Shenk et al. 2001). Gurova (2002) found that p53 
suppression in LNCaP cells caused a 4-8 fold increase in PSA protein. The inhibitory 
effect of wild-type p53 was reduced by trychostatin A, a potent inhibitor of histone 
deacteylases (Murphy et al. 1999), (see section 1.5.4) suggesting the involvement of 
histone deacetylation in negative regulation of PSA promoter activity.
A 45 base pair cell specific transcription factor (p45) has been found to bind to a 
specific 150 base pair region within the PSA distal enhancer. In the absence of 
androgen, and independent of the androgen receptor, this can cause activation of the 
PSA promoter (Yeung et al. 2000).
To summarise, multiple factors are involved in the control of PSA transcription. One 
possible explanation for PSA-negativity is an alteration in the AR itself, either structural 
or functional, or in the PSA promoter or enhancer regions.
1.5.3.6 Prostate Specific Autocrine Factors
In a similar fashion to their response to paracrine growth factors, there may be an
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autocrine mechanism involved, with interaction with co-activators of the AR and the 
receptor itself. This results in a highly transcriptionally active ARE III in the absence of 
androgen and other growth factors. One such protein has been termed NF-1 (nuclear 
factor 1) but remains to be fully characterised (Yeung et al. 2003).
1.5.4 Methylation and Deacetylation
In the normal mammalian genome, methylation occurs only at the 5’ of a cytosine base 
of a Cp (phosphate) G dinucleotide. Many CpG dinucleotides have been lost by 
spontaneous deamination, and the remaining CpG areas have a high frequency of 
methylation (Jones & Laird 1999). Methylation promotes structural chromatin changes 
which can block transcription and thus inactivate a gene. CpG islands are GC and CpG- 
rich areas of approximately 1 kb, comprising about 1% of the genome, and usually 
located in the promoters of so-called housekeeping genes, namely those responsible for 
cellular function (Larsen et al. 1992). They are typically unmethylated. DNA is 
packaged into chromatin, which is composed of histone proteins around which the DNA 
is coiled. The HDAC and HAT proteins act together to modulate chromatin structure 
and transcription, via histone acetylation (Roth et al. 2001). Deacetylation of histone 
proteins appears to be the initial step in the recruitment of methyltransferase to the CpG 
islands, leading to hypermethylation (Patra et al. 2001). DNA methyltransferase and 
HDAC1 have been found to be up-regulated in prostate cancer, implying a role in 
inhibition of transcription via methylation (Patra et al. 2001) and hypermethylation of 
the PSA gene or AR gene may be responsible for failure of PSA production. This will 
be explored in Chapter 6.
51
1.5.5 LOH
1.5.5.1 Definition
Loss of one allele at a locus often followed by duplication of information from the 
remaining locus.
1.5.5.2 LOH in Prostate Cancer
In early prostate cancer, the loss of genetic material is five times more common than 
DNA amplification, with loss at 8p and 13q seen most frequently (Elo & Visakorpi 
2001). LOH is an important factor in gene activity as it affects both number of gene 
copies and function. An illustration of LOH is shown in figure 1.6. LOH is a potential 
factor in loss of PSA expression and has never been previously studied in this context.
1.5.6 PSA Protein Degradation Pathways
Important degradation pathways for proteins exist in the cytosol, endoplasmic reticulum 
(ER) and in lysosomes. In the cytosol, degradation occurs on proteasomes, large protein 
complexes dispersed throughout the cell. Proteasomes act on proteins that have been 
specifically marked for destruction by the covalent attachment of a small protein known 
as ubiquitin. It is possible that a conformational change in the PSA protein makes it 
more vulnerable to ubiquitin-targeted proteolysis, and hence contributes to low serum 
PSA levels by increased protein destruction.
Newly synthesised proteins enter the biosynthetic-secretory pathway in the endoplasmic 
reticulum (ER). They are subsequently mobilised from the ER to the Golgi apparatus 
and hence to the cell surface or other compartment by transport vesicles. A short four- 
amino acid sorting signal, KDEL, mediates the retention of soluble resident proteins
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within the ER. If this signal is transferred to proteins that are normally secreted, they 
will be retained within the ER and hence their systemic levels reduced. Protein 
modification, including phosphorylation and glycosylation occurs within the Golgi 
complex and can confer functional advantages to the protein product. Although protein 
degradation occurs within the ER, lysosomes remain the main site of intracellular 
digestion. Multiple pathways are involved, including endocytosis. However, some 
proteins contain specific sequences on their surface that direct them selectively to the 
lysosomes for degradation. An alteration in the normal surface sequence of PSA, by 
mutation, may cause enhanced lysosomal proteolysis and hence a reduced serum level 
of the protein product.
1.5.7 PSA Protein Processing and Secretion
Like many other secretory proteins, PSA is synthesised as an inactive protein precursor 
from which active molecules have to be liberated by proteolysis. PSA is synthesised as 
pre pro PSA, a 261 amino acid preprotein, with a 17 amino acid signal sequence at one 
end. This sequence is cleaved forming pro PSA, an inactive precursor protein of 244 
amino acids (Lundwall & Lilja 1987) (Figure 1.7). A 7 amino acid activation sequence 
at the N terminal is subsequently removed by KLK2, cleavage usually occurring 
between arginine at position 7 and isoleucine at position 8, to produce the active 237 
amino acid form of PSA. This has 5 intrachain disulphide bonds and a single 
asparagine-linked oligosaccharide. PSA may also be activated by other prostate 
kallikreins including hK4 or prostase (Lundwall & Lilja 1987). The cleavages occur in 
the trans Golgi network and in the secretory vesicles. As described later, differential 
processing may occur resulting in varying isoforms. Once an extracellular signal is
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received, the secretory vesicles fuse with the plasma membrane to release their contents. 
Prostate secretory granules (PSG) act as reservoirs of PSA and prostatic acid 
phosphatase (PAP). These PSG’s are almost absent in malignant cells (Cohen et al.
2000) and alternative pathways exist for PSA secretion (section 1.5.6 )
In seminal plasma, about 30 % of PSA is the active enzyme, with a further 5 % in a 
complexed form with protein C inhibitor (PCI) (Mikolajczyk et al. 2000). The 
remainder of the PSA is composed of inactive forms, collectively known as benign PSA 
(bPSA) because of their anatomical location within the prostate transition zone and their 
relatively increased levels in BPH rather than in tumour (Mikolajczyk et al. 2000). They 
are created by internal cleavages between residues 85-86, 145-146, or 182-183.
In serum, the majority (70-90%) of PSA circulates as a complex with the serine protease 
inhibitor al-antichymotrypsin (ACT) (Lilja et al. 1991). Trace amounts are also bound 
to API (previously known as a  1-antitrypsin), ITI (interatrypsin inhibitor) or PCI. 
Another fraction of the PSA is bound to the 25-fold larger a2-macroglobulin (A2M) 
molecule. Because of its larger size, this completely encapsulates the PSA molecule, 
leaving no free epitope sites of PSA for detection and the PSA-A2M can only be 
measured by assay after the complex has been opened (Zhang et al. 1998). Free PSA 
(fPSA) represents 10-30 % of total PSA (tPSA). This is largely composed of the 
catalytically inactive forms (bPSA) produced by the internal cleavages as described 
above. As the level of these components is greater in benign tissue, and the serum level 
consequently higher in patients with BPH rather than tumour, the ratio of free to total 
PSA has been used as a discriminator between BPH and prostate cancer with lower 
ratios present in prostate cancer patients (Catalona et al. 1998). The molecular forms of
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PSA in prostate tissue, seminal fluid and plasma are summarised in table 1.2.
1.5.7.1 Mechanism of the Differential Expression of PSA in Cancer and Benign 
Disease
In prostate cancer, due to loss of the basal cell layer and disruption of the normal 
glandular architecture, there is a decrease in the luminal processing of both proPSA and 
of complexed PSA (ACT-PSA), and they are able to reach the circulation directly 
causing increased levels of both components in serum (Figure 1.8). In contrast, in 
normal tissue and in BPH, PSA reaches the circulation much more slowly by leaking 
“backwards” into the extracellular space where it is susceptible to proteolytic 
degradation (Stenman 1997). Chen et al (1997) predicted the existence of a protease 
substance in BPH nodules that was subsequently isolated from serum, and is responsible 
for the inactivation or “nicking” of PSA in BPH tissue. Such nicked PSA reacts poorly 
with ACT in vitro (Leinonen et al 1996). A higher level of nicked PSA in BPH may 
contribute to the reduced ability to form complexes with ACT. The reaction rates of 
PSA with inhibitors, together with the metabolic clearance rates of the different forms, 
determine the concentration of each form in circulation. PSA-A2M complexes are 
removed from circulation with a half -life of 2-5 minutes (Imber & Pizzo 1981). This is 
thus likely to be the major metabolic pathway for PSA reaching the circulation. Free 
PSA has a 1-2 hour half-life whereas PSA-ACT has a much longer half-life of 2-3 days 
(Bjork et al. 1998;Richardson et al. 1996).
The fact that PSA reaches the circulation by different routes in benign and malignant 
tissue may explain the comparatively higher levels of PSA in circulation in prostate 
cancer. It has been postulated that higher local ACT expression in prostate cancer could
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facilitate formation of PSA-ACT complexes (Bjork et al. 1994). However, the 
proportion of complexed PSA in serum is low in men without prostatic disease, 
although the expression of ACT is similar in normal and malignant prostatic tissue. The 
PSA reaching the circulation through the extracellular space is more extensively 
“nicked” and can form complexes less easily than that secreted directly into the blood 
stream.
Other potential explanations include increased production of active PSA from proPSA 
in cancerous tissue compared to BPH (Mikolajczyk et al. 2000). From proteomic 
studies, levels of ACT may be reduced in some prostate cancers (Meehan et al. 2002) 
which would affect the level of serum PSA detected by most assays. With these factors 
in mind, it is clear that any alterations in the processing of PSA, in the formation of 
complexes (due to changes in the levels of the co-complexors or because of structural 
mutations in the PSA protein), or in secretion itself may affect serum PSA levels. An 
alteration in the half life of PSA due to increased systemic proteolysis may also occur.
1.5.7.2 Relationship between Serum and Tissue Levels of PSA
The serum PSA level for an individual with prostate cancer is proportional to the size of 
the prostate gland (Partin et al. 1990), volume of BPH (Cadeddu 1995), and volume and 
differentiation of the tumour (Abrahamsson et al. 1988). An inverse relationship 
between Gleason grade of the cancer and levels of PSA in serum and tissue has been 
described (Aihara 1994). A further study by Weir (2000) corrected the serum PSA in 
radical prostatectomy cases for gland size and tumour volume and examined tissue 
PSA staining. They confirmed the relationship between serum total PSA and volume of 
prostate carcinoma and that an inverse correlation exists between corrected serum PSA
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density and Gleason score. They noted, however, that despite less serum PSA produced 
per gram of tumour, more poorly differentiated tumours of higher grades are associated 
with greater tumour volume, advanced stage and higher serum PSA (Partin et al. 1990). 
The positive relationship in these cases between serum PSA and Gleason score is thus 
mainly a function of tumour volume rather than tissue capacity for PSA production. 
This cannot explain the low PSA-negative tumours, where from the volume of 
metastatic disease one would expect serum PSA levels to be at least 100 ng/ml. Lack of 
correlation between serum and tissue PSA may relate to differences between the amount 
of PSA produced by prostate cancers and the amount secreted. In high volume disease, 
there is usually gross disruption of the architecture of the prostate gland, causing 
variations in the amount of PSA secreted into the systemic circulation. There may be 
variations between individual neoplastic cells in terms of their secretory regulation. In 
addition, there is often marked heterogeneity in tumours in terms of histological 
differentiation and the dominant clone may be primarily PSA negative at either tissue or 
serum PSA level, or indeed both. In the context of metastatic disease, the dominant 
clone may be in the primary tumour or in the metastasis.
1.5.7.3 PSA Isoforms
Truncated forms of proPSA, particularly those cleaved between leucine 5 and serine 6, 
termed [-2] pPSA are biologically inactive and circulate as part of the free PSA fraction 
in serum (Mikolajczyk 1997). They are assumed to result from post-translational 
proteolytic cleavage of the 7 amino acid leader sequence in proPSA. The same author 
found higher levels of this isoform in the fPSA fraction in biopsy positive patients with 
tPSA in the 6 to 24ng/ml range and these isoforms may be a useful adjunct to PSA 
testing. Monoclonal antibodies to [-7] pPSA, [-4] pPSA and [-2] pPSA have been used
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to examine cancer serum in patients with total PSA levels around 10 ng/ml. 
(Mikolajczyk 2001) confirming five-fold greater levels of [-2] pPSA in biopsy positive 
patients compared to biopsy negative patients. Similar results were shown for the other 
pPSA isoforms and they remain the source of ongoing studies. When used in 
combination with levels of bPSA, which is being evaluated as a potential marker for 
BPH, they may provide a more specific serum test for prostate cancer, particularly in the 
context of rising total PSA after definitive local treatment (Mikolajczyk 2002).
1.5.7.4 Confounding Factors Affecting Serum PSA Levels 
Biological
In an individual patient, serum concentrations of PSA vary with time (Prestigiacomo & 
Stamey 1996), with fPSA variation being greater than tPSA. The effect of ejaculation is 
small despite causing transitory rises in tPSA for up to a day (Herschman et al. 1997). 
Significant manipulation of the prostate by biopsy, cystoscopy and TRUS can cause 
rises in serum PSA although the effect of DRE is debated (Collins 1997).
Sample Handling
Storage of serum unfrozen may cause loss of PSA within a few days (Leinonen 1993) 
and this PSA decline has also been noted in samples stored for years at -20°C (Stenman 
et al. 1994). The initial changes in unfrozen sera are due to loss of free PSA and 
subsequently complexed PSA is also reduced, probably due to cleavage of ACT and the 
release of active PSA which then binds to A2M and becomes undetectable (Stenman et 
al. 1999).
Treatment of Benign or Malignant Prostate Disease
As PSA is an androgen-dependent gene (see section 1.5.3), serum levels of PSA fall
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significantly following medical or surgical castration and also decline subsequent to 
TURP. The use of finasteride in BPH causes a 50 % or so reduction in PSA after 6 
months of treatment by blockage of 5a-reductase II and PSA levels in patients receiving 
finasteride should be multiplied by two (Andriole 1998).
PSA Assays
Sensitive immunoassays are required due to the much lower levels of PSA in serum 
than in seminal fluid. The complexed forms of PSA tend to be underestimated 
especially by assays using polyclonal antibodies (Stenman 1991). This is because some 
of the antigenic sites on PSA are eliminated when it binds to ACT (Pettersson 1995).
PSA-ACT can be determined by using a sandwich assay with a catcher antibody to PSA 
and a detection antibody to ACT. However, the method is plagued by high levels of 
non-specific background staining (Leinonen et al. 1993). Similar sandwich assays have 
been developed for PSA-API (Zhang et al. 1996) and an immunoadsorption assay can 
be utilised for PSA-A2M (Zhang et al. 1998).
Assays however, demonstrate a huge variability in terms of the technique employed, 
and type of antibody used, which is further complicated by the number of commercially 
available assays. It is thus important for assay calibration standards to be performed, 
using such protocols as a standard composed of 90% PSA bound to ACT and 10 % free 
PSA. Other authors have suggested using a 100 % free PSA assay as a standard (Brawer 
et al. 1997). Difficulties arise when comparing sequential PSA results from the same 
patient performed using different assays.
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1.6 Alternative Markers for PSA-Negative Prostate Cancer
Given the absence of raised serum PSA levels, and the possible lack of tissue 
immunostaining, other serum and/or tissue markers may aid diagnosis and management.
1.6.1 PAP
Before PSA evaluation was available, serum PAP levels were routinely used to monitor 
prostate cancer (Gutman et al. 1936). However, in a study of 74 patients, serum PSA 
never lagged behind PAP in identifying recurrence/progression, and it preceded PAP 
rises in 90% of patients. Due to these findings, PAP has been replaced by PSA as the 
tumour marker of choice. It has, however, been postulated that PAP may have a role in 
bone metabolism, by acting on bone remodelling cells to facilitate the formation of 
blastic lesions (Bok & Small 2002). Within the osteoblast, phosphatase and calcium act 
on the mineral apatite to induce crystal growth and bone formation, with the subsequent 
release of PAP into the bloodstream. PAP and PSA levels are usually concordant in 
prostate cancer, but cases of advanced disease have been noted wherein serum PSA 
remained undetectable whilst PAP levels were elevated (Goldrath & Messing 1989; 
Leibman et al. 1995). Discordance of results at tissue level has also occasionally been 
described (Aihara et al. 1994). Immunostaining with PAP and PSA often shows marked 
heterogeneity within tumour populations, with scattered or groups of cells showing 
negative reactivity for either one or both markers (Keillor & Aterman 1987). There is no 
information on PAP levels either in serum or at tissue level in PSA-negative prostate 
cancer, and it may prove a useful diagnostic or response to treatment marker in either 
capacity.
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1.6.2 AR
The role of the AR in PSA transcription has been previously outlined (section 1.5.3.) 
Androgen receptor gene expression is amplified in AIPC (Linja 2001) with increased 
PSA-immunostaining seen in AR-amplified primary tumours (Koivisto & Helin 1999). 
One potential mechanism for the loss of PSA secretion in PSA negative tumours is the 
deletion, mutation or lack of function of the androgen receptor as described above. If 
this is indeed true, then immunostaining for AR will be absent. In addition, 
neuroendocrine cells lack AR (Bonkhoff et al. 1993) and hence AR loss may reflect this 
tumour subtype.
1.6.3 Kallikreins
The kallikrein family have been previously described in this chapter (Section 1.4.2) 
HK2 in particular, shows promise as an alternative tumour marker as it is both prostate- 
localised and tumour associated, although it has been shown to be expressed in breast 
tumours (Black. 2000). Nevertheless, there is 21% greater amplification at the HK2 
gene level in prostatic tumours (Herrala et al. 2001) and HK2 serum levels have already 
been shown to add significant information in the detection of prostate cancer 
particularly at low serum PSA levels (Kwiatkowski. 1998; Recker 1998). However, 
difficulties exist with regard to immunoassays for different molecular forms of HK2 
which has hampered large scale trials (Stephan et al. 2000).
1.6.4 PSMA
Prostate specific membrane antigen (PSMA) is a 100 kD type II integral membrane 
glycoprotein, expressed in all forms of prostate tissue, and over-expressed in prostate 
cancer (Israeli 1994). The gene, which is located on chromsome l ip  encodes for a
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protein consisting of a 19 amino acid internal portion, a 24 amino acid transmembrane 
portion and a 707 amino acid external portion (Leek 1995).
It appears to be up-regulated after androgen ablation (Wright, Jr. 1996) and is then 
correlated with androgen-independent progression (Murphy 1995). After examining 
bone marrow and serum from 50 patients with androgen-independent prostate cancer, 
Kim (2000) concluded that PSMA was a useful serum marker in AIPC with extensive 
metastatic disease but his work has not been duplicated as yet, primarily due to 
problems with antibody consistency. Alternative assay methods such as RT-PCR have 
been attempted which, despite improving sensitivity, are not sufficient to put into 
widespread clinical use (Murphy 1998) It is, however, a useful diagnostic tool when 
using a PSMA antibody complexed to Indium111 as a radiological marker, particularly in 
the context of possible recurrent disease after definitive primary treatment (Elgamal et 
al. 1998). As a tissue marker, however, it has been shown, albeit in small series, not 
only to consistently immunoreact with prostate cancer specimens but to be positive in 
cases where PSA staining was negative (Chang 2001a; Wright, Jr., Grob et al. 1996). 
Increased PSMA staining has also been documented in poorly differentiated 
adenocarcinomas rather than in well-differentiated tumours (Kawakami & Nakayama 
1997) and intensity of staining has been shown to correlate with the Gleason tumour 
score (Bostwick 1998 ;Burger et al. 2002). This latter author also found that prostate 
epithelial cells in most BPH did not express PSMA at a level detectable by 
immunohistochemistry. It is possible, therefore, that PSMA, may provide different 
diagnostic information in PSA-negative tumours.
1.6.5 AMACR
a-methylacyl-CoA racemase (AMACR) is a tissue marker that is significantly up-
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regulated in prostate cancer at both the RNA and protein level, showing 97% sensitivity 
and 100 % specificity for prostate cancer detection (Rubin 2002). No studies exploring 
serum levels are yet in place.
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1.7 Rationale for Thesis
Although men with treatment naive PSA-negative metastatic prostate cancer represent a 
small number of cases, they pose a significant management dilemma. Diagnosis is often 
difficult and treatment may thus be delayed. There is little information outlining their 
presentation and response to treatment and prognosis. They have been assumed to be a 
different entity to high PSA prostate cancer. The absence of a useful biochemical 
marker makes monitoring response to treatment extremely difficult. Their histological 
characteristics have not been established and the mechanism for PSA-negativity has 
never been established.
The main aims of the work presented in this thesis are:
1) To collect a tissue bank and clinical database of patients presenting with treatment 
naive metastatic prostate cancer and serum PSA < 10 ng/ml.
2) To describe the clinical presentation, response to treatment and prognosis of primary 
PSA negative metastatic prostate cancer.
3) To assess the expression of PSA and potential alternative tissue markers using 
immunohistochemistry.
4) To investigate the mechanism causing some prostate cancers to be PSA negative. 
Alterations in any one of three pathways is plausible:
□ Synthesis of the protein
□ Degradation and metabolism within the tissue
□ Secretion of PSA into the systemic circulation
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Due to constraints on time and access to tissue blocks, this work principally examines 
the control of PSA protein synthesis although all hypotheses are equally valid. The key 
factors in synthesis that are presented are:
□ The methylation status of the androgen receptor and PSA
□ LOH of PSA gene
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Table 1.1 Previous Studies of PSA-Negative Prostate Cancer (Serum PSA < 
lOng/ml)
Study No. Previous
Management
Pattern of 
metastases
Histology of 
primary tumour
Tissue PSA
Kageyama
1996
3 Treatment
naive
Bone 2 
Liver 1
Poorly
differentiated
All negative
Gaffney
1992
10 Treatment
naive
Metastatic Undifferentiated AH negative
Yamamo
to
2001
8 Treatment
naive
Bone 7 
Liver 1
Poorly 
differentiated 4 
Undifferentiated 2 
Heterogenous 1 
Moderately 
differentiated 1
Negative 3 
Positive 2 
No Tissue 3
Cohen
1995
8 Treatment
naive
Locally
advanced
Moderately
differentiated
AH negative8
Feiner
1986
7 Treatment
naive
Metastatic Undifferentiated Negative 6
Beado
2001
1 Radical
Prostatectomy
Bone Poorly
differentiated
Negative
Leibman
1995
2 Radical
Prostatectomy
Lung 1 
Brain 1
Poorly
differentiated
Positive 1 
Negative 1
Selia
2000
18 Androgen
independent
Liver 10 
Bone l l b 
Lung 6
Small Cell 6 
Poorly 
differentiated 2 
Both 10
Positive 11°
Negative 4C 
No Tissue 3C
a when monoclona PSA antibody used . 7/8 were positive with PSA polyc onal
antibody
b lytic rather than osteoblastic lesions 
c all positive for neuroendocrine marker
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Prostatic tissue Serum
Molecular
forms Carcinoma Normal/BPH Seminal plasma PCa patients BPH patients
7.25 pg/mg protein 20.2 pg/mg protein 0.2-5 g/liter, 30-50% enzymatically
active
5.58 pg/mg protein 15.1 pg/mg protein >95% of tPSA
0.019 pg/mg 
protein
0.068 pg/mg 
protein
0.008 pg/mg 
protein
0.099 pg/mg 
protein
TPSA
FPSA
ACT-PSA
CPSA
API-PSA
m-PSA
A2M-PSA
PCI-PSA
Nicked PSA Smaller proportion Higher proportion
ProPSA 3.0% of tPSA Small amounts
BPSA 4.33% of tPSA 11.4% of tPSA
2.0 pg/mg protein
Table 1.2 Molecular Forms of PSA (from Lilja et al 1991)
>2 pg/liter 1-20 pg/liter
Not detectable
Small amounts 
<5% of tPSA 
30% of tPSA 
Not detectable
5-30% of tPSA 10-50% of
70-95% of 
tPSA
70-95% of 
tPSA
3.2% of tPSA 
<1% of tPSA 
12% of tPSA 
Not detectable 
Small amounts 
25% of fPSA
tPSA
50-90% of 
tPSA
50-90% of 
tPSA
4.1 % of tPS A 
<1% of tPSA 
17%
4  Ctrtfromtr*
5 kb
TAP
4 6 kb 6.2 kb 5.8 kb 5.8 kb 5.1 kb 9.5 kb 10 5 kb 6 5 kb
KLK1
KLK15 r  PSA > ]r KLK2 >hK  KLK-L1 IrC KLK-L2 r <  Zyme
r . . . . . . . . . .KLK15 .... ......"VKLK3
V
KLK2 NJKLK4 \ l  ........KLKS NJ KLK* h <
HSCCE -//
23.6kb 
5.7 kb
1.5 kb 
7.1 kb
23.3 kb 
5.4 kb
13 3 kb 
5.3 kb
26.7 kb 
5.8 kb
31.9 kb
8.9 kb
5.9 kb 
6.3 kb
KLKT
6.3 kb 12.1 kb
5.4 kb
Nfeuropsin]- r < ^ ' KLK-L3 t|<  ~NES1 hr <  ' TLSP |~r<f KLK-ti KLK-L4 h \
KLK8 KLK9 KLK10 KLK11 KLK12 KLK13 I
KlK-16 SIGLEC-9
t >
43.2 kb
' ' ' 'KLK14
2.1 kb 4.5 kb 3.4 kb 1.6 kb 21.3 kb 12.9 kb
Figure 1.1 Gene Locus of the New Kallikrein Family Around Chromosome 19ql3.4 at a 300kb Region
Direction of transcription indicated by arrows. Boxes represent the former gene names. The new kallikrein name is shown below the
boxes. The genomic length of each gene is shown above the relative boxes. Distances between genes are shown between boxes. The 
kallikrein gene is framed by the Siglec and TAP genes 
(After Yousef et al 2001 and Stephan et al 2000)
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Figure 1.2 Gene Regulatory Elements in Transcription
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IARA.70
Target gene activation
phosphorylation
Co-activator
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Figure 1.3 Mechanism of Androgen Action
SHBG:sex hormone binding globulin; DHT:dihydrotestosterone;HSP:heat shock 
protein;AR:androgen receptor;ARA70:a co-activator o f the AR;GTA:general 
transcription apparatus;(derived from Balk et al, 2003)
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PSA proximal prom oter
distal
enhancer
(-400 to -365) 
ARR
I-------------\
GGATC 999 AGTCTC 
CCTAG cccTCAGAG
(-170 to -156) 
ARE TATA PSA coding
i------------------ 1
AGAACA gca AGTGCT 
TCTTUT cgtTCA CGT
PSA distal enhancer
weak ARE weak ARE
t----------------------- \
VI V IV
-4366*1 1 (  \   I >■
t----------------- \
GGAACA tat TGTATT 
CCTTGT ata ACATAA
ARE consensus: GG(A/T)ACA nnn TGTTCT
-3870
Figure 1.4 The M ajor Transcriptional Regions Regulating PSA Gene Expression
ARR:androgen responsive region. (ARE II at position -395) TATA: TATA box. 
ARE:androgen response element I at position -170. The distal enhancer is the major 
region controlling PSA transcription. It contains a central strong ARE (ARE III) closely 
related to the defined consensus ARE and multiple weak ARE.
(Derived from Balk et al, 2003)
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Androgen Receptor-Interacting Proteins
C o act iva torsC oreau la tors Other prote ins
Domain: N-terminus
ARA24/RAN BRCA1 Cyclin E 
RAF TFIIH , CAK RB 
ARNIP GAPDH TFIIF
(Gin), (Gly)n
hA R
DBD/Hinge
l ANPK 
I ARIP4 
PDEF I 
SNURF 
Ubc9  
I ARIP3 
c-iun 
iCalreticulin: 
RelA 
Filamen 
GR 
OCT-1/2
LBD
ARA54 ARA55 
GRIP-1 RIP140 
TIF2 Tip60 
ARA70 m Z a c lb  
F-SRC-1 
H s p s  Ydjlp
ARA160 CBP FHL2 535 625 Domain  u n know n 919
Interact with TRAM-1 E6-AP HMG-1/2
multiple d o m a in s
ERM TR4 ER-a Cyclin D1 BAG-1 L
Note: Prote ins  are g ro u p ed  by thcAR dom ain  with which  they  interact and may interact  
with more  than o n e  AR domain. The locat ion  of a particular protein therefore  d o e s  not L
indicate  its p r e c i s e  region of interaction with AR. S e e  list for more detai led informaton. 200(
GRIP1 SRC-1 TRAM-1
-
Figure 1.5 Proteins Interacting with the AR (from Androgen Receptor Database www.mcgill.ca/androgendb)
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LOH MSI
N T  N T
Figure 1.6 Schematic Illustration of LOH and Microsatellite Instability
LOH is seen as lack of one of the allelic bands in the tumour
(T) (arrow) as compared to the heterozygous normal tissue (N), and microsatellite
instability appears as new allelic bands in the tumour tissue (arrows).
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-22 -7 1
leader
sequence
237
hK2, hK4
propeptide: APLILSR
[-5JpPSA4 f[-2]pPSA
85-86 145-146 182-183
preproPSA
(inactive)
237
proPSA 
(inactive)
237
^  PSA
(active)
(inactive)arg phe iys-lys lys-ser
Figure 1.7 Structure of PSA Isoforms
Leader sequence on preproPSA is cleaved to generate proPSA, which is inactive. HK2 
cleaves the propeptide in the lumen, generating active mature PSA. Truncated forms of 
proPSA can also be generated by alternate cleavage of the propeptide, producing [-
2]pPSA and [-5]pPSA, which are inactive. Active PSA in the lumen of prostate ducts 
can be further cleaved at the indicated positions to generate inactive PSA. Active PSA 
in the bloodstream rapidly binds to protease inhibitor.
(After Balk, 2003)
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Figure 1.8 Model of the Metabolism of PSA in Extracellular Fluid and Circulation
PSA in normal and hyperplastic prostate leaks passively into extracellular fluid and the 
circulation. In cancer, it can be actively secreted due to disruption of normal 
architecture. “Nicked” PSA forms from further degradation of the active PSA and reacts 
slowly with A2M but not with ACT. Due to its rapid metabolism, formation of PS A- 
A2M appears to be the major catabolic pathway of PSA.
(After Stenman et al 1999)
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Chapter 2 Materials and Methods
2.1 Principal Techniques
2.1.1 Immunohistochemistry on Cells Grown on Coverslips
2.1.1.1 Cell Fixation.
After cells were grown in the appropriate conditions for the experiment using a 24 well 
plate, (section 6.3.1) the medium was aspirated from each well and the coverslips were 
rinsed twice in 1ml of 1 x PBS. One ml of ice-cold 1:1 acetone:methanol was then 
added to each well, and the plate left on ice for 10 mins to allow cell fixation. The 
coverslips were then rinsed twice with 1ml of 1 x PBS and if not used immediately, 
stored at 4°C in 1ml 0.1 % sodium azide in 1 x PBS to prevent microbial growth. Cells 
were stable for up to 1 month under these conditions.
2.1.1.2 Immunostaining
The Vectastain Elite® (Vector PK-6100) ABC kit was used for immunostaining. The 
system is based on the biotin/avidin system, using unlabelled primary antibody, 
biotinylated secondary antibody and an Avidin and Biotinylated horseradish peroxidase 
macromolecular Complex is formed, detected by diaminobenzidine tetrahydrochloride 
(DAB) as the chromagen. A fresh solution of 0.3% peroxide in 70 % methanol was 
prepared and 1ml added to each well to saturate any endogenous peroxidase to thus 
prevent background staining. The 24 well plates were incubated at room temperature for 
30 mins, then each coverslip washed twice with 1 x PBS for 5 mins. The coverslips 
were then incubated with normal horse serum (NHS) (Blocking serum, Vector S-2000) 
50|li1 in 2.5 mis of 1 x PBS at room temperature for 20 mins. After aspiration of the 
blocking serum and sequential washes with PBS, the coverslips were incubated with the
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primary antibody (mouse anti human) at the appropriate dilutions (section 4.3.2) for 1-2 
hours at room temperature. After sequential washes in 1 x PBS, the coverslips were 
incubated for 30 minutes at room temperature with biotinylated secondary antibody 
(horse anti mouse IgG), (Vector BA-1400) diluted lOpl in 1 ml of NHS. After 
sequential washes in PBS, the samples were incubated with VECTASTAIN Elite® 
reagent, a mixture of avidin DH and biotinylated horseradish peroxidase H for 30 mins 
at room temperature. After further washes with PBS, one drop of DAB solution, (DAB 
peroxidase substrate kit, Vector SK-4100) -a pre-prepared mixture of DAB, hydrogen 
peroxide and buffer- was added per coverslip and left until the desired stain intensity 
was obtained. This was achieved after ~ 3 mins. The DAB was aspirated, the coverslips 
washed with water and counterstained with Harris’s haematoxylin for 10 seconds then 
rinsed with water. The coverslips were then dehydrated by passage through sequential 
alcohols, washed in xylene to remove the alcohol and mounted on a glass slide using 
DEPEX (Gurr) mounting medium.
2.1.2 Immunohistochemistry on Formalin Fixed Paraffin Embedded 
Sections
2.1.2.1 VectaBond™ Slides for Immunohistochemistry
Clean glass slides were placed in a rack and immersed in acetone for 5 minutes. 7ml of 
VECTABOND™ (Vector) reagent treatment were added to 350 ml of acetone and the 
slide racks were submerged in this solution for 5 mins, then gently dipped into distilled 
water and left to air dry.
2.1.2.2 H&E Staining
Samples from prostatic resection or diagnostic biopsy were obtained as described in
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chapter 3. 3pm sections were cut onto non-bonded slides and stored at room 
temperature until required. The tissue sections were heated at 60°C in an oven for 30 
minutes, then de-waxed for 3 minutes in xylene twice, and taken through a series of 
graded alcohols to dehydrate. After rinsing in running tap water, they were then stained 
with the regressive stain Harris’ haematoxylin for 5 minutes, rinsed in tap water for 3 
minutes and placed in 1 % acid alcohol for 6 seconds to differentiate. They were then 
left in Scott’s tap water for 5 minutes, rinsed in tap water, counterstained with 1 % eosin 
for 5 minutes, rinsed in running tap-water for 60 seconds and then taken through a 
series of graded alcohols and xylene to dehydrate. Coverslips were then applied using 
DEPEX mounting medium.
2.1.2.3 Antigen Retrieval
3pm sections were cut onto VECTBOND-coated slides. For each antibody, a specific 
method of antigen retrieval was used (table 4.1). After dewaxing in xylene, the sections 
were taken through a series of graded alcohols to water. For PSMA, TIMP2, Bcl-2, 
MMP-2, FGF8 and FGFR, the optimum method of antigen retrieval was determined by 
using both of the microwave methods with each of the antigen retrieval solutions in 
turn, and then the pressure cooker method, to elicit the strongest degree of staining 
using positive controls. For the microwave method, the slides were placed in a rack in a 
large plastic container containing 600 mis of buffer (citrate, Dako pH 6.0 (S1699), 
Dako pH 9.9 (S3007) or Tris-EDTA buffer pH 9.0, (section 2.2.2) and microwaved at 
full power for 20 to 25 minutes, then the container was transferred to a sink of cold 
running water and allowed to stand for 10 minutes. For the pressure cook method, 3 L 
of citrate buffer pH 6.0 was placed in the pressure cooker, brought to boiling point and 
racks containing slides placed within and cooked at full pressure for 2 minutes. The
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slides were then cooled with running tap water.
2.1.2.4 Antibodies
After antigen retrieval, endogenous peroxidase activity was quenched by incubation 
with peroxidase blocking solution (DAKO S2023) and the slide rinsed with washing 
buffer (DAKO K5006). 200 pi of each primary antibody was incubated at the required 
concentration in antibody diluent (DAKO S2022) for 60 minutes at room temperature. 
The EnVision system (DAKO), which uses a one-step system for the secondary 
antibody and streptavidin-biotin complex, and reduces background staining from 
endogenous biotin, (Vyberg & Nielsen 1998) was employed for all 
immunohistochemical staining with the exception of PSMA. For the EnVision 
technique, the EnVision HRP rabbit/mouse reagent (DAKO K5007), containing dextran 
coupled to peroxidase and goat secondary antibody molecules against rabbit and mouse 
was incubated at room temperature for 60 minutes. The immunoperoxidase antigen- 
antibody reaction products were visualised by incubation in diaminobenzidine (DAB) 
for 10 minutes at room temperature. The tissue was counterstained with Harris’ 
haematoxylin for 2 minutes, dehydrated in alcohols and cleared in xylene.
2.1.2.5 Immunohistochemical Staining for Her-2/Neu
The Dako Hercept kit was used (A0485). After dewaxing in xylene, the sections were 
taken through a series of graded alcohols to water. 400mls of epitope retrieval solution 
(ERS) (Dako S1699) at a 1:10 dilution was heated for 12 mins at high power in an 
800W microwave, placed in a water bath and maintained at 98°C. Sections were briefly 
pre-warmed to 98°C in the water bath, before placing in ERS for 40 mins. The ERS 
container was removed from the water bath, left to stand for 20 mins and the slides
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rinsed in water, then in TBS/Tween (1 x TBS containing 0.1 % TWEEN) before 
incubation with peroxidase blocking solution for 5 mins. After rinsing in TBS/TWEEN, 
the pre-diluted 1/2000 Her-2 antibody was applied for 30 minutes. After further washes, 
the visualisation reagent was applied for 30 mins at room temperature, and a 10 minute 
incubation with DAB used to visualise the product as previously described. Sections 
were lightly counterstained with haematoxylin, washed in tap water and differentiated in 
1 % acid alcohol, then dehydrated in the ethanols and cleared in xylene. Coverslips were 
applied using DEPEX mounting medium.
2.1.3 Protocols for Cell Line Experiments
Unless otherwise stated, the constituents of all solutions are detailed in section 2.2.4
2.1.3.1 Cell Culture
Three immortalised prostate cancer cell lines were used: LNCaP - originally derived 
from a supraclavicular fossa node, which expresses PSA and a mutated form of the 
androgen receptor (Horoszewicz et al. 1983); DU 145 - derived from a brain metastasis, 
which expresses neither AR or PSA (Stone et al. 1978) and PC3-derived from a bone 
metastasis, which again expresses neither PSA or AR (Kaighn et al. 1979). All cell lines 
were obtained from Prof J Masters at the Prostate Cancer Research Centre. Cells were 
maintained in 5 mis RPMI complete medium in a T25 flask or in 15 mis of RPMI 
complete medium in a T80 flask. The medium was changed at 3 day intervals and the 
cells split using trysin-versene when 90% confluence was seen. Cells were maintained 
at 37°C with 4 % C 0 2.
2.1.3.2 Cell Counting
Cell culture was performed as outlined above. The medium was aspirated from each
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T80 flask and 3 ml of trypsin-versene added to detach cells. Trypsin-versene consists of 
0.5g/L of trypsin at a ratio of 1:250 of 0.2g/L of versene in buffered saline solution. 7 
mis of RPMI medium complete was added to terminate the reaction and the flask 
contents transferred to a 15 ml Falcon tube giving a cell sample suspended in 10 ml 
total. IOOjj.1 of cells in suspension was then added to 100(il 0.1 % trypan blue viability 
stain in a micro-centrifuge tube. The mixture was micro-pipetted onto the edge of a 
coverslip placed on a Neubauer® haemocytometer, allowing the suspension to be drawn 
under by capillary pressure, the cells counted and the number of cells per ml of solution 
calculated.
2.1.3.3 RNA Extraction Protocol
RNA extraction was performed using the RNeasy® mini kit (QLAGEN #74104)
The medium was aspirated from each T80 flask and 3ml of trypsin-versene added to 
detach the cells. 7 mis of RPMI complete medium were added to neutralise the trypsin 
and the suspension transferred to a 15 ml sterilin tube, and centrifuged at 1000 rpm at 
4°C for 10 minutes and the supernatant removed. The pelleted cells were then disrupted 
by adding 350pl of Buffer RLT (#79216), which had been previously made stable by 
the addition of lOpl of p-Mercaptoethanol per 1ml of buffer RLT. Buffer RLT 
inactivates RNases to ensure isolation of intact RNA. Samples were vortexed and 
pipetted onto QIAshredder columns (#79654) and centrifuged for 2 mins at maximum 
speed to homogenise the cell lysate. 350|il of 70 % ethanol was added to the lysate to 
provide appropriate binding conditions and the sample applied to an RNA mini spin 
column in a 2 ml collection tube, and centrifuged for 15 seconds at 10,000 rpm. 700pl 
of Buffer RW 1 (provided in kit) which acts as a DNA-ase, was added onto the RNeasy
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column, centrifuged for 15 secs at 10,000 rpm to wash and the flow-through discarded. 
After transferring the column to a new collection tube, 500pl Buffer RPE (provided in 
kit) was added, and the column centrifuged for 15 secs at 10,000 rpm to wash and the 
flow-through discarded. 500|l x 1 Buffer RPE was added, and the column centrifuged at 
10,000 rpm speed for 2 mins to dry the membrane and ensure no residual ethanol was 
present. The column was transferred into a new collection tube, 30pl of RNase-free 
water added, and centrifuged for 1 min at 10,000 rpm to elute. Samples were stored at 
-70°C.
2.1.3.4 RT-PCR
Reverse Transcriptase to Synthesise First Strand cDNA.
A 12 pi RNA / water mixture was made in a microcentrifuge tube with the following 
constituents:
lpg extracted RNA stored as Xpl volume** 
lpl oligo (dT) 0.5pg/ml (Invitrogen Y01212)
12jnl -  (1+Xpl) of RNase free water (section 2.2.2)
**The RNA concentration was calculated using the OD obtained using the 
spectrophotometer. This provided a pg per pi concentration, giving a value of Xpl 
containing lp l of RNA.
The RNA was heated for 10 mins at 70°C in a thermocycler then maintained on ice.
The following components were added to the mixture:
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4 pi 5 x first strand buffer (Invitrogen Y00146)
2|il 0.1 M DTT (Invitrogen Y00147)
ljLil 10mM dNTP (nucleotide triphosphates) mix (section 2.2.2)
The mixture was incubated at 42°C for 2 minutes, and 1 pi of Superscript II RNaseH 
reverse transcriptase (Invitrogen 18064-014, 200U/pl) added. The mixture was then 
incubated at 42°C for 50 minutes, heated at 70°C for 15 minutes to inactivate the 
reactions and the resulting cDNA stored at -20°C.
For all experiments an additional control tube was set up containing no RNA to ensure 
validity of the method.
Polymerase Chain Reaction (PCR)
A 50 pi master mix for each primer was made with the following components 
maintained on ice throughout:
3pl cDNA
5 pi 10 x Buffer IV (AB-0289)
3 pi MgCl2 (25mM)
5 pi dNTP mix (section 2.2.2)
2pl Primer 1 (sense)
2pl Primer 2 (antisense)
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29.5jil RNase free water
0 .5j l i 1 Red Hot ® DNA polymerase (Taq) thermus icelandicus (AB-0406/B)
To the above reaction mixture, one drop of mineral oil was carefully layered over to 
prevent evaporation of PCR products.
For all PCR experiments, a negative control containing reagents only was set up to 
ensure no contamination of the technique had occurred.
PCR conditions were optimised for each experiment. The general conditions used were: 
DNA denaturation/7V/g activation 2 min 95°C
DNA denaturation 45 secs 95°C -\
X 36 
cyclesPrimer annealing 45 secs 60°C
Extension 45 secs 74°C
Final extension 10 min 72°C
2.1.3.5 Gel electrophoresis
Gels of the following composition were used:
200ml 1.5 % agarose gel for 28 well gel
3 g agarose (Cambrex BioScience 44366) was dissolved in 200 mis 1 x TAE (Section 
2.2.2). 5|il per 100ml Ethidium bromide (10 mg/ml solution) was added (to allow bands 
of DNA to be visualised against a background of unbound dye). After the addition of 
appropriate amounts of PCR-product and loading buffer, (section 6.3), the gel was run
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in an electrophoresis tank using 1 X TAE as running buffer to optimise product 
separation.
100 ml 1.5 % agarose gel
1.5 g agarose dissolved in 100 mis 0.5 x TBE with ethidium bromide added as before 
and 0.5 x TBE used as the running buffer.
2.1.3.6 Western Blotting
Unless otherwise stated, the constituents of all solutions are detailed in section 2.2.4 &
5.
Protein Extraction
Cells were trypsinised, washed twice with 1 x PBS, once in complete RPMI medium, 
spun and the pellet collected and kept on ice. 400pl of RIPA (radioimmunoprecipitation 
assay) lysis buffer was added to each tube, vortexed and left on ice for 15 minutes. 
Samples were vortexed, spun at 10,000 rpm in a microcentrifuge for 10 mins at 4°C and 
the supernatant protein extract kept on ice or stored at -70°C. Protein concentrations 
were quantitated using the Sigma Diagnostics Lowry method protein assay kit (P5656). 
A standard protein concentration curve was constructed using the protein standard 
solutions supplied, and the protein concentration of each sample measured with a 
spectrophotometer set at 500 nM wavelength read from the standard curve.
The lysates were separated using a 13 % gel or 8 % gel depending on the protein size. 
The stacking gel was poured onto the resolving gel, the comb inserted and left to set. 
50p,g of protein were loaded per well, made up to 20pl with RIPA buffer and lOpl 1 x 
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) loading
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buffer. SDS is an anionic detergent which denatures proteins. Samples were heated for 6 
mins at 96°C and loaded onto the assembled gels in the electrophoresis tank filled with 
SDS-PAGE running buffer. Samples were run for 90 mins at 100 V. 10pl of a Rainbow 
™ protein size marker (Amersham) was run alongside the samples. The proteins were 
transferred from the gel onto a PVDF (polyvinylidine difluoride) membrane in a 
blotting apparatus filled with 1 x transfer buffer overnight at 40V at 4°C.
The following day, the blot was incubated with blocking solution at room temperature 
for 60 mins on an orbital shaker to block non-specific binding. It was then incubated 
with primary antibody, (anti-AR, anti-PSA, or anti-actin) at the appropriate dilution 
(Section 6.3) in 4ml of 1 % milk protein:PBS, for 60 mins at room temperature on an 
orbital shaker. After washing with PBS-TWEEN , the membrane was incubated in a 
secondary antibody solution consisting of 1/5000 dilution of HRP-conjugated anti­
mouse IgG in 1 % milk protein, for 60 minutes at room temperature on an orbital shaker. 
After further washes with PBS-TWEEN and PBS alone, the blots were developed using 
the Supersignal® WestPico chemiluminescent substrate kit (Pierce 34080). If no signal 
was seen after developing the film after 5 or 30 mins exposure time, the blots were 
exposed overnight at 4°C.
2.1.4 LOH Protocols
2.1.4.1 DNA Extraction of Microdissected Specimens
Samples from prostatic resection or diagnostic biopsy were obtained as described in 
section 4.3 and Laser Capture Microdissection (LCM) performed as detailed in section 
5.3.2. Two methods of DNA extraction were employed.
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DNeasy® (QIAGEN #69504) Tissue Kit Method
The kit allows extraction of purified DNA free from contaminants and enzyme 
inhibitors. 180|il of Buffer ATL (tissue lysis buffer #19076) and 20 pi of proteinase K 
(20mg/ml #19131) to cause direct cell lysis were added to a clean 0.5pl Eppendorf® for 
each microdissected sample. The LCM cap was transferred to the eppendorf, firmly 
inserted and the eppendorf vortexed and inverted to ensure maximum contact of the 
microdissected cells with the tissue lysis solution. The samples were placed in a 
humidified oven at 55°C overnight. The buffering conditions subsequently optimise 
selective DNA binding to the DNeasy membrane. The following day, the samples were 
vortexed for 15 seconds and 200pl of buffer AL (#19075) added to each tube, vortexed 
and incubated at 70°C for 10 minutes. 200pl of 100 % ethanol were added, the samples 
vortexed and pipetted onto a DNeasy mini column sitting in a 2 ml collection tube, 
centrifuged at 8000 rpm for 1 minute and the flow-through discarded. 500pl of wash 
Buffer AW1 (#19081) was added, the samples centrifuged at 8000 rpm for 1 minute and 
the flow-through discarded. 500pl of wash buffer AW2 (#19072) was added, 
centrifuged for 3 minutes at 10,000 to dry the membrane and the flow-through 
discarded. The column was placed in a new microcentrifuge tube, and lOOpl of Buffer 
AE (#19077) added to the membrane to elute. Samples were then incubated at room 
temperature for 1 minute, centrifuged at 8000 rpm for 1 minute and the elutate stored at 
-20°C.
In-House Protocol for DNA Extraction
Protocol obtained from Breakthrough Breast Cancer Laboratories, Institute of Cancer 
Research.
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A sterile solution of proteinase K extraction buffer was made, using 50mM KCL; 
lOmM Tris-HCL, pH 8.0; 2.5 mM MgCl2; 0.1 mg/ml gelatin; 0.45% NP40; 0.45% 
Tween 20. Proteinase K (PK) (Invitrogen # 25530049, 20 mg/ml) was diluted 1:40 in 
proteinase K extraction buffer and 20|xl of the PK/ buffer solution added to a clean 
0.5ml eppendorf. The LCM cap was then transferred to the eppendorf, pushed in tightly 
and inverted to ensure contact of the microdissected cells with the extraction solution. 
Samples were incubated overnight at 55°C in a humidified chamber. The following 
morning, the tubes were microcentrifuged for 30 seconds at maximum speed to spin 
down the solution, and placed in a thermocycler at 95°C for 10 minutes to inactivate the 
PK. The samples were microcentrifuged for 1 minute at maximum speed, the eluted 
DNA pipetted into a fresh tube and stored at -20°C.
2.1.4.2 PCR using LOH PSA Primer
A 15pl reaction mix was made with the following constituents:
1.5pl 10 x Reaction buffer (contains 750 mM Tris-HCL, pH 8.8)
6.1 pi Distilled water 
1.5|ul dNTP 1:10 dilution 
1.5|il MgCl2
1.6pl PSA Primer sense (forward microsatellite marker) 5(iM concentration 
1.6fil PSA Primer antisense (reverse microsatellite marker) 5|nM concentration
0.2|il AmpliTaq Gold (ABI 4311806)
l.Ofal DNA
AmpliTaq Gold is a heat stable DNA polymerase obtained from the Thermus Aquaticus 
bacterium. AmpliTaq Gold® DNA Polymeraseis a chemically modified form of 
AmpliTaq® DNA Polymerase.When the chemical moiety is attached to the enzyme, the 
enzyme is inactive. During set-up and the first ramp of thermal cycling (when the 
reaction is going through non-optimal annealing temperatures), the enzyme is inactive. 
The result is that mis-primed primers are not extended. When the reaction reaches 
optimal annealing temperatures, the chemical moiety is cleaved during a heat activation 
step, releasing active AmpliTaq® DNA enzyme. The yield of specific product increases 
because reactants are not wasted in the formation of unintended products. AmpliTaq 
Gold® DNA enzyme's chemical hot-start capability can release active enzyme in a 
"time-release" manner. With or without a limited up-front heat activation step, active 
enzyme is released slowly during thermal cycling to match template concentration and 
increase specificity.
To the above reaction mix, one drop of mineral oil was added to each eppendorf to 
reduce evaporation of the PCR products. Optimisation of the PCR conditions is 
described in section 6.3.2.
The final conditions used were as follows:
DNA denaturation/7ag activation 15 mins 95°C
DNA denaturation 45 secs 95°C
Primer annealing 45 secs 58°C X 50 
cycles
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Extension 45 secs 74°C
Final extension 10 min 72°C
The sequences for the PSA LOH primers were as follows:
Forward primer GGAGCTCTGACTCAGTTCTACTCTATC;
Reverse primer GACTGAGACATCCTCTCCCACCAT. The forward primer was 
labeled with FAM (6-carboxyfluorescein) to give a blue identification line on analysis.
Two controls were used throughout: LNCaP DNA as a positive control and reagents 
only as a negative control to ensure there was no contamination of the reaction.
2.2 Reagents & Buffers
2.2.1 Reagents for Immunohistochemistry
2.2.1.1 Harris Haematoxylin
lOg Haematoxylin powder
40ml Acetic acid
50ml Ethanol
Made up to 1L with distilled water.
2.2.1.2 Scott’s Tap water
7g Sodium bicarbonate
40g Magnesium sulphate
2L Tap water
2.2.1.3 Acid Alcohol 1 %
99ml 70% alcohol
lml Concentrated HC1
1% Eosin (lg  Eosin, 100ml Distilled water)
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2.2.2 Buffers for Immunohistochemistry
2.2.2.1 Tris Buffered Saline (TBS) pH7.4
80g Sodium chloride
6.05g Tris (tris hydroxymethylamine)(Sigma)
44ml 1M HC1
10L Distilled water
pH to 7.4 with 1MHC1.
2.2.2.2 Citrate Buffer pH 6.0
29.4g Sodium citrate (BDH)
54ml 1M HC1
10L Distilled water
pH to 6.0 with 1M HC1.
2.2.23 EDTA Buffer pH 8.0
18.61g EDTA
52ml lM NaOH
5L Distilled water
pH to 8.0 with lMNaOH.
2.2.2.4 Tris-EDTA Buffer (X10 concentrate)
12g Tris
lg EDTA
10ml 1M HC1
500ml Distilled water
Keep refrigerated. Dilute 1/10 with distilled water and pH to 9.9 before use.
2.2.3 Reagents for Tissue Culture and Molecular Biology
2.2.3.1 RPMI Complete Medium
500ml RPMI- 640 medium without L-glutamine (Invitrogen 31870-025)
5ml L-Glutamine (stock 200 mM concentration)
40ml Foetal calf serum (stock)
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2.2.3.2 RNase-Free Water.
lml DEPC (diethyl pyrocarbonate) (Sigma) to 100ml distilled water
Shake vigorously, incubate for 12 hours at 37°C then autoclave for 15 minutes to 
remove DEPC traces.
2.2.3.3 dNTP for RT
10pl of lOOmM stock solution of each dNTP (Invitrogen) (dATP, dCTP, dGTP, dTTP) 
added to 60pl RNase free water
2.2.3.4 dNTP for PCR
lOjul of lOOmM stock solution of each dNTP (dATP,dCTP,dGTP,dTTP) added to 460pl 
RNase free water , vortexed.
2.2.4 Buffers for Tissue Culture and Molecular Biology 
(Electrophoresis)
2.2.4.1 0.5x TBE (Tris-Borate EDTA)
Diluted from lOx TBE stock (Promega V4251)
2.2.4.2 50x TAE
242g TRIS Base (Sigma)
57.1ml Glacial acetic acid
100ml 0.5M EDTA pH 8.0 (Merck)
Diluted to lx
2.2.5 Reagents for Western blotting
2.2.5.1 5x PBS (Phoshate Buffered Saline)
42.5g Sodium chloride
32.4g Disodium hydrogen phosphate
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0.78g Sodium phosphate
Made up to 1L with ultrapure water, pH 7.3 ( de-ionised, RNA-ase free water)
2.2.5.2 20x TBS (Tris Buffered Saline)
60.6g Trizma hydrochloride (Sigma)
13.9g Trizma base (Sigma)
87.6g Sodium chloride (Sigma)
500ml Ultrapure water
2.2.5.3 RIPA Lysis Buffer
50mM Tris-HCl pH 8.0
150mM NaCl
5mM EDTA
1% (volume/volume) NP 40 (USB)
0.5% (weight/volume) sodium deoxycholate
0.1% (weight/volume) SDS (USB)
10% (volume/volume) glycerol
Immediately before using, the following protease inhibitors were added to the RIPA 
solution:
Phenylmethylsulphonyl chloride (PMSF) ImM, aprotinin (lOpg/ml), leupeptin 
(10pg/ml), and pepstatin (10pg/ml),
2.2.5A SDS-PAGE Gel Loading Buffer
4ml Distilled water
lml 0.5M Tris pH 6.8
0.8ml Glycerol
1.6ml 10% SDS
0.4ml 2-mercaptoethanol
0.2ml 0.2% bromophenol blue
2.2.5.5 5x SDS-PAGE Running Buffer
7.5g Tris base
36g Glycine
2.5g SDS
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2.2.5.6 lOx Transfer Buffer for Electroblotting
15g Tris base (Trishydroxymethylmethylamine-BDH)
72g Glycine
10% Methanol
2.2.5.7 Blocking Solution
5% Milk protein (Marvel)
made up in:
500ml lx PBS
0.5 ml TWEEN-20 (polyoxyethylene (20) sorbitanmonolaurate-BDH Lab Supplies)
2.2.5.8 Stacking Gel
3 ml Water
0.67ml 30% acrylamide mix
0.25ml 1M Tris, pH 6.8
40jil 10% SDS
40pl 10% ammonium persulphate (APS)
6pl TEMED
2.2.5.9 Resolving Gels
15% 8%
Water 2.5ml 4.6ml
30% acrylamide 5mls 2.7ml
1.5mM Tris buffer pH 8.8 2.5ml 2.5ml
To the above, lOOpl 10% SDS, lOOpl ammonium persulphate and 6pl of TEMED 
(Sigma-tetramethylethylenediamine, to catalyse acrylamide polymerization) were 
added, and 3.5 ml thin gel poured into the assembled gel plates, which were left for 30 
minutes to polymerize.
2.3 Chemicals & Reagents Suppliers
Applied Biosystems (AB) Foster City, California, USA
Amersham Biosciences, Piscataway, New Jersey, USA.
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Biocarta US, San Diego, California, USA 
BDH (VWR-International Ltd), Poole, Dorset, UK 
Boehringer-Mannheim, Germany
Cambrex Bio Science Verviers, S.P.R.L., Verviers, Belgium. 
DakoCytomation, Glostrup, Denmark 
Invitrogen Life Technologies, Paisley, UK.
Merck & Co Inc, New Jersey, USA 
Monosan, Uden, The Netherlands.
Pierce Biotechnology Inc, Rockford, IL, USA
Qiagen Ltd, Crawley, West Sussex, UK
Santa Cruz Biotechnology, Inc., Santa Cruz, California, USA
Sigma Diagnostics, St Louis, Missouri, USA.
Vector Laboratories, Burlingame, California, USA
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Chapter 3 The Clinical Features of Patients Presenting with 
Treatment-Naive Metastatic Prostate Cancer and Serum 
Prostate Specific Antigen (PSA) < 10 ng / ml - the “PSA- 
Negative” Patients
3.1 Introduction
As previously outlined, the level of serum PSA usually correlates with the volume of 
tumour present, hence in the great majority of patients with metastatic disease, PSA is 
markedly increased (Daver et al. 1988). Typically less than 1 %, (Oesterling 1993) 
present with abnormally low serum levels of PSA, below 10 ng/ml. (“PSA-negative” 
disease) (Oommen et al. 1994;Wolff, Zimnyet et al. 1998;Yamamoto et al. 2001b). 
Information on this patient group is sparse, though an association with high tumour 
grade (Gleason 8-10) has been described (Pantelides et al.l992;Partin et al. 1990).
Overall survival is anecdotally thought to be poorer than for patients with PSA-positive 
metastatic prostate cancer (Yamamoto et al. 2001a). The disease is thought to represent 
a different clinical entity, with a pattern of metastatic disease unlike that of high PSA 
tumours, showing an increased number of visceral and soft tissue metastases (seen in up 
to 55 % of patients) and non-typical pattern of bone disease (Sella et al. 2000). 
However, this data is obtained from patients with androgen-independent clinically 
progressive disease, rather than from patients presenting as treatment naive metastatic 
prostate cancer with low serum PSA.
3.2 Aims
The aim of this study was to describe the clinical features of patients presenting with
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metastatic prostate cancer and serum PSA levels of less than 10 ng/ml, in the largest 
group thus far characterised.
3.3 Materials and Methods.
Patients presenting with histologically proven untreated metastatic prostate cancer and a 
serum PSA of < 10 ng / ml were identified from the British Association of Urological 
Surgeons (BAUS) Cancer Registry. Data was collected from patients who presented in 
2000 and 2001. All database information was anonymised, with the patient identifiable 
by hospital ID and date of birth, referring consultant and referring centre. Details on 
stage, grade of tumour, presenting PSA and treatment decision were extracted. There 
was no policy of exclusion of cases with neuroendocrine histology. Referring 
consultants were contacted by post, and asked to forward consent forms and study 
information sheets on to patients. Copies of the patient information sheet, consent form 
and letters to the urologists, patients and pathologists can be seen in Appendix 1. 
Agreement had been previously obtained from the Multi Centre Research Ethics 
Committee that consent was not needed from next of kin where patients had died. 
Patients were also identified from local referrals to uro-oncologists at the Meyerstein 
Institute of Oncology at the Middlesex Hospital. Approval for this study was given by 
the Joint UCL / UCLH Committees on the Ethics of Human Research (Study number 
01/0215) and the South East Multi-Centre Research Ethics Committee (MREC 
02/01/16).
One investigator (AJB) then reviewed the patient’s notes at centres nationwide. 
Presentation, pattern of metastases, initial PSA, histology, treatment and treatment 
response times, and overall survival were reviewed. Hall’s definition of clinical
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progression as “new symptoms or signs, or worsening of those already existing, clearly 
attributable to prostate cancer” was used (Hall 1997) together with the time to first 
subjective progression, evaluated using similar criteria for response as in the EORTC 
Phase III 30853 study of hormonal therapy in metastatic prostate cancer (Denis, 
Carnelho de Moura et al. 1993). In this study, subjective progression was defined as a 
progression of urological symptoms with the appearance of severe symptoms requiring 
surgical relief or catheterisation, weight loss of more than 10% within one year, or 
deterioration of WHO performance status. An increase in pain score as reflected by a 
step up in the WHO analgesia classification and ladder (Ventafridda 1985) was also 
considered to reflect progression. If sequential radiological assessment was performed, 
progression was defined as the appearance of new lesions on bone scan or new lesions 
on X-ray film, or a greater than 25% increase in index lesions measured as the sum of 
products of the largest perpendicular diameters. PSA response, which is often used as a 
surrogate marker for treatment response, was inappropriate for this study. Survival 
curves were plotted using the Kaplan-Meier method. Archival prostate blocks were 
obtained for a pathological and morphological review at the department of 
Histopathology, University College London Hospital.
3.4 Results
3.4.1 Cases Collected
60 cases were identified from the BAUS Cancer Registry, from 2708 cases of metastatic 
prostate in total diagnosed during the 2000 and 2001 database collection period, the 
PSA-negative group hence representing 2.21% of the total number of registered cases. 
41 replies were elicited for these 60 cases. Of these, 14 cases were excluded either 
because review of the clinical notes revealed that the serum PSA was greater than 10 ng
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/ ml (range 22.1-121) at presentation, lack of evidence of metastatic disease, equivocal 
diagnosis of prostate cancer, or refusal by the consultant to approach the patient for 
consent (due to such factors as terminal illness). Six other cases were collected from 
referrals to the local cancer centre at the Meyerstein Institute of Oncology. 33 sets of 
clinical case notes were reviewed. Three additional cases registered as having 
neuroendocrine differentiation were omitted as clinical case notes were missing and / or 
no pathology blocks were available.
3.4.2 Patient Demographics
The median age was 67 years (range 48-81 years) with median serum PSA at 
presentation of 3.5 ng/ml (range 0.1-9.8) (Table 3.1). The median age of the group was 
slightly lower than that of prostate cancer overall (72.3 years) (BAUS Section of 
Oncology 2002). No patient had a prior history of pelvic radiotherapy. The presenting 
features, pattern of metastases and extent of local disease are summarised in Table 3.1. 
The pattern of bone disease was typical of prostate cancer, predominantly affecting the 
axial skeleton, pelvis and long bones.
3.4.3 Histopathology
Histopathological confirmation of disease was obtained in all patients; 57 % of patients 
were diagnosed on needle biopsy, while the others had transurethral resection of the 
prostate for symptoms and diagnosis (Table 3.2). Referral pathology reports suggested 
that the Gleason scores for the PSA negative group were only slightly higher than those 
for all metastatic prostate cancer patients on the BAUS cancer registry (Figure 3.1). On 
review by a specified urological histopathologist (AF), 25 cases (76%) had high grade 
cancers with mean Gleason score of 9 (Table 3.2). None showed neuroendocrine
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differentiation.
3.4.4 Treatment
All patients received hormonal manipulation as primary therapy (Table 3.3) with a 
subjective response rate of 73 %. Benefit in responding patients was symptomatic 
(80%), with either a reduction in the amount of analgesia required, or improvement of 
performance status. One patient received initial hormones as part of an intermittent 
hormonal study, which were then discontinued until rising PSA. 23/33 (69%) patients 
received palliative radiotherapy for symptomatic bone pain or spinal cord compression, 
with 3 patients receiving palliative prostatic radiotherapy to improve haematuria and 
perineal pain.
3.4.5 Responses to Treatment
Symptomatic response durations to primary treatment were 0-14 months with a median 
time to progression of 7 months (Figure 3.2). Subsequent treatment was most frequently 
(36%) the combination of an LHRH agonist and non-steroidal anti-androgen (maximal 
androgen blockade, MAB). Third line hormone therapy was commenced in 12 % of 
patients. 5/33 (15%) patients received chemotherapy (Table 3.3).
No evidence of symptomatic benefit was seen in 83 % of patients placed on maximal 
androgen blockade or in any of those commenced on third line hormones. Three 
symptomatic and radiological responses were seen in the five patients treated with 
chemotherapy (1 with single agent mitozantrone, 2 with epirubicin, carboplatin & 5- 
fluorouracil), but relapse occurred shortly after completing treatment (3-7 weeks). The 
number of chemotherapy cycles ranged from 3 to 6.
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The frequency of serum PSA estimation subsequent to the initiation of treatment varied 
considerably. PSA levels fell from the baseline values in 6 cases, but an association 
between fall in PSA (i.e. within the 0-10 range) and improvement in clinical symptoms 
was seen in only 2 patients. In only 2 patients did PSA values rise above 10 ng / ml (to
27.8 and 43.1 respectively) at any time during the course of their disease. 
Hypercalcaemia was seen in 3 cases (9%), either at initial presentation or during disease 
progression.
3.4.6 Survival
Median overall survival was 12 months with a range of 1 -36 months (Figure 3.3). All 
22 deceased patients died of their disease. With a median follow-up of 19 months, 11 / 
33 (33%) patients remain alive, 7 with progressive disease and 4 (12%) alive and well.
3.5 Discussion
Metastatic prostate cancer that is “PSA-negative”, presenting with abnormally low 
levels of PSA accounts for only a small proportion of patients, but presents a significant 
management dilemma. This study has described the clinical features from the largest 
series so far documented. The median age of the group was slightly lower than that of 
prostate cancer overall (67 years versus 72 years) (BAUS Section of Oncology 2002). 
The presenting symptoms were typical of metastatic prostate cancer in general, and 
most patients presented with symptoms of advanced local disease or symptomatic bone 
metastases. Despite reported rates of soft tissue metastases of up to 55% (Sella et al. 
2000) there was a relatively low rate (30%) of non-bone disease, either visceral 
metastases or non-regional lymph nodes metastases in this study.
In the staging of newly diagnosed cases, various studies have recommended a threshold
101
below which imaging investigations are unlikely to reveal metastases. In a study of 861 
men with a PSA below 20 ng / ml, eight (0.9%) had positive bone scans and 13 (1.5%) 
had CT- defined nodal disease (Levran et al. 1995).
It has been proposed that an undifferentiated component correlates with non­
responsiveness to hormonal therapy (Gaffney et al. 1992) and other series have been 
composed almost exclusively of poorly differentiated and undifferentiated tumours 
(Yamamoto et al. 2001a). In 3 cases of metastatic prostate cancer with serum PSA < 10 
ng / ml, all tumours were of high Gleason grade and the author postulated that the 
tumours had lost the characteristics of the original prostate tissue itself, and this affected 
PSA release into the blood stream (Kageyama. 1996). Other authors have also described 
the association between advanced prostate cancer stage with a low PSA and poorly 
differentiated tumours (Partin et al. 1990). However, although our series included a high 
proportion of poorly differentiated Gleason 8-10 tumours (76% on histology review), 
the remainder were moderately differentiated. It is possible that in these last cases the 
bulk of the tumour had a different morphology from that sampled. None of the 33 cases 
contained morphological evidence of neuroendocrine differentiation. In 3 further cases 
identified from the BAUS Cancer Registry that were not studied, either due to lack of 
case notes or no tissue remaining on the pathology blocks, there were features of 
neuroendocrine differentiation reported by the referring centre pathologist, but it was 
not possible to verify this.
Response to treatment in this group of patients is difficult to measure. PSA is of limited 
value given that baseline values were < 10 ng / ml. There was a fall from baseline PSA 
levels in 6 patients, but this correlated with improvement in clinical symptoms or signs
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in only 2. In these two cases, it is likely that the dominant clone produced small 
amounts of PSA, contrasting with the other 4 patients who demonstrated a fall in PSA 
levels from baseline but had clinically progressive disease. In all but two patients, PSA 
values never rose above 10 ng/ml, a remarkable observation in the context of 
widespread symptomatic progressive disease. In the two patients demonstrating a PSA 
rise, this may reflect the presence of a mixed PSA-negative and PSA-positive clonal 
population. The total PSA rather than free/total PSA ratio was the only data available. It 
was not possible to stratify patients into the prognostic groups defined by Fossa (Fossa 
et al. 1992) based upon serum creatinine, haemoglobin and alkaline phosphatase, due to 
incomplete data recording at the referring centre.
Hypercalcaemia is uncommon in prostate cancer. Recent data from a bisphosphonate 
trial suggest <1% incidence of hypercalcaemia in the placebo arm in hormone 
refractory metastatic prostate cancer (Saad 1995). When reviewed, the rare cases of 
hypercalcaemia in prostate cancer have been largely associated with neuroendocrine 
carcinomas (Smith et al. 1992). The high rate (9%) of hypercalcaemia in our study 
would reinforce the differing biological nature of the PSA- negative tumour despite the 
absence of neuroendocrine differentiation.
The median duration of response to first line therapy in our study was 7 months, in 
marked contrast to the figure of 12 to 18 months seen in randomised studies of 
previously untreated metastatic prostate cancer (Eisenberger et al. 1998;Ventafridda et 
al. 1985). Our response rate is similar to that seen in a smaller case series of PSA- 
negative tumours, where response to 1st line hormonal therapy was seen in 2 / 4 patients 
(Yamamoto et al. 2001a). Nonetheless, the majority of patients did have a symptomatic
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response to androgen deprivation and this remains the recommended initial treatment.
For patients with metastatic prostate cancer in relapse, further responses to subsequent 
endocrine treatments are seen in 35-45 % (Labrie 1988;Small & Vogelzang 1997) with a 
median survival time of 9 months after second line treatment is initiated (Hussain et al. 
1994). In the current study, no responses were seen in 83% of patients in whom a non­
steroidal anti androgen was added to their initial LHRH agonist or in any of those 
commenced on third line hormonal therapy.
Of the 5 patients receiving chemotherapy, 3 responses were seen, maintained 
throughout the chemotherapy course but not durable once treatment was completed. 
Response rates of 10-15% to chemotherapy have been quoted in the context of 
metastatic prostate cancer (Brausi 1995) with responses maintained for up to 9 months. 
More recently, Phase II studies have proved encouraging with responses of over 40% in 
selected hormone refractory patients for combinations such as 5-fluoruracil, epirubicin 
and cisplatin (Chao et al. 1997) or various taxane containing regimes (Petrylak 2002). 
Given the poor response to second or third line hormonal therapy in the PSA-negative 
group, early chemotherapy may well be worth considering in patients with good 
performance status.
The median overall survival time of 12 months for the patients studied is much shorter 
than that seen in treated metastatic prostate cancer overall, where a figure of 27 months 
(Eisenberger et al. 1998) or one year after the first progression is described (Denis et al. 
1993).
This study has described the clinical features in the largest series thus far reported of 
patients presenting with metastatic prostate cancer and a serum PSA of less than 10 ng /
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ml, the PSA-negative metastatic group. Although the presentation and pattern of 
metastases are similar to those of high PSA metastatic disease, response to hormonal 
therapy is poor, with short response durations to first line treatment and minimal 
response to subsequent management other than chemotherapy. Hypercalcaemia appears 
to be a prominent feature. Overall survival rates are much less than those of high PSA 
disease and alternative strategies for management, including early chemotherapy in 
appropriate patients should be considered.
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Table 3.1 Patient Demographics
Age (years) 48 -  81 (median 67)
PSA at diagnosis (ng/ml) 0.1 -9 .8  (median 3.5)
Previous TURP for BPH 5 (15%)
Previous Urinary Investigations 6(18% )
Presenting symptoms
Urinary symptoms/pelvic pain 17(51%)
Acute retention 6(18%)
Cachexia / malaise 3(10%)
Bone pain 7(21 %)
Bone metastases 27 (81 %)
Axial skeleton 16 (48 %)
Pelvis 9 (27 %)
Femur / Humerus 8 (24%)
Soft tissue3 4(12%)
Lung 2
Liver 1
Gians penis (cutaneous) 1
T Stage
T2 1
T3a / b 12
T4 20
Abdominal nodal metastases 6(18%)
Bone marrow infiltration 2 (6 %)
a In addition to bone metastases
Table 3.2 Histopathology
Source of material
TURP 13 (39 %)
Prostatic biopsy 19 (57 %)
TUR bladder neck 1
Histology at local centre
Gleason 8-10 20 (60%)
Gleason 6-7 13 (40%)
Histology review
Gleason 8-10 25 (76 %)
Gleason 6-7 8 (24 %)
TURP transurethral resection of prostate
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Table 3.3 Treatment and Response
Treatment Number of patients Responses
First line therapy 33 24
LHRH agonists3 27 21
NSAA 3 1
Orchidectomy 3 2
Second line therapy
MAB 12 2
Zoladex restarted 3 1 1
Third line therapy
Diethylstilboestrol 4 0
Chemotherapy: 5 3
single agent 3 1
combination 2 2
MAB Maximal androgen blockade;a 1 patient treated with intermittent hormone
therapy; NSAA non-steroidal anti-androgen monotherapy
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Figure 3.1 Histopathological Grading of PSA-Negative Metastatic Prostate Cancer 
and Metastatic Prostate Cancer Overall (data from local centres)
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Chapter 4 The Immunohistochemical Features of Treatment- 
Naive Metastatic Prostate Cancer Presenting with a Serum 
PSA < 10 ng/ml
4.1 Introduction
The management of prostate cancer has been transformed by the measurement of serum 
levels of PSA as already discussed (Stamey et al. 1987) with markedly elevated levels 
of PSA reflecting the tumour burden (Daver et al.1988). In this thesis, the low PSA 
group is defined as men presenting with untreated metastatic disease with serum PSA 
levels of less than lOng/ml (Birtle et al. 2003). As outlined in chapters 1 and 3, the 
small percentage of men who present with previously undiagnosed metastatic prostate 
cancer and low serum PSA levels tend to have a worse prognosis. This is evidenced by 
their poor response to hormonal manipulation and the difficulty in monitoring, due to 
the lack of a reliable serum marker (Birtle et al, 2003).
The identification of alternative tissue markers could allow investigation of 
corresponding serum markers to facilitate diagnosis and monitoring in PSA-negative 
disease.
The two primary candidate alternative prostate cancer markers are prostatic acid 
phosphatase (PAP) and prostate specific membrane antigen (PSMA) neither of which 
has been evaluated in the context of low serum levels of PSA. PAP was in widespread 
clinical use to monitor prostate cancer prior to the advent of PSA, but is less sensitive 
and specific (Bogdanowicz 1991). Prostate specific membrane antigen (PSMA) was 
discovered after PSA, and has been shown to be present in larger amounts in malignant
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than in benign prostatic tissue (Chang. 2001b). However, it has not found a routine role 
in clinical practice.
4.2 Aims
The aims of this study were:
□ To examine the histopathological features of men presenting with 
untreated metastatic prostate cancer and serum PSA less than 10 ng/ml
□ To investigate the extent of staining for tissue PSA
□ To determine whether alternative tissue markers might be useful in this 
patient group to aid diagnosis and histopathological assessment.
4.3 Materials and Methods
4.3.1 Cases Studied
Patients presenting with untreated histopathologically proven metastatic prostate cancer 
and a serum PSA of less than 10 ng/ml were identified as outlined in Chapter 3. Paraffin 
embedded formalin-fixed archival prostatic tissue specimens were obtained. H & E 
slides of each case were cut and reviewed by a pathologist with a special interest in 
urological pathology (AF) to confirm the diagnosis and grade of carcinoma. The Local 
Ethics Committee of UCLH NHS Trust and the South East Multi-Centre Research 
Ethics Committee approved the study.
4.3.2 Specific Immunohistochemical Staining (see Section 2.1.2 for 
Immunohistochemistry General Technique)
3pm serial tissue sections from each case were mounted onto Vectabond-coated slides 
and immunostained using commercially available antibodies to PSA, androgen receptor
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(AR), PSMA, PAP, Chromogranin A, and CD56. In addition, cytokeratins (CK) 7 and 
20 and 34(3E12 antibodies were used to exclude transitional cell carcinoma (Varma et 
al. 2003). Appropriate positive and negative controls were included for all 
immunohistochemistry using standard methods of antigen retrieval and previously 
validated antibody concentrations for all antibodies other than PSMA. The optimal 
dilution of and preferred method of antigen retrieval for PSMA was determined by 
titrating the antibody using a high-grade radical prostatectomy sample as a positive 
control. The tissue sections were dewaxed in xylene and taken through a series of 
graded alcohols to water. The method of antigen retrieval, primary antibody 
concentration and method of staining are summarised in Table 4.1. The general 
technique for immunohistochemistry using the EnVision method was followed as 
described previously (section 2.1.2).
4.3.3 PSMA Immunostaining
PSMA was visualised using a goat peroxidase anti-peroxidase system (Sternberger 
1970). After antigen retrieval and washing as described above, slides were incubated 
with normal rabbit serum 1:10 for 10 minutes at room temperature. Primary antibody 
(goat) was then added for 60 minutes followed by a 1:200 dilution of rabbit anti-goat 
secondary antibody in excess. 200 pi of 1:100 goat-peroxidase-anti-peroxidase was then 
added for 60 minutes at room temperature with DAB detection as before.
Immunohistochemical staining was assessed independently by two observers, including 
a pathologist with a special interest in urological pathology (AF). A semi-quantitative 
assessment was performed taking into account the intensity (0: negative; 1+: low 
intensity, just above level of background staining; 2+: moderate intensity; 3+: high
114
intensity) and extent (focal/diffuse) of staining. For all immunohistochemistry, the score 
and extent were recorded in areas of carcinoma. Very focal areas (less than 10 cells) 
showing low intensity staining (1+) staining were classified as negative. Given the 
subjective nature of assessment, the 2+ and 3+ grades were reported together, in 
keeping with other authors.
4.3.4 Potential Diagnostic Markers as Therapeutic Targets
10 of the 33 cases were selected at random (5 biopsy specimens and 5 from 
transurethral resection) to perform an additional immunohistochemistry panel of 6 
antibodies including TIMP2, MMP2, Bcl-2, Her-2, FGF8 and FGFR2. Each of these 
represented a potential molecular therapeutic target. The details of this small study are 
given in Appendix 2.
4.4 Results
4.4.1 Clinical and Histopathological Features
In 19 cases (57 %) archival tissue was obtained from ultrasound-guided prostatic biopsy 
specimens, with a further 13 specimens derived from transurethral resection of the 
prostate and one from a bladder neck resection. 27 / 33 cases (81%) had bone 
metastases, with four patients presenting with soft tissue metastases. All patients 
received primary hormonal manipulation (for details, see Birtle et al, 2003).
25 cases (76 %) had a combined Gleason score of 8-10, with the remaining 8 cases 
(24%) having a combined Gleason score of 6-7. No cases showed morphological 
features of neuroendocrine differentiation. One case classified as a prostatic carcinoma 
with a combined Gleason score of 10 was subsequently re-classified as a urothelial 
carcinoma because of the immunohistochemical expression of urothelial markers (see
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below).
4.4.2 PSA Immunostaining
9/ 33 cases (27 %) showed negative staining for PSA with a further 3 classified as focal 
1+ (Table 4.2). 21 of the 33 cases (63 %) demonstrated 2-3+ immunoreactivity which 
was focal in 19/33 cases. The association of PSA staining with AR, PSMA, PAP, 
chromogranin A and Gleason score is summarised in Table 4.2.
4.4.3 AR Immunostaining
A strong diffuse nuclear staining for AR was observed in 30/33 cases. Moderate or 
strong staining for AR was seen in 9/12 cases that were negative or focally 1+ for PSA 
(Table 4.2).
In these 3 latter cases, the AR staining was in an area that was negative for tissue PSA. 
Of the 3 cases that were completely negative for PSA/AR, one was later regarded as a 
urothelial tumour by virtue of positive CK 7 and 34(3E12 staining.
4.4.4 PAP Immunostaining
24/33 cases (84 %) were positive for PAP, although the pattern of staining was mainly 
focal (79 %). There was also strong positive co-staining of PSA and PAP staining in 
60% of cases, with 16 cases showing moderate or strong staining for both PSA and PAP 
and 3 cases being negative for both antibodies.
4.4.5 PSMA Immunostaining
30 / 33 cases (90 %) demonstrated PSMA staining, which was diffuse in 70% of the 
positive cases. In the 12 cases that were PSA negative or focal 1+, PSMA was diffusely
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positive in 9 cases. In those tumours showing a mixture of PSA positive and negative 
areas, there was no association seen between the staining pattern for PSA and that for 
PSMA.
The pattern of immunostaining seen with respect to PSA, AR, PSMA and PAP is 
illustrated in Figure 4.1, where images A-E represent one patient with negative 
tissue staining for PSA, and images F-J represent a second case with positive 
immunostaining for PSA.
4.4.6 Chromogranin A Immunostaining
Chromogranin A immunostaining was negative in 24/33 cases (72%), with 8 of those 
cases also tissue PSA negative (Table 4.2). In 6 cases (18%) 2+/3+ intensity of 
immunostaining was observed, but the pattern of staining was focal. One case displayed 
focal 3+ intensity of staining, but this was present in only 2 cells, and in keeping with 
other authors’ publications (Deftos et al. 1996;Sciarra et al. 2003), was not considered 
sufficient to reflect neuroendocrine differentiation.
4.4.7 Urothelial Markers
3 cases were examined with urothelial markers, as a result of uncertainty over the 
diagnosis of prostate cancer morphologically. 2 cases were CK 7 positive and CK 20 
negative, the other CK 7 negative / CK 20 positive. 34 (3E12 was positive in one of the 3 
cases, which was also CK 7 positive and was thought more likely to be a urothelial 
tumour than a prostate carcinoma (data not shown).
4.5 Discussion
This study has investigated the immunohistochemical profile of 33 primary tumours in
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men presenting with treatment-naive metastatic prostate cancer and serum levels of PSA 
less than 10 ng/ml. Although three quarters of cases were Gleason 8-10, the remainder 
were moderately differentiated. All 12 cases where tissue PSA immunostaining was 
classified as negative or focal 1 + were high grade tumours. Other authors have found 
the same association, and have also noted a similar relationship with serum PSA levels 
(Aihara et al. 1994). It has been suggested that such cases undergo “de-differentiation”, 
losing their original prostatic tissue characteristics and hence altering the relationship 
between serum PSA levels and tumour volume (Kageyama et al. 1996). This de­
differentiation has been associated with a more aggressive phenotype, and agrees with 
the finding that first line hormonal responses and overall survival are much shorter in 
this group of patients (Birtle et al. 2003) (Chapter 3).
Interestingly, given the low serum PSA levels, positive immunostaining for tissue PSA 
was seen in two thirds of the cases, although in many of these the staining was focal and 
could potentially be missed on prostatic biopsy sampling. Some authors have argued 
that both monoclonal and polyclonal antibodies to PSA should be used (Gray 1996) 
because prostate carcinomas showing negative immunostaining for PSA monoclonal 
antibody may have an epitope that cannot be recognised by monoclonal antibody. The 
PSA antibody used in this study was monoclonal but similar work by Feiner (Feiner & 
Gonzalez 1986) showed negative immunostaining for both monoclonal and polyclonal 
PSA antibody in high grade prostate cancers and monoclonal antibody work remains the 
mainstay of the diagnostic laboratory. Hence the current study did not repeat the 
staining using a polyclonal antibody.
Although PSA and PAP are usually concordant in advanced prostate cancer (Stamey et
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al. 1987) occasional discordance in immunohistochemical studies has been described 
(Mettlin. 1993). Concordant results for PSA and PAP were seen in 28/33 cases (84%), 
although in only 6 cases (18%) was PAP immunostaining diffuse. In a similar fashion to 
PSA, PAP staining could be subject to a geographical miss on prostate biopsy and thus 
is likely to confer no additional diagnostic benefit.
In contrast, PSMA staining was seen in 30/33 (90%) cases and was diffuse in the 
majority, in agreement with the observations of Bostwick (Bostwick et al. 1998). This 
observation may be important in cases where tissue PSA immunostaining is negative or 
focal 1+. Our results are also similar to those obtained by Chang (Chang et al. 2001a) 
who found positive immunoreactivity for PSMA in prostate cancers where tissue PSA 
was negative. In tumours where both PSA negative and positive areas were seen, PSMA 
staining occurred in both regions, suggesting there is no association between the pattern 
of PSA and PSMA expression. As areas which are focally positive for PSA are easy to 
miss on biopsy, these results indicate that PSMA staining may be of value in this patient 
group to aid diagnosis and confirm prostatic origin despite the low serum PSA.
Alterations in the androgen receptor by mutation, deletion or over-expression have all 
been implicated in the development of hormone refractory prostate cancer (Feldman & 
Feldman 2001). Given that PSA is an androgen-dependent gene (Balk et al. 2003) 
androgen receptor deletion is a potential mechanism to explain the low levels of serum 
PSA in treatment-naive metastatic prostate cancer. However, strong predominantly 
diffuse nuclear AR staining was observed in most of the tumours and was seen in all but 
three of the cases that were negative or weakly positive for PSA. A mechanism in which 
the AR is present but bypassed by a ligand-independent pathway, leading to an increase
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in proliferation and a decrease in apoptosis has been suggested (Feldman & Feldman 
2001) and this may be a more plausible explanation. From the results in the current 
study, it appears that the mechanism of low serum PSA cannot be explained by AR loss 
resulting in altered transcription of PSA. In a similar manner to the observations with 
PSMA, the diffuse nature of the AR staining could reduce the likelihood of 
misdiagnosis on prostate biopsy.
It has been previously been postulated that neuroendocrine markers might complement 
the PSA assay in selected cases of poorly differentiated tumors (Sciarra et al. 2003). In 
the same study, tissue neuroendocrine markers including chromogranin A and neuron- 
specific enolase were identified in 18 patients with clinically progressive androgen- 
independent prostate cancer and low serum PSA, leading to the belief that the majority 
of low serum PSA metastatic prostate cancers were neuroendocrine in origin. In 
contrast, in our group of hormone-naive metastatic prostate cancers, no tumour had a 
predominantly neuroendocrine phenotype. CD56, which has also been previously useful 
in detecting neuroendocrine differentiation (Kaufmann et al. 1997) was unhelpful, 
being focally positive in only 3/33 (9%) cases. Neuroendocrine markers do not appear 
to provide additional information in this group of cases. Thus whilst neuroendocrine 
differentiation may be one mechanism by which prostate cancers develop resistance to 
androgen ablation, it does not explain the primary presentation of prostate cancer with 
low serum PSA levels in this group of patients.
In conclusion, men presenting with treatment-naive metastatic prostate cancer and 
inappropriately low levels of serum PSA (less than 10 ng/ml) are difficult to manage 
and have a poor prognosis. Both tissue PSMA and AR immunostaining are often
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diffusely positive in these tumours, particularly in cases where the PSA is negative or 
weak and focal, and may thus aid the histopathological diagnosis of prostate cancer in 
these patients, allowing treatment to be commenced more promptly. The potential value 
of PSMA as a serum biomarker of prostate carcinoma also merits further investigation.
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Table 4.1 Summary of Primary Antibody and Conditions
Primary
antibody
Concentration Species/ Catalogue Antigen
Retrieval*
AR 1/100 Mouse/Dako M3562 9.9
PSA 1/20 Mouse/ Dako M0750 NT
PSMA 1/100 Goat/Santa Cruz sc-101271 9.9
PAP 1/1000 Mouse/Dako M0792 NT
Chr A 1/10 Mouse/Dako M0869 NT
CD56 1/10 Mouse/Monosan MON9006-1 PC
CK7 1/100 Mouse/Dako N1626 TE
CK 20 1/100 Mouse/Dako N 1627 TE
34pE12 1/50 Mouse/Dako M0630 MWD
*9.9 : 25 minutes microwaving at full power, stand 10 mins, in Dako high pH retrieval 
solution (S3007)
NT : no antigen retrieval used
TE: 20 min microwave at full power in Tris-EDTA buffer, pH 9.0
MWD : 25 minute microwave at full power, 10 minutes stand, in Dako Retreival
Solution (S1699)
P C : 2 minutes pressure cooking at full pressure in citrate buffer pH 6.0
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Table 4.2 Summary of Immunohistochemistry Results in 33 Cases
PSA 0 F1+ F2+ /34- 
(Diffuse staining 
in 2 cases only)
AR
0 3* 0 0
F 1+ 0 0 1
Diffuse 2+ / 3+ 6 3 20
PSMA
0 1* 0 2
F 1+ 1 0 8
Diffuse 2+ / 3+ 7 3 11
PAP
0 3 0 3
F 1+ 1 0 2
2+ / 34- 5 3 16
No diffuse staining
seen
Chr A
0 8 4 12
F 1+ 1 0 2
F 2+ / 3+ 0 1 5**
No diffuse staining
seen
Gleason score
6 0 0 1
7 0 1 6
8 0 0 3
9 5 1 7
10 4 1 4
F: Focal
D: Diffuse
* One case which was AR/PSA/PSMA negative was positive for urothelial markers 
** Very scattered staining
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Figure 4.1 Immunohistochemical Features Illustrated by 2 Cases
Case 1 (A-E),
Case 2 (F-J)
Key:
A: H & E x 40
B: negative PSA staining x 40 
C: 3+ nuclear diffuse AR staining x 40 
D: 3+ focal PAP staining x 20 
E: 3+ diffuse PSMA staining x 20 
F: H & E x 40
G: 3+ focal PSA staining x 20 
H: 3+ diffuse AR staining x 40 
I: 1+ focal PAP staining x 20 
J: 2+ diffuse PSMA staining x 40
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Figure 4.2 Positive Controls
a: normal prostate showing strong lum inal staining for PSA (x 20)
b: normal prostate showing strong nuclear staining for AR (x 20)
c: prostate carcinom a showing strong diffuse staining for PSMA ( x 10)
d: normal prostate showing strong lum inal staining for PAP (x 40)
e: nerves showing strong focal staining in neuroendocrine cells for chromogranin A (x
40)
f: nerves showing strong focal staining for CD 56 (x 20)
g: invasive bladder carcinom a showing strong diffuse staining for 34pE12 (x 20) 
h: invasive breast tum our showing positive staining for CK 20 (x 20)
I: invasive bladder tum our showing positive staining for CK 7 (x 40)
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4 . Vf,T -1
3IH>:
a: normal tonsil shows negative PSA staining (x 40) 
b: normal breast, shows negative AR staining (x 20) 
c: normal bladder shows negative PSM A staining (x 20) 
d: normal bladder shows negative PAP staining (x 20) 
e: normal breast shows negative chrom ogranin A staining (x 20) 
f: normal breast shows negative CD 56 staining ( x 20) 
g: prostate carcinom a shows negative 34PE12 staining (x 20) 
h: bone marrow showing negative CK 7 staining (x 20) 
i:bone marrow showing negative CK 20 staining (x 20)
127
Chapter 5 Loss of Heterozygosity as a Mechanism for PSA- 
Negativity
5.1 Introduction
5.1.1 Definition
Loss of heterozygosity may be defined as loss of one allele at a locus followed by 
duplication of information from the remaining locus.
5.1.2 Background to LOH Detection
Allelic loss at a certain region of a chromosome at a high frequency is known to indicate 
the presence of a tumour suppressor gene. Due to the high level of specificity, loss of 
heterozygosity is often invaluable as a marker for diagnosis and prognosis of cancer 
(Thiagalingam 2002). The genetic changes that result in LOH known to date are mitotic 
recombination, deletion, gene conversion, translocation, chromosome breakage, 
chromosomal fusion or telomeric end-to-end fusions, or loss of a whole chromosome 
(Aaltonen. 1993).
In the non-coding regions of the genome, so-called tandem repeats exist which are areas 
of repeated DNA sequence eg (CA)n . A microsatellite or short tandem repeat is one in 
which 1-5 base pairs are involved. For PSA, this is a dincleotide CA repeat. The number 
of the repeats is variable and they thus differ between the paternal and maternal alleles. 
This results in alleles of differing sizes and thus heterozygosity can be detected by high 
resolution electrophoretic techniques.
5.1.3 Clinical Relevance of LOH
In colorectal cancer, LOH has been associated with poorer outcomes in untreated
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patients. Retention of heterozygosity appears to indicate improved chemotherapy 
responses (Barratt. 2002) and is being investigated as a potential marker to stratify 
patients into appropriate treatment groups. LOH may be of use in diagnosis and 
determining prognosis of cancer. Allelic loss is a common finding in prostatic 
adenocarcinomas, present in more than 50 % of cases on chromosomes 8, lOq and 16 q 
and allelic loss appears to be more common in high grade tumours (Stamey et al. 1987).
5.1.4 Microsatellite Instability (MSI)
Microsatellite instability describes the emergence of new microsatellite alleles within a 
tumour, of lengths that differ from the host’s two parent alleles for that microsatellite. It 
was first observed in hereditary non-polyposis colon cancer (Aaltonen et al. 1993). 
Microsatellite DNA is thought to arise from strand misalignment during replication, 
recombination or repair and is attributable to mutations in mismatch repair genes. When 
DNA containing a microsatellite repeat is amplified by PCR, the resulting products will 
be of different lengths, even if by only a few base pairs. It has been identified in other 
tumour types such as colorectal and lung carcinomas and may be implicated in prostate 
cancer.
5.1.5 Assessment of LOH
To assess LOH, the sample must have two alleles of different lengths in the normal 
tissue and is termed informative. However, at about 30 % of loci, the alleles will be 
homozygous, having the identical number of microsatellite repeats within the amplified 
segment, and alleles of equal size. The sample is then deemed non-informative as LOH 
cannot be distinguished from the homozygous pattern in the normal tissue. Mutation 
may also result in a change in the number of repeats in the tumour tissue.
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5.2 Aims
The main aim of this study was to investigate LOH at the PSA locus in treatment naive 
metastatic prostate cancer with low serum PSA levels. If it is present, it is possible that 
LOH is the mechanism for the lack of PSA production in these patients. It may also be a 
useful prognostic molecular marker.
5.3 Materials and Methods
5.3.1 Clinical Specimens
10 formalin-fixed paraffin embedded prostate blocks were chosen from the bank of 
archival tissue collected as described in Chapter 3. All cases were men presenting with 
previously untreated metastatic prostate cancer and a serum PSA of less than 10 ng/ml. 
A mixture of diagnostic core biopsy and resection specimens were used and the blocks 
chosen were from tumours that had shown low immunoreactivity for PSA (Chapter 4). 
3pm sections were taken and mounted onto non-coated slides. H & E staining was 
performed as outlined in Section 2.1.2, although only one slide for each patient was 
cover-slipped for the purposes of outlining areas of tumour and normal tissue. All other 
slides were left uncovered to facilitate laser capture microdissection (LCM). Areas of 
tumour and normal tissue were identified and outlined on each cover-slipped slide by 
one histopathologist with a site-specialised interest in urological tumours, Dr Alex 
Freeman in the Department of Histopathology at UCL.
5.3.2 LCM
This work was carried out with assistance from Pete Simpson and Chris Jones at the 
Breakthrough Breast Cancer Laboratories, The Institute of Cancer Research, Fulham 
Road, London. The PIX CELL II ARCTURUS system was used. The LCM technique
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was developed by the NIH in the USA and has been commercially developed since 
1997 with Arcturus. In principle, a specific transfer film is bonded to the underside of a 
transparent cap. A side arm positions the cap onto the area of interest on a section and a 
laser beam focally activates the transfer film. The targeted cells bond to the film and are 
held within the polymer. This is shown in figure 5.1. The diameter of the beam may be 
adjusted so that individual cells can be microdissected and beam diameters of 7.5, 15 
and 30pm are available. The cap is then transferred to a 1.5ml Eppendorf and stored at 
room temperature until DNA extraction is performed. Multiple areas of tumour and 
benign tissue were microdissected for each case, where tissue availability permitted. To 
facilitate microdissection, sections were dehydrated in 70 %, 90% and 100 % alcohol 
for 2 minutes, then in xylene for 3-5 minutes and air-dried prior to microdissection. An 
initial laser energy of 85mW was applied, increasing to lOOmW if microdissection was 
difficult. For samples that proved difficult to lift off, the alcohol and xylene step was 
repeated. Examples of LCM are shown in figure 5.2.
5.3.3 DNA Extraction
The methods of DNA extraction have been detailed in Section 2.1.4.
The DNeasy® (QIAGEN) kit was initially used as this provided purer DNA extracts by 
virtue of the mini column system. However, because of the small amount of 
microdissected tissue held on each cap, the samples obtained were extremely dilute and 
hence an in-house DNA extraction method, as practiced by the Breakthrough Breast 
Cancer Laboratories was employed (section 2.1.4.1). DNA was extracted from paired 
microdissected samples from tumour and benign areas for each of the 10 cases.
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5.3.4 PCR Optimisation
A standard 15(0.1 reaction volume was used for each PCR, as per the protocol in section 
2.1.4. Optimisation of the PCR conditions in terms of number of cycles and annealing 
temperature was performed, using DNA previously extracted from LNCaP cells as a 
positive control. To optimize the conditions for the microdissected tissue DNA, LOH 
primer B1991, a primer known to provide validated results, was kindly provided by 
Charlotte Foley from The Institute of Urology Prostate Cancer Research Centre and the 
PCR repeated with the number of cycles changed from 40 to 50 and 60. The optimum 
results were found using 50 cycles.
5.3.5 Annealing Temperature
The melting and hence the annealing temperature for the microsatellite markers is 
affected by the number and proportion of base pairs, ie. the guanine-cytosine and 
thymidine-adenine bonds formed. The calculated melting point for each primer was 
obtained using the following equation:
Tmelting = 81.5 +[ 0.41 x (%GC) -  (675 / number of base pairs)]
For the forward primer this was 76.2°C, for the reverse primer 75.5°C, giving an 
average calculated melting temperature of 75.9°C. The annealing temperature was 
calculated from the following:
^anneal = Tm -  (2 tO 6 °)
However, a range of annealing temperatures were tried, via a temperature gradient plate 
on the Hybaid thermocycler®, using temperatures from 48-60 °C with optimum results 
seen at a T anneal of 58°C.
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Once the optimal conditions had been established, the PCR was performed as described 
in Section 2.1.4. PCR products were run on a 1.5% agarose gel to check that product of 
the correct size had been generated.
5.3.6 Construction of Plate for Genotyping
The spatial calibration for the ABI Prism 3700® DNA Analyser is carried out using Hi- 
Di Formamide (Applied Biosystems 43114320). Hence all samples run through the 
machine must be suspended in Hi-Di Formamide to ensure accurate sequencing. In a 
1.5 ml eppendorf, 1ml of Hi-Di Formamide was added to 15pl of the size standard 
Genescan® 400High Density (ROX) (ABI PRISM 402985) and mixed. ROX consists 
of 21 single stranded fragments of 50-400 bp range. Each fragment is labelled by a 
single fluorophore which results in a single peak when run on a polyacrylamide gel in 
the ABI A3700. GeneScan™ Size Standards are sets of fluorescent-labelled DNA 
fragments of known sizes used for determining the size of unknown DNA fragments run 
on ABI PRISM® DNA sequencers. The standards are run in the same lane or capillary 
injection as the samples, which contain fragments of unknown sizes labelled with 
different fluorophores. GeneScan® Analysis Software automatically calculates the size 
of the unknown DNA sample fragments by generating a calibration or sizing curve 
based upon the migration times of the known fragments in the standard. The unknown 
fragments are mapped onto the curve and the sample data is converted from migration 
times to fragment sizes. 8 pi of the HiDi/ROX mix was micropipetted into each well on 
a 96 well reaction plate (MicroAmp Optical)
Serial dilutions of the PCR products were made, giving 1:20, 1:40 and 1:80 
concentrations. 2pl of the appropriate concentration was added to each well on the plate
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giving a total volume of lOpl per well. One well contained water only as a negative 
control. The plate was then sealed, vortexed and the DNA denatured by heating in a 
PCR machine for 5 minutes at 95°C. This also allowed incorporation of the HiDi into 
the DNA. The plate was then placed in ABI PRISM 3700® DNA analyser for 4 hours 
and run. The ABI 3700® software allows each of the 96 lanes to be labelled with a 
sample name. The PCR products were therefore arranged in the 96 well plate so that the 
fluorescent electropherogram generated compared tumour with normal DNA for each of 
the 10 samples.
The ABI 3700® is a high voltage electrophoresis circuit. The machine loads the Hi/Di, 
ROX and PCR product mix into a well containing buffer and the cathode. Over a period 
of 50 seconds this reaction mix is injected into a capillary containing polyacrylamide 
gel. After the samples have been injected into the capillaries the injection wells are 
washed and re-filled with buffer. A 1000V potential difference is applied between a 
loading bar, the cathode, and an electrode, the anode, at the back of the cuvette 
assembly (Figure 5.3). PCR products migrate within the capillary to the other end, 
smaller products moving faster. As DNA fragments leave the other end of the capillary, 
they are carried through a transparent cuvette by a moving polymer, passing through the 
beam of an argon laser. As the fluorescently labelled fragments pass through the laser 
they emit a blue (FAM) or red (ROX) light that is detected by a camera. The amount of 
light detected is proportional to the quantity of product and so the amplitude of the 
curve on the fluorescent electropherogram.
5.3.7 Data Analysis
The data from the 3700 was imported for analysis into the Genescan® software. The
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allelic peaks are preceded by so-called stutter peaks, which represent slippage of the 
Taq polymerase during DNA amplification (Bright et al. 1997). The allelic peak is the 
highest peak after the stutter peaks. The first allelic peak is usually higher than the 
second as it is made up of its own product as well as a stutter peak of the second, larger 
allele. The software was set to mark the size in base pairs of each peak within the 
predicted size range of 176-192, and the peak height to quantify each different length of 
DNA product.
The definition of loss of heterozygosity is based on the relative ratio difference between 
the two alleles from the normal tissue sample and the two alleles from the cancer. This 
can be calculated as the ratio of the smaller peak to the larger peak for the tumour DNA 
compared to the same ratio in the normal DNA from the same sample (Narla 2001) ie. 
X lo h =  ([T1/T2]/[N1/N2]). The value for LO H  can hence range from zero (complete 
loss) to 1 (no allele loss).
The definition of a significant difference also varies throughout the literature and ranges 
from 0.3 to 0.75 (Barratt et al. 2002; Narla et al. 2001). For heterozygous alleles where 
one allele has been lost by the cancer, there should in theory be only one allele present 
in the cancer sample compared to two in the benign sample. In practice, however, it is 
difficult to avoid contamination with normal tissue. Thus the two alleles contained in 
these contaminants are detected and contribute to a smaller peak in the cancer sample.
As previously mentioned, if the sample in the normal tissue is homozygous, the pattern 
is deemed non-informative. This is because a homozygous result in the tumour sample 
could either be due to true LOH or to be simply a reflection of the homozygous pattern 
in the normal tissue.
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5.4 Results
If sections had been dried for too long or at too high a temperature during the initial 
sectioning stage, microdissection proved extremely difficult. PCR products from the 
extracted tumour DNA were visualised on a 1.5 % agarose gel (Figure 5.4). Products 
were seen for all 10 tumour samples and the LOH protocol was thus then carried out. 8 
of the 10 tumour /normal tissue pairs yielded peaks within the predicted range of 176- 
192 base pairs. Two of the tumour/normal pairs did not show a signal and it is likely 
that despite using a range of DNA concentrations, the DNA for these samples was too 
dilute. For all other samples, identical results were seen at all levels of DNA 
concentration (ie at 1:20, 1:40 and 1:80).
2/8 samples displayed a homozygous pattern in both tumour and normal tissue and were 
classed non-informative. (Fig 5.5)
2/8 samples displayed a heterozygous pattern, with a ratio for LOH of 1.0, showing that 
there was no allelic loss. (Fig 5.6)
4/8 samples showed microsatellite instability, namely that microsatellite alleles of 
different lengths from the normal tissue’s two parent alleles were seen. (Fig 5.7)
None of the 8 matched tumour/normal tissue samples exhibited LOH.
5.5 Discussion
Although 10 matched tumour/normal tissue samples from each patient were analysed, 
two of the pairs did not produce a detectable signal. This was despite three different 
concentrations of DNA being loaded for the LOH analysis. For the other eight samples, 
identical results were seen at 1:20, 1:40 and 1:80 concentrations. When the results were
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compared with the images and data recorded during the microdissection process, it was 
apparent that these two cases had been difficult to microdissect, even after an additional 
alcohol/xylene step. This probably reflected overdrying or overheating in the initial 
sectioning stage. It is likely that there were in fact very few cells lifted from these 
sections, and thus minimal amounts of DNA extracted.
There is debate as to whether samples showing microsatellite instability can be termed 
informative. Barratt et al noted that MSI may in fact obscure relative allele abundance 
in the tumour (Barratt et al. 2002). If the MSI samples are considered informative in this 
study, then 6/8 samples were informative in total. If there was only a 10% rate of LOH 
at the PSA locus, this would not be picked up with such a small sample size.
Although the samples were microdissected, there may have been some contamination of 
the tumour with benign tissue. In this case, if too many cycles were used during the 
PCR process, it is possible that the normal DNA acting as a contaminant of a supposed 
tumour sample was amplified, and any LOH in the tumour masked.
In addition, different cancer foci within the same tumour area may display varying 
characteristics, namely that some may have LOH and others not. In such circumstances, 
those foci without loss may mask those with LOH.
The high rate of MSI (50 %) seen in this study is unusual. The tissue specificity of 
microsatellite instability in other tumour types, such as hereditary non-polyposis colon 
cancer (Aaltonen et al. 1993) has been speculated to be an indication of tissue specific 
mutagens or the existence of tissue specific genes which are targets of spontaneous 
mutations, providing a growth advantage to that particular cell type (Eshleman & 
Markowitz 1995). As already described elsewhere in this thesis (section 3), patients
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presenting with treatment naive metastatic prostate cancer and a serum PSA of less than 
lOng/ml have a much poorer response to hormonal treatment and significantly shorter 
overall survival than patients with metastatic prostate cancer and appropriately high 
serum PSA levels. It may be that MSI contributes to the aggressive phenotype of the 
PSA-negative metastatic tumour by conferring a selective growth or survival advantage.
An alternative explanation is that for microdissected samples, the amount of template 
DNA may vary considerably and interfere with optimum PCR amplification. Sieben 
(Sieben 2000) found that in particular, the DNA microdissected from paraffin- 
embedded sections had a higher rate of LOH artefact than that obtained from frozen 
sections. They recommended a minimum of 10 ng DNA for reliable PCR analysis from 
paraffin embedded material when using a di, tri or tetranucleotide marker, to reduce 
LOH errors. PCR artefacts may also occur due to fixation induced change of DNA and 
conditions in the amplification of the repetitive sequence, (especially for CG rich 
sequences) favouring mis-annealing and hairpin formation (Diaz-Cano 2001). The DNA 
extracted in this study was extremely dilute, and optical density reading could not be 
obtained on the samples extracted using the DNeasy method. The in-house DNA 
extraction protocol had been developed to improve the concentration of extracted DNA 
but it is possible that the amount of DNA present was still less than 10 ng and that the 
MSI seen was artefactual rather than a true result.
In summary, loss of heterozygosity for PSA was not found in these cases of treatment -  
naive metastatic prostate cancer with low serum PSA levels. An element of caution is 
required however, as it is possible that a low rate of LOH could not be detected given 
the small number of cases examined. Microsatellite instability would appear to be a
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frequent occurrence and may be a factor in the aggressive behaviour of these tumours, 
although technical difficulties may be implicated.
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Figure 5.5 Example of Non-Informative Homozygous Sample
The polym orphic region in between the m arkers is the same length in the maternal and 
paternal alleles and so one allelic peak is seen in both tum our (top line) and normal 
tissue from  the same patient (second line). The negative control (water) and the red size 
standard are also shown (bottom  two lines). The am plitude on the Y axis represents 
amount o f product. The position on the x axis is determined by the number of base pairs 
(in box) and hence size.
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Figure 5.6 Heterozygous Informative Result
LOH ratio between the tum our (above) and normal tissue (below) of alleles is 1.0.
The amplitude on the Y axis represents am ount o f product. The position on the x axis is 
determined by the num ber of base pairs (in box) and hence size.
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Figure 5.7 M icrosatellite Instability
Both alleles are present but there has been a position shift and there are now different 
sizes in the tum our when com pared to the parent alleles. This is thought to be due to 
defective DNA repair. The amplitude on the Y axis represents amount of product. The 
position on the x axis is determ ined by the num ber of base pairs (in box) and hence size.
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Chapter 6 Methylation as a Mechanism for PSA-Negativity
6.1 Introduction
Methylation is an enzyme-linked chemical modification that adds methyl groups at 
selected sites on DNA, RNA and proteins. As previously discussed, (Chapter 1) DNA 
methylation is a key mechanism for the suppression of gene activity by the induction of 
structural changes and reduction of the binding of transcription factors. Methylation is 
thought to be a key event in carcinogenesis. Whether methylation is the initiating or 
secondary event in gene silencing has not been established. Hypomethylation of certain 
proto-oncogenes such as c-MYC has been reported in various human cancers (Feinberg 
& Vogelstein 1983). DNA methyltransferase and HDAC1 (a histone deacteylation 
enzyme) have been found to be up-regulated in prostate cancer, implying a role in 
inhibition of transcription via methylation (Patra et al. 2001).
Many tumour suppressor genes are found to be hypermethylated in malignancy (Jones 
& Laird 1999). In prostate cancer, GSTP1 promoter hypermethylation is frequently seen 
in prostate cancer and is present in potential precursor lesions (Jeronimo 2001). 
Aberrant methylation of the AR has been described (Chlenski 2001) and this may be a 
factor in functional silencing of the AR leading to lack of PSA production. There may 
also be methylation of the PSA promoter or enhancer.
DNA methylation has been considered as a therapeutic target, using demethylating 
agents such as 5-aza-2’-deoxycytidine (5-aza-2’CdR) which inhibits DNA 
methyltransferases and causes global hypomethylation. Methylation of the AR may be 
considered analogous to work in breast cancer where hypermethylation of the oestrogen 
receptor (ER) has been proposed as a mechanism for initiating or maintaining
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oestrogen-receptor negative status in breast cancers (Lapidus et al. 1998). ERa has been 
found to be reactivated in prostate cancer cell lines after treatment with agents to induce 
demethylation (Li et al. 2000). These drugs cause terminal differentiation of cells by 
removing excess methyl groups. Difficulties with demethylation agents have arisen due 
to the non-specific nature of this class of drugs, but some success has been obtained in 
haematopoetic disorders such as acute promyelocytic leukaemia (Lo et al. 2002).
As PSA is an androgen-responsive gene, it is possible that methylation of the AR leads 
to functional silencing of both the AR and PSA. If this is the underlying mechanism of 
PSA-negativity, it may offer a potential therapeutic target.
6.2 Aims
The aim of this study was to investigate whether DNA methylation of the AR and of 
PSA itself was a significant feature in specific prostate cancer cell lines, which do not 
express PSA or the AR in their normal state. This will be done by:
□ Investigating PSA and AR expression in prostate cancer cell lines by RT- 
PCR, after treatment with an agent known to cause demethylation
□ Investigation of PSA and AR expression in prostate cancer cell lines by 
immunohistochemical staining after demethylation treatment.
□ Investigation of protein expression of PSA and AR in prostate cancer cell 
lines by western blotting after demethylation treatment.
6.3 Materials and Methods
6.3.1 Ceil Lines
The prostate cancer cell lines DU 145, PC3 and LNCaP were used (section 2.1.3) with
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conditions maintained as previously described.
6.3.2 Demethylation Optimisation.
The most commonly used agent for demethylation is 5-aza-2’-deoxycytidine (5-aza) 
(Jones 1985). A variety of schedules have been used by other workers in demethylation 
studies with 5-aza concentrations ranging from lOnM to 10|iM, with treatment times 
varying from 1 to 14 days and a similar range of days before harvesting cells. Initial 
optimisation of conditions was performed in conjunction with Mr Simon Bott in the 
Prostate Cancer Research Centre. Prostate cancer cell lines LNCaP and PC3 were 
treated with 3pM concentration of 5-aza (Sigma A3656) for one week and then 
harvested. A parallel protocol using 500nM concentration of 5-Aza and a treatment time 
of 24 hours, followed by a 5 day period before harvesting was also used, with GSTP1 
methylation status assessed. The GSTP1 was used as a control gene known to be 
methylated in prostate cancer cell lines and in tissue (Singal et al. 2001). The 3pM 
concentration schedule was found to cause significant and excessive cytotoxicity 
affecting all cell lines. Re-expression of GSTP1 was noted with the 500nM schuedule 
(Bott 2002). This was therefore utilised as the basis of subsequent methylation 
protocols.
6.3.3 Demethylation of Prostate Cancer Cell Lines by Treatment with 
5-Aza.
2 x T80 flasks of LNCaP, DU 145 and PC3 cells, plated at 500,000 cells per flask and 
maintained as previously described were left to attach overnight. The following day at ~ 
40% confluence, a 500nM solution of 5-Aza made up in fresh medium (RPMI 
complete) was added to one flask per cell type. The second of each pair was media
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changed, and used as a negative control. After 24 hours, the medium was aspirated from 
all flasks and replaced with 15 ml of drug-free medium. Cells were harvested after 5 
days and cell numbers per flask counted as previously outlined (section 2.1.3.2). The 
cell preparation obtained was used for western blotting or RT-PCR as detailed below.
6.3.4 RT-PCR using Primers for AR and PSA
RNA extraction, RT-PCR and the use of negative controls to ensure the validity of the 
method was performed as previously described, (section 2.1.3). The primers used were 
for PSA, AR, PSMA, PAP and GAPDH (glyceraldehyde 3 phosphate dehydrogenase, a 
housekeeping gene) as a positive control for the PCR process. The primer sequences 
were:
PSA (forward) 5’- ACTGCATCAGGAACAAAAGCGTGA-3’
PSA (reverse) 5 ’ -CGC AC AC ACGTC ATTGG A A AT A AC-3 ’
AR (forward) 5 ’ -CGAAATGGGCCCCTGGATTTATAG-3 ’
AR (reverse) 5 ’ -AGTCGGGCTGGTTGTTGTCGTGTC-3 ’
PSMA (forward) 5’-GGAATCTCCTTCACGAAACCG-3’
PSMA (reverse) 5-C ACTGAAAGGTGGT AC A AT ATCCGA-3 ’
GAPDH (forward) 5 ’ -CCACCCATGGCAAATTCCATGGCA-3 ’
GAPDH (reverse) 5 ’ -TCTAGACGGCAGGTCAGGTCCAC-3 ’
PAP (forward) 5 ’ -TTGTGACTTTGGTGTTTCGGC-3 ’
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PAP (reverse) 5 ’ -TGTCATAGCACTCATCAAAGTCCG-3 ’
The conditions used for PCR were as previously outlined (section 2.1.3). All PCR 
products were separated by size after gel electrophoresis, the product size for PSA being 
362 base pairs, AR 524 bp, and GAPDH 597 bp. 10 |il of PCR product together with 
5pl of loading buffer was loaded into each well on a 1.5 % agarose gel, and the gel run 
at 100V for 40-60 minutes. Prior to electrophoresis, 3pl of a lkb DNA ladder was 
loaded into an empty well on the gel, allowing comparison of PCR products size against 
DNA fragments of known size. Products were visualised under ultraviolet light. All 
experiments were performed in triplicate.
6.3.5 Demethylation of Prostate Cancer Cell Lines and Assessment of 
PSA and AR Status by Immunohistochemistry
6.3.5.1 Demethylation
DU 145, LNCaP and PC3 prostate cell lines were used as before. Trypsinisation and cell 
counting were performed as described in section 2.1.3 and 12,500 cells of each cell type 
in 1 ml of RPMI complete medium were added to each well in a 24 well plate, each of 
which contained a cover-slip inserted under aseptic conditions. 4 wells were set up for 
each cell type and the cells were left to attach overnight. The following morning, the 
medium was aspirated and 1 ml of a 500 nM solution of 5’aza added to each well. This 
was removed after 24 hours, replaced with 1ml of fresh medium, and the plate left for 7 
days. The cells were then fixed as described previously.
6.3.5.2 Immunohistochemistry of Cells Grown on Coverslips
The protocol for immunohistochemistry was preformed as detailed in section 2.1.1. The 
primary antibodies used were anti-PSA diluted 1:20 (mouse monoclonal BioGenex
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AM01405M) and anti-AR (mouse monoclonal Biogenex AM256-2M) at 1:100 made up 
in normal horse serum (NHS). A negative control was set up using one cover-slip for 
LNCaP cells with secondary antibody and NHS only. LNCaP cells, which express PSA 
and a mutated form of the AR acted as the positive control. The experiments were 
repeated in triplicate.
6.3.6 Demethylation of Prostate Cancer Cell Lines and Assessment of 
PSA and AR Protein Expression by Western Blotting
Western blotting was performed following the protocol as described in section 2.1.3.6. 
Initially 25pg of protein was loaded for all three cell lines, with an additional well 
loaded with 2.5pg of the LNCaP protein extract. This was because of the concern of 
over-saturation of PSA and AR from the high expression found in LNCaP cells. A 15 % 
resolving gel (section 2.2.2) was used for AR and for actin, with a 6 % gel required for 
PSA due to the much smaller size product. The primary antibodies used were at the 
following initial concentrations:
AR 1:1000 Mouse monoclonal Biogenex (AM256-2M)
PSA 1:250 Mouse monoclonal Biogenex (AM01405M)
Actin 1:20,000 Mouse monoclonal (Santa Cruz sc-8432)
Due to poor results with the PSA antibody, this was repeated at a 1:100 concentration 
and the blot left to develop overnight. As no results were seen with the LNCaP positive 
control for PSA (see below) the experiment was subsequently repeated using a 1:100 
concentration of a different primary antibody for PSA (Santa Cruz sc-7316 mouse 
monoclonal) which was again allowed to develop overnight. Protein expression was
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normalised to actin.
6.4 Results
6.4.1 RT-PCR using AR and PSA Primers
6.4.1.1 Cell Numbers
(See table 6.1) After treatment with 5-Aza, all cell lines showed either a reduction in 
total cell numbers or only a small increase from baseline. The relative numbers of cells 
in the untreated flask were 3-20 fold greater than the treated group, illustrating the 
potential cytotoxic and cytostatic effect of the demethylating agent.
6.4.1.2 PCR Results
(See Figures 6.1 & 6.2)
AR
No re-expression of AR was seen in either DU 145 or in PC3 cells treated with 5’Aza. 
AR expression was seen in both the treated and untreated LNCaP cells, which are 
known to express AR in their normal state.
PSA
A product of the appropriate size for PSA (362 base pairs) was seen in the treated DU 
145 cells. No product was seen in the untreated DU 145 cells which do not normally 
express PSA or in either treated or untreated PC3 cells. PSA expression was seen in 
both LNCaP control cells.
PAP and PSMA
PAP and PSMA expression was detected in untreated and treated LNCaP cells, with no
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expression seen for either treated or untreated DU 145 or PC3 cells.
GAPDH
GAPDH expression was seen in all appropriate experimental lanes, with no band seen 
in the 2 control lanes, containing no RNA or no DNA respectively, confirming validity 
of the experimental method.
6.4.2 Immunohistochemical Staining for PSA and AR after 
Demethylation of Prostate Cancer Cell Lines
(See Figure 6.3) Strong staining for PSA and nuclear staining for AR was observed in 
both the control and demethylated LNCaP cells. PSA staining was observed in the 
treated DU 145 cells (demethylated) but was not seen in the untreated DU 145 cells, or 
the treated or untreated PC-3 cells. There was negative staining for AR in all untreated / 
treated DU 145 and PC-3 cells.
6.4.3 PSA and AR Expression after Demethylation using Western 
Blotting
(See Figure 6.4)
PSA protein expression
Initially, no PSA expression was observed with the experimental cell lines or with the 
positive LNCaP control, despite leaving the immunoblot in contact with the film 
overnight to develop. The experiment was hence repeated using a different PSA 
antibody (Santa Cruz) as described above and PSA protein expression was observed for 
the LNCaP controls only. No PSA protein expression was observed in either the
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treated/untreated DU 145 cells, or the treated/untreated PC-3 cells.
AR protein expression
AR expression was seen in the positive control LNCaP cells only. No re-expression of 
the AR was observed in either the treated / untreated DU 145 cells or the treated / 
untreated PC-3 cells.
Actin protein expression
Actin expression was observed for all treated / untreated cell lines and for the LNCaP 
controls, confirming consistent protein loading for the experiment.
6.5 Discussion
A potential mechanism for PSA-negativity is functional silencing of the AR by 
hypermethylation. CpG islands are small areas where the frequency of CpG is much 
higher than usual and are found in over 60 % of human promoters. The AR contains a ~
1.5 kb region extending across the transcriptional start site that is 65 % GC with an 
expected/ observed CpG ratio of 0.62 (Jarrard et al. 1998). This fulfils established 
criteria for identifying a CpG island. (Gardiner-Garden & Frommer 1987). Jarrard et al 
(Jarrard et al. 1998) found aberrant methylation in the AR expression negative prostate 
cancer cell lines DU 145, DuPro, TSU-PR1 and PPC1 and noted that re-expression of 
AR after demethylation was associated with re-expression of PSA. However, the results 
of treatment with a demethylation agent such as 5 aza-2’deoxycytidine (5-aza) have 
been conflicting. Nakayama et al (2000) found weak re-expression of mRNA AR in 
DU 145 cells after 5-aza treatment but no-re-expression in PC-3 cell lines.
In contrast, Chlenski et al (2001) described weak re-expression in PC3 cells with no re­
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expression in DU 145. There is thus no consistency between reported results, and a 
variety of demethylation protocols have been used, with differing concentrations of 5- 
aza, different treatment times, and varying times for the cells left to grow after removal 
of the drug. In our study, a schedule for demethylation was developed.
Methylation status has also been examined in prostate tumours. AR methylation was 
evident in 50 % of advanced AR-negative and metastatic prostate cancer, but not in 
primary localised prostate cancer or normal tissue (Kinoshita 2000). The methylation 
status of PSA itself has not been investigated, primarily because it is not thought to 
contain CpG islands. However, its expression may be affected by functional silencing of 
the AR.
PSMA has been identified as a potential alternative tissue and/or serum marker in PSA- 
negative prostate cancer (section 4.4.5). Its expression varies among prostate cell lines 
and methylation of the PSMA promoter represses PSMA transcription in LNCaP cells. 
However, work in the current study is in agreement with other authors who noted that 
demethylation did not reactivate PSMA transcription and subsequent protein expression 
in DU 145 cells (Noss, Singal et al. 2002). Similar results were observed for PAP which 
was not re-expressed following demethylation. This study indicates that for PSMA and 
PAP, methods other than methylation are involved in their expression.
In this study, PSA re-expression after demethylation treatment was observed in DU 145 
cells, a cell line that does not normally express either PSA or the AR. This was clearly 
demonstrated by RT-PCR and to a lesser extent, by the immunohistochemistry. The fact 
that no protein was detected on immunoblot is likely due to the greater sensitivity of 
RT-PCR in detecting low levels of expression compared to western blotting.
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It is interesting that no re-expression of the AR was seen after demethylation. This 
would imply that there is a pathway, other than that via the AR, which is methylated in 
prostate cancer cells, and directly affects expression of PSA. The identity of this 
remains unidentified; nevertheless, it would appear that methylation plays a role in PSA 
expression and may be a factor in PSA-negativity. Further work should include the 
investigation of methylation status of PSA and AR in prostate cancer tissue where 
serum PSA is inappropriately low. This could be achieved by methylation specific PCR.
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Table 6.1 Cell Line Numbers with/without Demethylation
0.5 x 105 cells were originally inserted per flask.
Treated flasks were incubated for 24 hours with 500nM 5’Aza. 
Cells harvested after 5 days.
Flask contents Number of cells
DU 145 treated 3.15 x 10s
DU 145 untreated 58.8. x 10"
LNCaP treated 6.15 x 10s
LNCaP untreated 19.3 x lO"
PC 3 treated 8.46 x 105
PC3 untreated 27.9 x lO5
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Figure 6.1 RT-PCR Results using PSA, AR and GAPDH Primers after 
Demethylation Treatment of Prostate Cancer Cell Lines with 5-Aza
Lane 1 LNCaP cells treated with 5 Aza
Lane 2 LNCaP cells untreated
Lane 3 DU 145 cells treated with 5 Aza
Lane 4 DU 145 cells untreated
Lane 5 PC-3 cells treated with 5 Aza
Lane 6 PC-3 cells untreated
Lane 7 No RNA
Lane 8 Reagents only
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Figure 6.2 PCR Results using PSMA and PAP Primers after Demethylation of 
Prostate Cancer Cell Lines with 5-Aza
Lane 1 LNCaP cells treated with 5 Aza
Lane 2 LNCaP cells untreated
Lane 3 DU 145 cells treated with 5 Aza
Lane 4 DU 145 cells untreated
Lane 5 PC-3 cells treated with 5 Aza
Lane 6 PC-3 cells untreated
Lane 7 No RNA
Lane 8 Reagents only
Figure 6.3 Immunohistochemical Staining of Prostate Cancer Cell Lines Grown on 
Coverslips
Row 1: Control LNCaP cells staining for PSA
Control LNCaP cells showing nuclear staining for AR 
Treated DU 145 cells showing staining for PSA 
Row 2: Untreated DU 145 cells showing negative staining for PSA 
Untreated DU 145 cells showing negative staining for AR 
Treated PC-3 cells showing negative staining for PSA 
Row 3: Control LNCaP cells with secondary antibody only
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Figure 6.4 Western Blotting of Prostate Cancer Cell Lines Treated with 5-Aza to 
Investigate Re-Expression of PSA and AR after Demethylation
Lane 1 25.0 jag protein loaded, LNCaP cells treated with 5-Aza
Lane 2 25.0 pg protein loaded, LNCaP cells untreated
Lane 3 2.5 pg protein loaded, LNCaP cells treated with 5-Aza
Lane 4 2.5 pg protein loaded, LNCaP cells untreated
Lane 5 25.0 pg protein loaded, DU 145 cells treated with 5-Aza
Lane 6 25.0 pg protein loaded, DU 145 cells untreated
Lane 7 25.0 pg protein loaded, PC3 cells treated with 5-Aza
Lane 8 25.0 pg protein loaded, PC3 cells untreated
Lane 9 5.0 pg protein loaded, LNCaP cells treated with 5-Aza
Lane 10 5.0 pg protein loaded, LNCaP cells untreated
Lane 11 50.0 pg protein loaded, LNCaP cells treated with 5-Aza
Lane 12 50.0 pg protein loaded, LNCaP cells untreated.
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Chapter 7 General Discussion
7.1 Definition of the Clinical Features of PSA-Negative Untreated 
Metastatic Prostate Cancer
The clinical features of this patient group have been documented in the largest series 
thus far described, providing an evidence-base for this patient group. Historically, a 
well-documented inverse relationship between Gleason score and serum PSA levels has 
been described, reflecting the de-differentiation of the tumour during progression of 
disease (Aihara et al. 1994). Although a significant number of the cases studied in this 
thesis were moderately differentiated tumours, the high proportion of high-grade 
biologically aggressive cancers correlates with their poor response to hormonal 
treatment. Responses to first line-hormonal manipulation are of much shorter duration 
than for patients with metastatic prostate cancer and high serum PSA levels, and overall 
survival is approximately 50 % less, being 12 months rather than 24 months. In selected 
patients, early chemotherapy and Phase I/II studies should be considered for this patient 
group. The entry of these patients into clinical studies will allow data to be collected 
prospectively, and a database of tissue and sera to be collected.
7.2 The Immunohistochemical Characteristics of Serum PSA-Negative 
Prostate Cancer
The initial premise in the current study was that as levels of serum PSA and tissue PSA 
are generally concordant, tissue staining for PSA might be absent in the group of 
patients studied in this thesis and that some alteration in protein synthesis, most likely 
due to a change in the AR was the culprit. Other authors have observed reduced tissue 
levels of PSA in high grade prostate carcinomas, by both PSA mRNA measurement
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(Qiu 1990) and immunohistochemistry (Aihara et al. 1994). However, this work has 
clearly shown that in the majority of men with inappropriately low levels of serum PSA, 
there is positive tissue staining for both PSA and the AR. This makes silencing or 
deletion of the AR unlikely and shows that PSA synthesis at tissue level is present, 
although the extent of synthesis may be reduced. It should be born in mind that a 
functional assay of the AR was not performed and it is possible that although the AR is 
present, it is not functional. The archival prostate tissue used in this work was obtained 
from biopsy or resection of the primary carcinoma. It is well known that marked 
heterogeneity occurs within prostate cancer and there may be areas displaying 
differential amounts of tissue positivity for both PSA and AR within each tumour (van 
der Kwast 1991). It is possible that had tissue from the metastasis been available for 
each patient, the pattern of tissue PSA and AR immunostaining may have significantly 
differed from that observed in the primary tumours, and that a tissue PSA-negative 
metastatic tumour represented the dominant clone in this group of patients. It would be 
necessary to collect paired tissue from both primary and metastatic tumours to evaluate 
this hypothesis.
7.3 Alternative Diagnostic Tissue Markers
Positive tissue immunostaining for PSA was observed in two thirds of the cases, but 
was in general focal in nature and could potentially be missed on a diagnostic prostatic 
biopsy. The more diffuse pattern of immunostaining seen with PSMA in 90% of cases 
therefore reduces the chances of a geographical miss on diagnostic biopsy and should 
augment the histopathologist’s panel of the antibodies used when serum PSA is low. It 
was not possible to analyse the tissue for hK2 status, which shares 70% sequence 
homology with PSA, due to difficulties obtaining a specific validated antibody.
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7.4 Potential Serum Markers
Attempts have been made to utilise circulating serum PSMA levels as part of the 
screening of prostate cancer. Murphy and colleagues (1995) reported that serum PSMA 
levels are elevated in prostate cancer patients, and the elevation remains, even when 
PSA levels are low. Although Kim (2000) suggested that serum PSMA may be of use in 
androgen-independent prostate cancer, this has not been a universal finding. Attempts to 
improve detection have been made using RT-PCR assays; although RT-PCR of serum 
PSMA was more sensitive than that for serum PSA, it was not sufficiently sensitive to 
be used as a basis for clinical therapy (Murphy 1998). However, given the marked 
tissue immunostaining for PSMA in our group of patients, serum PSMA levels may 
well be of use in establishing early diagnosis in those cases presenting with metastatic 
disease and low serum PSA. In men with low serum PSA, serum PSMA should be 
explored as a potential tumour marker, but requires a reliable serum assay technique.
Before the advent of PSA as a serum tumour marker, serum PAP was extensively used 
in the diagnosis and management of prostate cancer (Gutman et al. 1936), but fell out of 
favour due to lack of tissue specificity and diurnal variations in serum levels. There 
have been occasional reports in advanced disease where PAP levels were elevated while 
the serum PSA remained undetectable (Goldrath & Messing 1989;Leibman et al. 1995). 
Perhaps it is time to re-vist PAP as a serum marker in the PSA-negative metastatic 
group.
7.5 Alternative Therapeutic Targets (Appendix 2)
The numbers examined for alternative molecular targets is too small to be reported with 
confidence. Nevertheless, the attraction of Her-2 as a molecular target is powerful.
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These patients do behave as though they are hormone -refractory from the outset, given 
their extremely short duration of response to first-line hormonal management. As Her-2 
has been shown to be over-expressed in hormone refractory prostate cancer, further 
exploration of Her-2 staining in these PSA-negative patients should be pursued as a 
potential therapeutic option.
7.6 The Mechanism of Low Serum PSA Levels - “PSA-Negativity”
7.6.1 Protein Synthesis
One aim of the work reported in this thesis was to investigate the potential mechanisms 
underlying PSA-negativity, specifically in relation to PSA protein synthesis. As 
described above, PSA is certainly expressed at tissue level, albeit in an often focal and 
patchy fashion, as demonstrated by the immunohistochistry results. The cell line work 
demonstrated that methylation of the AR causing functional silencing of PSA 
transcription was not a factor identified in this thesis. Some other factor affecting PSA 
production appeared to be methylated and PSA expression re-activated by appropriate 
demethylating agents. This implies that some mechanism, which bypasses the AR, 
appears to be methylated in prostate cancer cell lines and thus negatively affects PSA 
expression. One way of further examining this would have been to perform methylation 
specific PCR for PSA and AR using the prostate archival tissue after bisulphite 
treatment, but insufficient tissue remained to examine this in an adequate number of 
cases.
Loss of heterozygosity was not a factor in the samples studied. The method using 
archival laser-captured tissue was problematic, and analysis of the remainder of the 
samples would be optimised by macroscopically scraping slides where the volume of
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tissue remaining permitted this to be done.
7.6.2 PSA Degradation
Protein synthesis was only one of three potential mechanisms involved in PSA- 
negativity, the others being PSA secretion and protein degradation. Free PSA and PSA 
bound to certain protease inhibitors may only be present temporarily in serum, due to 
prompt degradation. Use of immunohistochemical antibodies to ubiquitin would help 
determine whether rapid PSA protein degradation and metabolism occurs, which would 
markedly reduce serum levels of PSA. Electron microscopy could then determine in 
which regions of the cell ubiquitin was present, thus demonstrating where a change in 
the degradation pathway was taking place.
7.6.3 PSA Secretion
PSA secretion into the systemic circulation may be the limiting factor. It is clear that 
PSA within the systemic circulation exists in several forms. For this study, absolute 
serum PSA levels were documented and it was therefore not possible to correlate serum 
free:total PSA ratios. Neutralising antibodies to PSA have been reported in up to 5% of 
all sexually active women but have not, as yet, been identified in patients with prostate 
cancer. PSA is normally secreted from prostatic luminal epithelium as pro-PSA, from 
which the 7 amino acid leader sequence is cleaved. Differential cleavage in the post- 
translational modification of PSA results in splice variants such as [-2] pPSA and [-7] 
pPSA. Current serum PSA assays are unable to detect these splice variants, which have 
been recently reported as being present at up to five-fold greater values in prostate 
biopsy-positive patients when compared to biopsy-negative ones (Mikolajczyk et al. 
2000;Mikolajczyk et al. 2001). It is feasible that men with inappropriately low serum
167
levels of PSA produce one such splice variant, which with the development of 
commercial assays, may be able to be routinely tested and used as a diagnostic and 
monitoring marker.
7.7 Further Work.
This work needs to be taken forward with further immunohistochemistry to examine 
hK2 status in these tumours and to assess this as an alternative diagnostic marker. As 
many of the patients examined in this work have already died, serum samples were not 
available but a pilot study is in place to collect sera prospectively from any patient 
presenting in this patient group to the Cancer Centre, and examine PSMA levels as a 
serum biomarker. Currently, serum PAP levels are also being routinely collected for a 
similar reason. Her-2 status should be examined in the remaining two-thirds of the 
samples.
In conclusion, diagnosis and monitoring of men presenting with untreated metastatic 
prostate cancer and low serum PSA levels may be augmented by the use of alternative 
tissue and serum marker such as PSMA. Given that reliable assays remain elusive, any 
such patient should have tissue and sera prospectively stored to enable retrospective 
analysis to be carried out when technical advances permit.
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Appendix 1 Documentation For Clinical Features Study
□ Letter to pathologist
□ Letter to urologist
□ Letter to patient from urologist
□ Patient information sheet
□ MREC consent form
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CONFIDENTIAL
Consultant Histopathologist,
Hereford Hospitals NHS Trust,
The County Hospital,
Union Walk,
Hereford.
HR1 2ER.
19th July, 2002.
Dear Dr.,
Re: PSA-Negative Prostate Cancers.
I am currently investigating PSA negative prostate cancers as part of a clinical and 
laboratory-based study. The BAUS Section of Oncology has agreed to support this 
project by allowing access to its minimum dataset for urological cancer to identify those 
patients who are PSA-negative and to approach the Consultants involved with each 
case. I plan to study the patients’ case notes to establish the clinical presentation, natural 
history and prognosis of this group of patients. The laboratory aspect of the project is to 
investigate the reason why these tumours are PSA negative. I hope to characterise the 
differentiation patterns of the tumours, confirm PSA negativity and check androgen 
receptor expression using immunohistochemistry. We also aim to examine mRNA 
expression and measure the methylation status of the gene. We hope to look for 
alternative tumour markers in addition.
The database has identified two patients of M r  , Hospital ID....,
DOB (who has consented to the project and whose consent form is enclosed) and
patient hospital no   d.o.b who is deceased. Approval has been given by
MREC not to seek consent from next of kin where patients have already died.
M r  has received a copy of the MREC approval to forward on to the local LREC
committee for their information. I have contacted M r ..................who is happy to provide
access to the patient’s notes and I would hope to be able to collect the specimens in 
person on the same visit. If it is not possible to have a block from the prostate, I would 
be very grateful for as many 3pm slides as possible, as I am hoping to use 5-7 uncoated 
slides for the molecular biology work and 8 vecta bonded coated slides for the 
immunohistochemistry.
I look forward to hearing from you and please do not hesitate to contact me if I can 
provide you with any further information,
Yours sincerely,
Dr. Alison Birtle MRCP.FRCR.
Clinical Research Fellow, Pathology letter. Version 1.9.01
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CONFIDENTIAL
Dear Mr............
Re: PSA-Negative Prostate Cancer 
Patient:
I am currently investigating PSA negative prostate cancers as part of a clinical and laboratory-based 
study.
The BAUS Section of Oncology has agreed to support this project by allowing access to its mimimum 
dataset for urological cancers to identify those patients who are PSA-negative and to approach the 
Consultants involved with each case. I plan to study the case notes of patients with locally advanced or 
metastatic disease to establish the clinical presentation, natural history and prognosis of this group of 
patients. The laboratory aspect of the project is to investigate the reason why these tumours are PSA 
negative. I hope to characterise the differentiation patterns of the tumours, confirm PSA negativity and 
check androgen receptor expression using immunohistochemistry. We also aim to examine mRNA 
expression and measure the methylation status of the gene. We hope to look for alternative tumour 
markers in addition.
I would be very grateful if you could write to your patient, Hospital no...................................   D.O.B.
.................... to ask for consent for me to have permission to access the medical records and to obtain
blocks of the prostate to perform the requisite investigations. I enclose a copy of the patient information 
sheet and consent form. I would be happy to meet with you, if you wished, to discuss the project and plan 
to review the medical records and to collect the samples in person.
If you are in agreement, please sign below, and retain a copy for your records.
I look forward to hearing from you and please do not hesitate to contact me if I can provide you with any 
further information,
Yours sincerely,
Dr.Alison Birtle MRCP.FRCR 
Clinical Research Fellow 
Please delete as appropriate:
1. I will send on the letter and information sheet to the patient, and when I have the patient’s consent I 
will give you access to the notes. I will ask my secretary then to pull the notes.
2. I would like to meet with you to discuss the project
Signed .........................................................................................
Date.............................................................................................
Address........................................................................................
Urologist letter .Version 2. 10.01
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CONFIDENTIAL
PSA -  NEGATIVE PROSTATE CANCER STUDY 
Dear
On behalf o f  my colleague, Dr Birtle, I would like to ask you to take part in 
a study into prostate cancer, which is being run from the Institute o f  
Urology in London, and is a national project. It would involve extra tests 
being done on the prostate tissue that was removed at your surgery but 
would not mean any extra hospital visits or tests on yourself. It is hoped 
that this study will help in the diagnosis and treatment o f prostate cancer.
I enclose the information sheet and consent form for the study and the 
contact details o f  the doctor involved. Please contact her if  you have any 
questions, and forward the consent form back to her at the contact address.
Thank you for considering this proposal.
Yours sincerely,
CONSULTANT UROLOGIST.
Patient letter. Version 02.10.01
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CONFIDENTIAL
PATIENT INFORMATION SHEET
PSA -  NEGATIVE PROSTATE CANCER STUDY
Most prostate cancers produce a protein called PSA (prostate specific antigen) which 
circulates in the blood stream. This can be used to detect prostate cancer and to see how 
well treatment is working. However, some cancers can either stop producing PSA or 
never produce it from the start.
We are interested in men who have prostate cancer, and have much lower measurements 
of PSA in the blood than expected. We would do specific laboratory tests on the 
prostate tissue that was removed at surgery. No tests other than those relevant to this 
particular project would be done and at the end of the project, the samples would be 
returned to your original hospital. We would also see if there were any other substances 
produced by the cancer that could be used instead of PSA to diagnose prostate cancer 
and to see how treatment was working. Our results will not benefit you directly but in 
time we hope this will help earlier diagnosis and better treatment for men whose 
prostate cancer do not produce PSA.
We also would like to look at your medical records, to see if there was anything in 
common with other men with similar cancers. This information would be confidential 
and only used for this project. There would be no extra tests done on you physically, 
only on the cancer that has already been removed. There would be no extra visits to the 
hospital.
You do not have to take part in this study if you do not want to. If you decide to take 
part you may withdraw at any time without having to give a reason. Your decision 
whether to take part or not will not affect your care and management in any way.
If you have any questions about the study, please contact Dr. Alison Birtle, Research 
Registrar, The Institute of Urology,  
. Telephone 
All proposals for research using human subjects are reviewed by an ethics committee 
before they can proceed. This proposal was reviewed by the Joint UCL/UCLH 
Committees on the Ethics of Human Research.
Info sheet Version 03.03.02
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Centre Number:
Study Number:
Patient Identification Number for this trial:
CONSENT FORM
Title of Project: PSA -  NEGATIVE PROSTATE CANCER
Name of Researcher: Dr Alison Birtle, Clinical Research Fellow.
The Institute of Urology & Nephrology,
1. I confirm that I have read and understand the information sheet dated 3.02 
(version 3) for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being 
affected.
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from the Institute of Urology or from regulatory authorities 
where it is relevant to my taking part in research. I give permission for these 
individuals to have access to my records.
4. I agree to take part in the above study.
Name of Patient Signature Date
Name of Person taking consent Signature Date
(if different from researcher)
Researcher Signature Date
Consent form Version 2.3.02.1 for patient; 1 for researcher; 1 to be kept with hospital 
notes
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Appendix 2 Potential Diagnostic Markers As Therapeutic 
Targets For Serum PSA-Negative Prostate Cancer
A2.1 Introduction
The poor prognosis of men presenting with untreated metastatic prostate cancer and low 
serum PSA has been previously described (Birtle et al 2003). Different management 
strategies are therefore needed and molecular targets represent an attractive option. 
Over-expression of particular gene products at tissue level may allow the development 
of targeted antibodies. Likely targets include Her-2/neu, matrix metalloproteinase 2 
(MMP 2), bcl-2, and fibroblast growth factors.
A2.I.1 Her-2/neu (C-erb-B2)
Her-2 encodes the 185-kDa transmembrane tyrosine kinase receptor, first identified as a 
homologue of the epidermal growth factor receptor gene (Yamamoto et al 1986) and 
found to be over-expressed in 20-30 % of breast and ovarian cancers (Slamon et al 
1989). In particular, over-expression of Her-2/neu (c-erb-B2) in prostate cancer models 
appears to be associated with androgen-independent growth, and may activate the AR 
in a ligand-independent manner (Craft et al 1999). In some studies, it has been 
associated with shortened survival (Sadasivan et al 1993). If Her-2/neu is involved in 
prostate cancer progression and the transition to androgen independence, it may be up- 
regulated in PSA-negative tumours, which themselves appear to behave in an androgen- 
independent manner from the outset. At present, analysis of prostate cancer specimens 
for Her-2 expression is not standard, but may be of value in identifying those patients 
likely to benefit from targeted therapy with such agents as Herceptin ™, a monoclonal 
antibody licensed for breast cancers over-expressing the protein, (Agus et al 1999), or
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P K I166 (Novartis Pharmaecuticals), a dual EGFR/Her-2 tyrosine kinase inhibitor found 
to be active in hormone refractory prostate cancer (Mellinghoff et al. 2002).
A2.1.2 Matrix Metalloproteinase 2 (MMP2) and its tissue inhibitor 
(TIMP2)
Matrix metalloproteinases (MMP1-20) are proteolytic enzymes capable of degrading 
the basement membrane and extracellular matrix promoting neoplastic cell invasion and 
metastases. Their activity is modulated by their tissue inhibitors (TIMP1-4). Increased 
expression of MMP’s has been associated with poor prognosis and reduced survival in 
patients with a variety of malignancies, including carcinoma of the colon, stomach, 
oesophagus and breast (Stetler-Stevenson 1990). Several studies have described an 
association in prostate cancer between a high MMP-2 :TIMP-2 ratio and increased 
tumour stage or grade (Still et al 2000). In a similar fashion, several studies have found 
a correlation between MMP-2 and advanced or progressive prostate cancer. Co­
expression of MMP-2 and its tissue inhibitor TIMP2, has a negative prognostic 
significance in patients with prostate cancer (Ross et al 2003). Pre-clinical studies of 
MMP inhibitors have shown anti-tumour effects in vivo (Lokeshwar 1999) and clinical 
studies of second-generation MMP inhibitors have shown clinical responses in 
pancreatic, lung and ovarian tumours (Brown & Giavazzi 1995).
A2.1.3 Fibroblast Growth Factors (FGF)
Fibroblast growth factors are multifunctional heparin binding polypeptides, which share 
structural similarity. Their signalling is mediated by transmembrane tyrosine kinase 
receptors, the FGFR’s (Yamasaki et al 1996) and both FGF and FGFR are involved in 
development, wound healing, angiogenesis and tumorigenesis (Basilico & Moscatelli
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1992). FGF8 or androgen induced growth factor has been shown to have a positive 
relationship with tumour grade (Leung et al 1996) although other workers have found 
the reverse (Wang et al 1999). Nevertheless, it would seem that FGF8 expression is 
linked with development of prostate cancer. Reduced expression of its receptor, FGFR2, 
has been suggested as a marker for the development of AIPC (Naimi et al 2002).
A2.1.4 Bcl-2
The anti-apoptotic factor Bcl-2 is frequently reported as being up-regulated in advanced 
prostate cancer (McDonnell 1992). Bcl-2 over-expression has been shown in AIPC and 
it has been suggested that this may be bypassing the apoptotic signal initiated by 
hormonal therapy (Feldman & Feldman 2001).
The aim of this pilot study was:
To investigate the expression of potential therapeutic targets for patients with untreated 
metastatic prostate cancer and low serum PSA.
A2.2 Materials and Methods 
A2.2.1 General immunostaining
10 of the 33 cases collected as in chapter 4, were selected at random (5 biopsy 
specimens and 5 from transurethral resection) to perform an additional 
immunohistochemistry panel of 6 antibodies. Commercially available primary 
antibodies to TIMP2, MMP2, Bcl-2, Her-2, FGF8 and FGFR2 were used. Appropriate 
positive and negative controls were included for all immunohistochemistry. The optimal 
dilution of and preferred method of antigen retrieval was determined by titrating the 
antibody using a high grade radical prostatectomy sample as a positive control for Bcl-2 
and an archival hyperproliferative keloid scar for TIMP2, MMP2, FGF8 and FGFR
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(Table A2.1). The standard cell line positive and negative controls as supplied by the 
manufacturer were used for Her-2. In brief, the tissue sections were dewaxed in xylene 
and taken through a series of graded alcohols to water. The method of antigen retrieval, 
primary antibody concentration and method of staining is summarised in Table A2.1. 
An identical method of immunostaining was performed as previously outlined in 
chapter 4, using the EnVision sysytem.
A2.2.2 HER-2/neu immunostaining
The Dako Herceptest Immunohistochemical kit for immunostaining with HER-2/neu 
(Dako Corp., Carpenteria, CA) was used as described previously (Edorh et al 1995). 
Assessment of the degree of staining was performed as outlined below.
Immunohistochemical staining was assessed by one pathologist who had a site- 
specialised interest in urological tumours (AF) and semi-quantitative staining was 
performed taking in to account the intensity (0, +, ++, +++) and extent (focal/diffuse) of 
staining. Membrane staining for HER-2/neu protein was categorised, ranging from zero 
to +3, as defined by the developers of the commercial kit and compared with the 
supplied positive and negative cell line controls. Score zero was defined as per the 
manufacturer’s instructions as undetectable staining or membrane staining in < 10% of 
the tumour cells. Score +1 was defined as faint membrane staining detected in > 10% of 
the tumour cells. Score +2 was considered as weak to moderate complete membrane 
staining observed in > 10% of the tumour cells and score +3 defined as moderate to 
strong complete membrane staining observed in > 10% of the tumour cells.
A2.3 Results
(See Table A2.2) 2/10 cases were positive for Her 2-neu, with 2/10 positive for Bcl-2.
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(Figures A2.1 and A2.2) Weak immunoreactivity for FGF8 was observed in 5/10 cases. 
All 10 cases demonstrated some staining for TIMP-2 with 9/10 cases also showing 
MMP-2 immunoreactivity (data not shown). All cases were negative for FGFR2 (data 
not shown).
A2.4 Discussion
The mechanism of low serum levels of PSA cannot be explained by AR loss leading to 
altered PSA transcription, as strong nuclear AR staining was seen in the majority of 
patients (Chapter 4). It has been suggested that up-regulation of Bcl-2, found in cases 
of androgen independent prostate cancer could bypass the apoptotic signal provided by 
hormonal therapy (Feldman & Feldman 2001). We found positive staining for Bcl-2 in 
2 of the 10 (20%) cases selected for the additional panel of antibodies, both cases being 
poorly differentiated tumours which were tissue PSA and AR negative. Overexpression 
of Her-2/neu has been observed in certain tumour types, including breast, ovary and 
lung carcinomas (Naber 1990;Slamon 1989), and associated with tumour progression. 
Recent studies in prostate cancer have suggested significant overexpression of this 
protein in primary metastatic prostate cancer, particularly after androgen-deprivation 
therapy (Osman 2001) and that Her-2/neu expression appears to increase with 
progression to androgen independence (Signoretti 2000). Given the short median 
duration of response to first-line hormonal therapy of 7 months in our group of patients 
with low serum PSA (Birtle et al 2003), it can be argued that those prostate tumours 
presenting with metastatic disease and low serum levels of PSA are hormone-refractory 
from the outset. It is an attractive option to consider targeted therapy with monoclonal 
antibody to Her-2/neu for these patients. However, Her-2/neu immunostaining was only 
performed in 10 patients with 1/10 showing 2+ staining and 1/10 1+ staining.
179
Fibroblast Growth Factor 8 (FGF 8) or androgen induced growth factor expression was 
studied as conflicting results for this factor in prostatic tissue have been documented in 
the literature. Leung has shown a positive relation between FGF8 and tumour grade in 
prostate cancer (Leung 1996). In contrast, other studies have shown an inverse 
relationship between these two parameters and a positive correlation with the AR 
(Wang 1999). We found only weak staining for FGF8 in 5/10 cases studied with no 
demonstrable association between either tumour grade or AR expression. In addition, 
FGF receptor 2 (FGFR 2) staining was negative in 10/10 cases. This agrees with work 
(Naimi 2002) where FGFR2 expression was downregulated in 18/30 prostate samples, 
particularly in androgen-independent ones, and it has been suggested that its 
inactivation may have a role in disease progression. Alternative methods such as real­
time quantitative polymerase chain reaction would be needed to look at this potential 
downregulation of FGFR2.
Unregulated secretion of matrix metalloproteinases (MMPs) or their endogenous protein 
inhibitors (tissue inhibitor of metalloproteinases TIMPS) have been implicated in 
tumour invasion and metastases (Liotta 1986). MMP-2 expression has been associated 
with more aggressive biologic behaviour in colorectal, breast and stomach cancer 
(Stetler-Stevenson WG 1990). More recently, Still (2000) has suggested a tight 
association between MMP-2 and TIMP-2 expression with an increase in the ratio of 
MMP-2:TIMP-2 in high grade or high stage tumours. The current study has shown an 
inverse relationship between MMP-2 and TIMP-2 in 2 cases both of which were 
Gleason 9 tumours.
Although the additional immunohistochemical markers were examined in one third of
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the cases only, over-expression of Her-2/neu may represent a potential therapeutic 
target. In addition, the down-regulation of FGFR and TIMP-2 may play a part in the 
particular aggressive pattern of disease in patients with treatment-naive metastatic 
prostate cancer and low serum PSA. Further work is needed to increase the number of 
cases examined.
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Figure A2.1 Her-2/Neu Immunostaining
A Serum PSA-negative prostate carcinoma showing 3+ Her-2/neu staining (x 20)
B Serum PSA-negative prostate carcinoma showing negative Her-2/neu staining (x 20) 
C Positive cell line control for Her-2/neu supplied in Hercept test ® ( x 40)
D Negative cell line control for Her-2/neu supplied in Hercept test® ( x 40)
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Figure A2.2 Bcl-2 Immunostaining
A Serum  PSA-negative prostate carcinoma showing Bcl-2 3+ staining (x 20)
B Serum  PSA-negative prostate carcinoma showing negative Bcl-2 staining (x 20) 
C Lymph node as positive control for Bcl-2 (x 20)
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Table A2.1 Summary of Primary Antibody and Conditions
Primary
antibody
Concentration Species/ Catalogue Antigen
Retrieval*
TIMP2 1/20 Rabbit/Santa Cruz 9.9
Bcl-2 1/10 Mouse/Dako M0887 PC
MMP2 1/100 Rabbit/Santa Cruz sc-10736 PC
FGF 8 1/200 Rabbit/Santa Cruz sc-7916 PC
HER-2/neu 1/2000 Hercept kit/Dako A0485 MW
FGFR2 1/100 Mouse/Santa Cruz sc-6930 PC
* Method of antigen retrieval
9.9: 25 minutes microwaving at full power, stand 10 mins, in Dako high pH retrieval 
solution (S3007)
MW: stand in Epitope Retrieval Solution (Dako S I699) at 98 °C in waterbath for 40 
minutes (as per manufacturer’s instructions)
PC = 2 minutes pressure cooking at full pressure in citrate buffer pH 6.0
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Table A2.2 Immunohistochemistry Results of Additional Markers Panel in 10
Selected Cases
Extent of Tumour Positivity
Patient GleasonScore PSA TIMP2 MMP2 FGF8 FGFR2 Her-2/neu Bcl-2
1 10 0 F 2+ F 2+ F 1 + 0 0 0
2 9 F 2+ F 1+ F 3+ D 1 + 0 0 0
3 10 0 F 2+ F 1+ F 1+ 0 0 D 3+
4 10 F 2+ F2+ F 3+ 0 0 0 0
5 9 F2+ F 1+ F 2+ F 1+ 0 2 + 0
6 10 0 F 2+ F 3+ 0 0 0 0
7 8 D 3 + F 2+ F2+ 0 0 0 0
8 9 0 F 3+ F 3+ 0 0 0 F 1+
9 9 0 F 1+ 0 F 1+ 0 F 1+ 0
10 9 F 2 + D 2+ D 2+ 0 0 0 0
F: Focal Staining
D: Diffuse Staining
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